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Objectives and general introduction
This thesis aims to provide strategies for detection, monitoring and treatment of pa-
tients with Von Hippel-Lindau (VHL) disease. It also aims to identify and optimise
the parameters for both symptomatic and presymptomatic detecting of gene carriers
in Dutch VHL families using DNA analysis. First, we describe the main objectives,
methods and outline of this thesis.
1.1 Objectives of this thesis
VHL disease is an autosomal dominantly inherited syndrome, predisposing carriers of
a germline mutation in the VHL gene to tumours in multiple organs. These tumours
include: haemangioblastoma in the retina and central nervous system, renal cell carci-
noma, phaeochromocytoma, islet cell tumours of the pancreas, and endolymphatic
sac tumours, as well as cysts and cystadenoma in the kidney, pancreas and epididymis
(Fig. 1). Most tumours in VHL patients occur multicentric or bilaterally, and manifest
at a younger age than in situations without an apparent VHL germline mutation. The
germline mutation spectrum is variable and with mutations scattered throughout most
of the VHL gene. Although some recurrent mutations have been reported, most fami-
lies have their own unique germline mutation.
Penetrance of VHL disease in mutation carriers is high. Almost all VHL germline
mutation carriers develop one or more VHL-related tumours at an age of 60 years.1
The most common symptoms include: loss of vision, raised intracranial pressure, neu-
rological deficits, paroxysmal raised blood pressure, and local pain. The median ex-
pected survival, based on life table analysis, has been estimated to be 49 years.2 How-
ever, data on the natural history of VHL disease are scarce and derive from studies
describing a heterogeneous group of clinically monitored as well as unmonitored VHL
patients.2-6 Accordingly, the mean life expectancy of undetected and untreated VHL
patients may be as low as 35 years old. At present, metastases from renal cell carci-
noma and neurological complications from cerebellar haemangioblastoma are the most
common causes of death in VHL disease. However, intensive radiological and clinical
monitoring and advanced operation techniques are likely to contribute to the reduc-
tion of both morbidity and mortality.7-10
Assuming that 1 in 40,000 people has a hereditary predisposition for this dis-
ease, in the Netherlands (with a population of 16 million people) there would be 400
VHL patients. Looking at comparable inherited tumour syndromes (e.g. the Multiple
Endocrine Neoplasias Types I and II), we can expect these 400 patients to be found in
approximately 40 families.
New families with VHL disease can be found by screening patients with VHL-
related tumours and a positive family history for germline mutations. In addition,
patients with a VHL related tumour and a negative family history are possible carriers
of a VHL germline mutation. Sporadic patients with an autosomal dominant trait and
apparently unaffected parents may arise from the following situations: 1) a novel
mutation in the sperm or egg cell that produced the child (de novo mutation); 2)
carriership of mutation in some but not all cells of the body (somatic mosaicism); 3)
the disease is not expressed in one of the parents (non-penetrance). When a germline
mutation in the VHL gene is found, a new VHL family is identified. Presymptomatic
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DNA analysis and identification of carriers of a VHL germline mutations in families
then permits physicians to follow the progress of tumour development from a rela-
tively early age and to optimise the time of treatment. Family members who are non-
carriers are relieved from the burden of repeated clinical monitoring. Since the neces-
sity for costly and time-consuming surveillance programs can be reduced and moni-
toring can be directed at those carrying the mutation,11 the ratio between cost and
effectiveness is expected to improve.
Fig. 1 Clinical manifestations of VHL disease
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We realise that there are numerous ethical issues involved in early disease detec-
tion. These issues are well descibed in the following principles of Wilson and Jungner:12
1) the condition being sought should be an important health problem, for the indi-
vidual and the community; 2) there should be an acceptable form of treatment for
patients with recognisable disease; 3) the natural history of the condition, including
its development from latent to declared disease, should be understood; 4) there should
be a recognisable latent or early symptomatic stage; 5) there should be a suitable
screening test or examination for detecting the disease at the latent or early stage, an
this test should be acceptable for the population; 6) the facilities required for diagno-
sis and treatment of patients revealed by the screening program should be available;
7) there should be an agreed policy on whom to treat as patients; 8) treatment at the
presymptomatic, borderline stage of a disease should favourably influence its course
and prognosis; 9) the cost of case finding (which would include the cost of diagnosis
and treatment) needs to be economically balanced in relation to possible expenditure
on medical care as a whole; 10) case finding should be a continuing process, not a
“once and for all” project. For reasons also advanced later in this thesis, VHL disease
meets, or is anticipated to meet, most of these criteria.
1.1.1 Methods
In order to detect new VHL families and patients, we took several initiatives to in-
crease the amount of persons - possibly affected with VHL disease - referred for DNA
diagnosis. Firstly, we asked the Departments of Ophthalmology in the university hos-
pitals for patients with retinal haemangioblastoma. Secondly, we put an appeal in the
journal of the Dutch Association for Neurology asking for patients with haemangio-
blastoma in the central nervous system. Thirdly, we approached approximately 80
medical specialist (including clinical geneticists, internists, endocrinologists, urolo-
gists, surgeons, neurosurgeons and paediatricians) with a known interest in hereditary
tumour syndromes. Fourthly, we contacted the eight genetic centres in the Nether-
lands and fifthly, we distributed patient information via the Dutch VHL support group
and the Internet.
VHL families and patients, as well as persons suspected of VHL disease, from
Dutch, Belgian and Turkish origin were referred to the DNA diagnostic laboratory
from the Department of Medical Genetics, UMC Utrecht. DNA analysis for VHL in
the Netherlands is also performed in the Department of Clinical Genetics, Rotterdam
University Hospital. Blood was taken from every proband of a VHL family and DNA
was isolated from peripheral blood samples according to established procedures. DNA
analysis included sequencing of the coding region and quantitative Southern blot analy-
sis (complemented by Fluorescence in situ hybridisation analysis when necessary).
Clinical data were collected after patients had signed an informed consent form.
Patients were approached via their consulting specialist or clinical geneticist. When
patients agreed to participate in the study they were given information about the dis-
ease and the research project. In addition, information about the disease and the re-
search project was explained and individualised by genetic assistants during home
visits. Some patients were asked if they were interested in becoming a contact person
for their family or family branch. These persons were asked to contact family mem-
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bers (also at meetings of the Dutch VHL support group) and to distribute informed
consent forms. Finally, clinical data were collected from the various hospitals and
stored in a database. The protocol for assembling clinical data was approved by the
medical ethics committee of the UMC Utrecht.
1.1.2 Summary of objectives
1. To detect VHL families and determine the family-specific germline mutation.
2. To identify presymptomatic family members who carry a VHL germline
mutation.
3. To screen for VHL germline mutations in patients with a single VHL-related
tumour and without a distinct family history.
4. To improve DNA analysis techniques in identifying germline mutations in
families where no mutation could be detected.
5. To collect clinical and genetic data to identify possible genotype-phenotype
correlations.
6. To formulate national guidelines for diagnosis and periodic monitoring of
VHL patients.
1.1.3 Outline of this thesis
This thesis describes strategies for the detection, follow-up and treatment of patients
with VHL disease (chapter 2), and the VHL germline mutation spectrum in classic
VHL families and patients suspected for VHL disease (chapter 3).
Chapter 1 is a general introduction to VHL disease. In section 1.1 the main ob-
jectives of the study are described. The history of the disease is the subject of section
1.2. Clinical features, including diagnosis, monitoring and treatment of the individual
tumours are described in section 1.3. Clinical diagnostic criteria are proposed in sec-
tion 1.4. Section 1.5 focuses on molecular genetic aspects of the VHL tumour sup-
pressor gene in which germline and somatic mutations of the VHL gene are described,
as well as current opinions on genotype-phenotype correlations. An overview of the
structure and possible functions of the VHL protein is provided in section 1.6.
Chapter 2 gives an overview of clinical management of VHL. Strategies for the
early detection for renal-, adrenal- and pancreatic tumours are described in detail in
section 2.1. It addresses the question: Which methods are suitable for detecting tu-
mours of organs in the upper abdomen in VHL patients?
In section 2.2 the treatment of renal cell carcinoma is evaluated in ten Dutch
patients by clinical and histopathological examination. We addressed the following
questions: What is the morphology of renal cell carcinoma in VHL patients and how
aggressive are the tumours? If the choice of treatment (nephrectomy versus nephron-
sparing surgery) of renal cell carcinoma depends on the tumour’s multi-centricity and
growth, what would be the best treatment for a VHL patient with renal cell carci-
noma?
A long-term follow-up of ophthalmological data is analysed in section 2.3 with
special attention given to the natural course and results of treatment in patients from
six VHL families. We tried to answer the following questions: Where do ocular hae-
mangioblastoma arise and through which stages of morphology do they proceed?
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What is the optimal treatment of retinal haemangioblastoma, when stage and ana-
tomical position is considered?
The last section (2.4) reports on guidelines for diagnosis and follow-up issued
by the Dutch VHL working group. The two principle questions addressed are: Which
persons are eligible for DNA analysis and which persons should be monitored follow-
ing an annual monitoring protocol?
The results of VHL germline mutation studies  are reported in chapter 3. Section
3.1 gives an overview from 34 germline mutations found in families and patients from
different ethnic origin, including their specific phenotypes. Section 3.2 focuses in
more detail on deletions found in five of these VHL families. We address the follow-
ing questions: What is the mutation spectrum of VHL germline mutations in the Neth-
erlands and how many previously unknown mutations can be detected? Do genotype-
phenotype correlations match previously established findings?
In addition, germline mutations are studied in patients with only haemangio-
blastoma (section 3.3) or phaeochromocytoma (section 3.4) to address the questions:
What is the genetic epidemiology of sporadic patients with single VHL-related tu-
mours and which patients should undergo DNA analysis? What is the contribution of
such cases to the total diagnosis of VHL disease?
In chapter 4 the principal findings are discussed and summarised in the light of
current literature on VHL disease. This chapter also includes a cost-effectiveness analy-
sis of clinical monitoring combined with a discussion of the psychological, ethical
and social consequences of early detection of VHL disease.
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1.2 History
The German ophthalmologist Eugen von Hippel (1867-1938) is usually credited with
the first full description of a retinal vascular abnormality.13 In 1911 he named this
abnormality angiomatosis retinae.14 This condition had already been reported in 1879,15
and the microscopic appearance was described in two siblings in 1894.16 Fifteen years
after the report of Von Hippel, the Swedish pathologist Arvid Lindau published a
paper describing 40 cases with cystic cerebellar tumours.17 He associated angiomato-
sis retinae with cerebellar and spinal haemangioblastomas, and cysts of the kidneys,
pancreas and epididymis. Lindau named this syndrome central nervous system angi-
omatosis. Streiff noted in 1951 that French physicians had first reported a probable
VHL patient who died with brain and retinal tumours in 1864.18 The first reports on
adrenal involvement in VHL appeared in 1953 and 195919,20 and in 1964 Melmon and
Rosen published the first major literature review.21. Following the leads of Cushing
and Bailey they preferred the eponym ‘Lindau’s disease’,22 although Von Hippel-Lindau
disease was already being used by others, first by Davinson et al. in 193623, and it was
also named Lindau-von Hippel disease by Graig et al. in 1941.24 Since the 1970s the
disease is most commonly called Von Hippel-Lindau disease or VHL.
In 1929, Möller was the first to suggest that VHL disease has an autosomal
dominant pattern of inheritance.25 Segregation analysis confirmed this finding in large
families with five and six generations, and in a Hawaiian family with 220 members.26-
28 In addition, it was increasingly recognised that most tumours in VHL patients show
typical hereditary features. As well as their familial manifestations, the tumours often
occur multiply or bilaterally, and at a young age. In 1988, a genetic locus for the
disease was mapped to the short arm of chromosome 3 by linkage studies in nine
(including one Dutch kindred) VHL families.29 Five years later, the VHL tumour sup-
pressor gene was identified following positional cloning studies in VHL families.30
Subsequently, germline mutations in the VHL gene confirmed the molecular genetic
basis of familial inheritance of the disease.
Nowadays, VHL disease is recognised as a hereditary tumour syndrome charac-
terised by predisposition to haemangioblastomas in the retina and central nervous
system, renal cell carcinomas, phaeochromocytomas, islet cell tumours of the pan-
creas, and endolymphatic sac tumours, as well as cyst(adenoma)s in the kidney, pan-
creas and epididymis (Fig. 1). The most recently discovered VHL-related tumour is
the adnexal papillary tumour of probable mesonephric origin (APMO).31 Sporadic
reports of lesions (cysts, cystadenoma, haemangioblastoma/angioma) in cerebrum,
liver, spleen, lungs, bladder, omentum, mesocolon, bones and skin have appeared in
the literature.21 Van der Hoeve classified VHL among the phakomatoses,32 neuro cuta-
neous syndromes, despite the fact that skin lesions rarely occur in patients with VHL
disease.
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1.3 Clinical features and management of VHL disease
1.3.1 Ocular haemangioblastoma
Haemangioblastoma are the most common and early tumours in VHL disease.2,4,33 In
VHL patients they may occur in the eye and central nervous system. Ocular haeman-
gioblastoma are considered to be the first manifestation of the disease in 43% of the
VHL patients.2 In the eye the typical lesion is the peripheral retinal haemangioblas-
toma, a globular reddish tumour with a dilated tortuous feeding artery leading from
the optic disc to the tumour and a similar draining vein leading back to the disc.34
Most ocular haemangioblastoma occur peripherally, 8% occur on the optical disc and
1% at the posterior pole (Fig. 2).35
On histopathological examination, the retinal tumours are seen to be composed
of a proliferation of capillaries, and stromal and glial cells, and are identical to the
cerebellar haemangioblastoma.36-38 In 1926 Lindau compared tissue slides from reti-
nal and rhombencephalic cord lesions and identified them as similar manifestations;
he called them angiomatosis. 17 The most recent trend is to refer to them as haeman-
gioblastoma instead of the classic - and commonly used - names ‘retinal angioma’ or
‘angiomatosis retinae’.
Peripheral retinal haemangioblastoma generally become symptomatic during the
third decade of life. They may cause decrease of visual acuity or induce a visual field
defect by retinal exudation, haemorrhages in the vicinity of the tumour, retinal de-
tachment, or wrinkles in the macula.39 Spontaneous regression can also occur.40 Re-
cently, Webster et al. studied the natural history in 183 patients from 81 unrelated
VHL families.35 The mean number of tumours in gene carriers was 1.85, and varied
between one and 15 lesions. The cumulative probability of incurring visual loss by
age 50 years was 35% in all gene carriers, 55% in those diagnosed with retinal tu-
mours, and was significantly worse in patients with symptomatic lesions. 68% of the
VHL patients studied were affected by retinal haemangioblastoma, and the tumours
were diagnosed at a mean age of 31 years (range 7 to 74 years). Webster et al. ob-
served that the prevalence of retinal tumours did not increase in older VHL patients.35,41
If there were a lifelong risk of retinal somatic mutation and subsequent ocular haem-
angioblastoma formation, then the prevalence of ocular tumours would be expected to
Fig. 2 Sagittal section of the
eye, showing the parts most
prone to haemangioblastoma
(retina, optical disc and the
optical nerve). The percent-
ages refer to the relative fre-
quency of tumours found in
the corresponding anatomi-
cal region.
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increase with age. They therefore suggested that the development of retinal haeman-
gioblastoma may be determined, as in retinoblastoma, at an early age.35,41
Diagnosis is made by ophthalmological examination, measuring visual acuity,
slit lamp examination, and fundoscopy. If haemangioblastomas are present or sus-
pected in the far periphery of the retina, inspection with a Goldmann three-mirror lens
can be performed. Additional fluorescein angiography is sometimes indicated. Many
different modes of therapy have been used to treat peripheral retinal haemangioblas-
tomas: diathermic-, xenon-, laser- and cryocoagulation. All have been reported effec-
tive depending on the location, size and number of the tumours. Decisions on treat-
ment are often difficult and sometimes only follow-up observations may be justified.
Diagnosis and treatment are described in more detail in section 2.3.34
1.3.2 Central nervous system haemangioblastoma
Central nervous system (CNS) haemangioblastoma in VHL disease arise preferen-
tially in the cerebellum (~ 75%), medulla oblongata (~ 10%), and spinal cord (~ 15%),
but are rare in the cerebrum (1%), see Fig. 3.4,33,42,43 Tumours located in the cerebellum
are mainly found in the hemispheres, or less frequently in the vermis.33 Spinal tu-
mours are essentially intradural and are most commonly found at the level of cervical
and lumbar bulges (Fig. 4).33
Fig. 3 Dorsal and lateral view of the central nervous system, showing hot spots and relative fre-
quency of occurrence of haemangioblastoma in VHL patients.
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Clinical symptoms depend on the site and size of the CNS haemangioblas-
toma.5,33,42,44 Headache is the most frequent initial symptom in cerebellar haemangiob-
lastoma. In cases with symptoms at diagnosis, headache, nausea, vomiting, ataxia and
dizziness occur most often. In addition, dysarthria, dysgraphia, ptosis, motor deficits,
sixth nerve palsy, sensory deficit and impaired hearing have also been described.42
Pain is the most common symptom in spinal haemangioblastoma and symptoms are
related to compression effects.
In approximately 40% of VHL patients, CNS haemangioblastoma is found to be
the presenting manifestation of VHL.33 The mean age at diagnosis is 30 years2,33,45
Haemangioblastoma are regarded as benign and slow-growing tumours that do not
normally invade the surrounding brain. However, complications may arise due to the
tumour’s tendency to form expanding cysts.33,37 Cerebellar shift may lead to hernia-
tion of the cerebellar tonsils through the foramen magnum and subsequently elevated
or even life-threatening intracranial pressure. Hydrocephalus may result in rapid de-
compensation with papilloedema.33 Cerebellar haemangioblastoma remain a major
cause of morbidity and mortality in VHL.3-5,33,42,46
Pathologically, haemangioblastoma are composed predominantly of vascular and
stromal cells.37,47 Allelic losses and mutations of the VHL tumour suppressor gene
have been found in stromal cells, suggesting that these cells represent the neoplastic
component of a haemangioblastoma.47,48 Mast cells are often abundant and their pres-
ence is helpful in diagnosis.33 The frequent presence of haemorrhages and cysts make
the morphological appearance of the tumours variable.37 Four macroscopic types of
haemangioblastoma can be individualised: 5% are cysts, 60% predominantly cystic,
26% predominantly solid, and 9% solid.33 The most frequently observed tumour is a
small solid lesion within a cystic nidus (Fig. 4).
Fig. 4 Comparison of MRI (left) and CT (right) of a typical haemangioblastoma in a VHL patient.
Both arrows indicate a cystic lesion with a solid lesion attached to the wall. This lesion is also called
nidus (i.e. Latin for nest) since the image resembles a bird’s nest with an egg.
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The method of choice for early diagnosis and follow-up examination of CNS
haemangioblastoma is gadolinium-enhanced magnetic resonance imaging (MRI)44,49
The tumours appear as a low signal on T1-weighted images and as a high signal on
T2-weighted images.
The standard treatment is complete microsurgical removal,33,42,50 aided if neces-
sary by preoperative embolisation to reduce the tumour’s vascularity.51 The prognosis
of VHL patients with CNS haemangioblastoma has improved by atraumatic micro-
surgery and progress in intensive care, but the possibility of development of other
VHL-related tumours is still a major problem.33 Postoperative mortality is 7-10% and
is higher in brainstem localisations.44,45,49 In cases of spinal haemangioblastoma, para-
plegia is the main risk of neurosurgery, especialy when the diagnosis is delayed.33
Many patients have recurent, difficult operations and CNS haemangioblastoma re-
main the main cause of death together with renal cel carcinoma.2,33,45,52
A new technique, stereotactic radiosurgery, offers the possibility of tackling
multiple cerebellar lesions in a single treatment, which is particularly important in
VHL patients. Essentially, stereotactic radiosurgery hits the tumour with beams of
radiation from hundreds of different angles. Each beam also passes trough normal
tissue, but that tissue gets only a very small dose of radiation. Where the beams meet
at the target site, the tumour gets the sum of dosages of all the beams, the surgical
dose. The recommended surgical dose ranges between 10 and 25 Gray.10,50,53 Dose
escalation above 60 Gray is associated with a significant risk of radiation-associated
neurotoxicity.53 Radiosurgery shrinks or stops the growth of small- or medium-sized
(i.e. smaller than 3 cm) solid haemangioblastoma.10,50,53 Adjoining cysts, however, do
not respond to radiosurgery and require later, sometimes repeated, evacuation.50 Spi-
nal haemangioblastomas are more difficult to target, but with further development of
the stereotactic radiosurgery it is anticipated that tumours of the thoracic and lumbar
spine will also be treatable with this technology.10
Finally, erythrocytosis (or polycythemia) is associated with the production of
erythropoietin (Epo) by haemangioblastoma in VHL patients.21,54-56 Krieg and co-work-
ers57 demonstrated that preoperative haemoglobin (14.7 vs 13.0 g/L) and haematocrit
levels (43.7% vs 39.2%) were higher in haemangioblastoma patients (both VHL and
non-VHL) than in a control group of patients with glioblastoma, which are not known
to induce erythrocytosis. In addition, in situ hybridisation on snap-frozen haeman-
gioblastomas revealed that stromal cells produced Epo. Since stromal cells are the
neoplastic component in haemangioblastoma,47,48 this suggests that Epo is upregulated
due to loss of VHL function.
1.3.3 Renal carcinoma and cysts
In VHL patients, renal lesions can be divided into three different forms with cystic,
combined cystic-solid, and solid renal cell carcinoma (Fig. 5).58 These renal lesions
occur multiply, bilaterally and at a relatively young age. While renal cell carcinoma in
sporadic patients occurs predominantly in the seventh and eighth decades of life,59 the
mean age of presentation in VHL patients is approximately 36 years.2,4,60-63 Poston et
al.60 found a mean of 7.8 cystic and 3.0 solid renal lesions in VHL patients (with a
mean age at diagnosis of 36 years), which is in agreement with other studies.5,58
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Fig. 5 The developmental stages from a renal cyst to a metastasing renal cell carcinoma. A Simple
renal cyst; B Magnification of the cyst, demonstrating proliferative cells in the cystic wall; C Inter-
mediate stage between a cyst and renal cell carcinoma, the tumour is still within a capsule; D Renal
cell carcinoma breaking through the capsule and metastases migrating via neighbouring blood ves-
sels.
Radiological aspects of kidneys in VHL patients are extensively discussed in
section 2.1. Some monitoring protocols recommend yearly alternate CT and ultra-
sound examinations to reduce both costs and exposure to radiation.71 In our opinion,
careful cross-sectional monitoring with alternate MRI and ultrasound gives the best
protection from aggressive renal cell carcinoma in most VHL patients.
The prognosis of patients with presymptomatically diagnosed renal tumours is
significantly better than that of patients with symptomatic lesions.8 Renal cysts are
usually asymptomatic, whereas renal cell carcinoma may present with haematuria or
with back pain. Renal cell carcinoma is the cause of death in 15-50% of VHL pa-
tients,2,5,6 and 30-50% of symptomatic renal cell carcinoma have already metastasised
to lymph nodes, liver, bone, lung or brain.3,21,64,65 Fortunately, nowadays, most renal
tumours are detected by periodical monitoring of VHL patients.
Pathologically, renal cell carcinoma is a malignant epithelial tumour of the renal
parenchyma and is often found in the renal cortex (Fig. 6). The tumour tissue is fre-
quently crowded with recent and old haemorrhages, necrosis and inflammation, and
is surrounded by a pseudocapsule.66,67 The most common cellular pattern is clear cell
carcinoma,68 arising from cells of the proximal tubuli.69 Microdissection of material
from individual lesions has shown that loss of the wild-type allele and retention of the
inherited, mutated VHL allele occurs both in cystic lesions and in renal cell carci-
noma.70 This clearly demonstrates that cysts are precursors for renal cell carcinoma
(Fig. 5).
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Options for treatment of renal lesions in VHL patients are considered in section
2.2. Recommendations range from bilateral nephrectomy to follow-up investigations
only. If both kidneys are affected with multiple cysts and tumours, a difficult decision
has to be made between radical nephrectomy or nephron-sparing surgery. This deci-
sion depends on risk factors (size, progression, capsule involvement and whether the
tumour is symptomatic) for metastatic spread. Management of metastatic lesions is a
difficult problem, since their response to chemotherapy and radiotherapy is poor. In
1999, the first report of a prospective analysis on treatment of renal cell carcinoma in
VHL patients appeared. Walther et al. evaluated 52 VHL patients who were operated
on with renal cell carcinoma smaller than 3 cm (group 1) and 44 patients who were
operated on with tumours larger than 3 cm (group 2).63 Median follow-up was five
years. In group 1 96% underwent nephron-sparing surgery, and 63% in group 2. The
remaining patients underwent a nephrectomy. No metastases occurred in group 1,
whereas 25% of the patients in group 2 developed metastatic renal cancer. The au-
thors concluded that using a 3 cm threshold as the upper limit for performing neph-
ron-sparing surgery may help to prevent metastases, and avoid unnecessary renal dam-
age due to frequent surgery, and renal dialysis or transplantation.
Fig. 6 The devastating effect of symptomatic renal cell carcinoma in the left kidney of a 42 year old
male VHL patient (B is a section through A). A and B  A small rim of normal renal tissue is visible
(B, arrow). The kidney contained 2 large cystic multiloculated tumours (14 x 10 x 8.5 and 7 x 6.5 x
5 cm) and 8 smaller lesions ranging from 0.6 to 3.0 cm. The large cystic tumours are well encapsu-
lated. In the cortex of the kidney a 0.5 cm vascular tumour was found (not visible in this figure)
resembling a haemangioblastoma. Microscopy showed clear cell carcinoma in both large lesions as
well as in the vascular tumour.
C Left kidney of a 45 year old female VHL patient. This patient was diagnosed with a symptomatic
phaeochromocytoma (small arrow), and on radiological examination a renal lesion (large arrow)
measuring ~3 cm was detected. Subsequent angiography indicated that the localisation and vascular
pattern made it impossible to perform nephron-sparing surgery. She underwent a nephrectomy and
the left adrenal gland was removed in the same session. The lesion measured 26 x 21 mm and was
growing into the perinephric fat. A cyst of 9 mm protruded from the tumour, and another cyst of 9
mm was present inside the lesion. The tumour was haemorraghic and had a thin grey capsule. In
addition, the renal cortex contained a cyst of 10 x 5 mm (not visible in this figure). The phaeo-
chromocytoma measured 6 x 5 x 4cm.
A B C
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1.3.4 Phaeochromocytoma
The first reports of phaeochromocytoma in VHL disease appeared in the 1950s.19,20
This catecholamine-secreting tumour originates from chromaffin cells of the neural
crest (paraganglion). Paraganglionic tissue is dispersed from the base of the skull to
the pelvic diaphragm. In 10-20% of the cases paraganglioma derive from extra-adre-
nal neural crest tissues that reside along the aorta (close to the sympathetic and
parasympathetic nervous system).72 The term phaeochromocytoma (paraganglioma
medullare) is officially reserved for tumours that arise in the adrenal medulla. How-
ever, most reports use the terms phaeochromocytoma and extra-adrenal phaeo-
chromocytoma.
Extra-adrenal paraganglioma have been reported in 12% of VHL patients.73 The
report of a thoracic paraganglioma in 1982 was the first on the occurrence of these
tumours outside the abdomen in VHL disease. In 1997 Bender et al.74 found VHL
gene germline mutations in three out of five patients with functioning thoracic gang-
lioma. Further extra-abdominal paraganglioma in VHL patients have been reported in
the carotid body and the sella turcica.75-78
Phaeochromocytoma (and paraganglioma) may cause hypertension or paroxys-
mal unstable blood pressure and symptoms such as headaches (67%), palpitations
(44%), chest discomfort (39%), flushing, sweating attacks, postural dizziness, and
pallor.79 In VHL patients, phaeochromocytoma often remain quiescent or produce few
symptoms, and investigation may show normal biochemical tests.80 However, the be-
haviour of phaeochromocytoma remains unpredictable; biologically inactive lesions
may suddenly become dangerous, or benign phaeochromocytoma may become ma-
lignant.81 About 5% of VHL patients die from phaeochromocytoma-induced endog-
enous catecholamine intoxication, which has also caused fatal pregnancy outcome
(for both mother and child).82-84
There is strong evidence that the presence or absence of phaeochromocytoma is
correlated with the type of VHL germline mutation (see genotype-phenotype correla-
tions, 1.5.6). Phaeochromocytoma may occur in a large range (0-58%) of affected
members within a family.4,5,58,85-88 Beside this clear interfamilial difference, intrafamilial
differences have also been observed.
VHL-associated phaeochromocytoma differs from isolated phaeochromocytoma
in sporadic patients in having a younger age of onset (on average 19 years earlier),
multiple lesions, and a very low proportion of malignant tumours.89 The mean age at
phaeochromocytoma diagnosis is 28 years,5,89,90 with the youngest reported patient
being five years old.90
Diagnosis is based on biochemical tests and radiology. Laboratory tests may
include serum and urine evaluation of: epinephrines, norepinephrines, nephrines,
metanephrines and urinary vanillylmandelic acid.80,89  Measurement of plasma
normetanephrine is the most sensitive test and detects 97% of the tumours in pa-
tients.80 However, this test is not the most suitable for annual monitoring of VHL
patients. It requires an intravenous canula in the forearm and patients must rest 15
minutes in a supine position before blood samples can be collected. Measurement of
24-hour urinary norepinephrine excretion is the next most sensitive of the biochemi-
cal tests and is less of a burden to the patient. Radiology testing may include ultra-
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sound, CT, MRI, and metaiodobenzylguanidine (MIBG) scintigraphy as described in
section 2.1.
Adrenalectomy is the standard treatment for phaeochromocytoma. Operative
treatment can be considered in symptomatic phaeochromocytoma or if a growing mass
in the adrenal gland is present (Fig. 6). Satisfactory results have been reported from
laparoscopic removal of adrenal tumours, both in non-VHL patients91-93 and in VHL
patients. 94 Since bilateral tumours develop in 47% of VHL patients with
phaeochromocytoma, most patients become dependent on steroids after bilateral
adrenalectomy.95 Enucleation rather than adrenalectomy is therefore recommended
by an increasing number of surgeons.95,96. Adrenal-sparing surgery is safe, effective
and can preserve adrenal function in VHL patients.
1.3.5.1 Pancreatic cysts and cystadenoma
The incidence of pancreatic involvement varies in VHL families from 0-56% of af-
fected family members.3,5,97-99 In a review of 275 reported cases, 69 (25%) patients had
cysts, 4 (1.5%) of which proved to be serous cystadenoma, 14 (5%) cases had islet
cell tumours, 2 (0.7%) adenocarcinoma, and 1 patient had an haemangio-endothe-
lioma.100 Pancreatic lesions may be the only abdominal manifestation in VHL (12%)
and may precede any other manifestation98. The earliest age of discovery reported is
15 years.101 Cystadenomas, like cysts, contain serous fluid and are benign in VHL
disease.71,97
Pancreatic cyst formation is found in 70-72% of VHL patients at autopsy3,102.
Cysts are often multiple and enlarge the pancreas,97 or may eventually replace the
entire gland.103 Complications can arise from space-occupying effects (local pain, bile
duct obstruction, pancreatitis), while exocrine and endocrine hormonal insufficiency
may occur.21,71,97,99,100,104-107 .
Different imaging techniques, such as ultrasound, MRI, and CT, have compara-
ble diagnostic value.108 Ultrasound is therefore the method of choice for monitoring
programs.97 However, for identifying smaller solid lesions, CT scanning or MRI may
be superior to ultrasound.58,108 Radiological diagnosis of pancreatic lesions is speci-
fied in section 2.1.
Since the disease is usually asymptomatic, conservative measures are consid-
ered adequate for cystic lesions.97,100 However, aggressive resection is mandatory for a
solid pancreatic lesion in VHL.100 Patients with space-occupying cysts have been treated
with percutaneous drainage and hypertonic saline sclerosis.71 Cholestatic jaundice may
be treated by endoscopic implantation of a biliary stent,109 or a biliary bypass.100
1.3.5.2 Pancreatic (neuroendocrine) islet cell tumours
Solid islet cell tumours may occur in 5-17% of patients100,110,111 and may be unrelated
to pancreatic cystic disease.71 Familial islet cell tumours in VHL were first reported in
1979.99 The mean age at diagnosis of islet cell tumours in VHL patients is 36 years,
and many lesions are slow-growing, asymptomatic and do not generally lead to raised
pancreatic hormone levels.71,99,110,111 Immunostaining of 23 pancreatic lesions, which
were all non-functional, demonstrated focal positivity for pancreatic polypeptide (6/
23), somatostatin (4/23), insulin (2/23) and/or glucagon (1/23) in 35% of the tumours.112
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Libutti et al.111 reported that 5 out of 17 VHL patients (from a series of 256 VHL
patients) with neuroendocrine tumours were found to have metastatic disease of the
pancreas, of whom two died as a result of extensive liver involvement. The size of the
primary pancreatic tumour in patients with liver metastasis was significantly larger
than in patients without liver metastasis (5 cm vs 2 cm).
Pancreatic islet cell tumours occur more frequently in patients with phaeo-
chromocytoma and may be considered as an additional form of the multiple endocrine
neoplastic syndromes.71,99,110,111 Islet cell tumours arise either from pancreatic islet cells,
which are believed to be derived from the neural crest,113 or from a single neuroendo-
crine-programmed ectoblast.114 This might indicate that islet cell tumours share a com-
mon origin with phaeochromocytomas.
Ultrasound shows that benign islet cell tumours are usually well demarcated,
round or oval, and hypoechoic relative to pancreatic parenchyma. Fat-suppressed and
dynamic gadolinium-enhanced MRI is superior to CT in depicting islet cell tumours.115
In VHL patients, an organ-sparing strategy consistent with the managing of re-
nal and adrenal tumours, is advised. Libutti et al.111 have published guidelines for the
management of solid pancreatic tumours in VHL patients. Lesions smaller than 1 cm
must be monitored every 12 months with CT or MRI. Lesions between 1 and 3 cm are
dealt with on a “case by case” assessment. Lesions larger than 3 cm that are sympto-
matic or functional and lesions that are increasing in size are removed. Intra-operative
ultrasound may be useful in identifying focal masses when pancreas-sparing surgery
is being considered.
1.3.6 Endolymphatic sac tumours (ELST)
Endolymphatic sac tumours (ELST) are rare neuroectodermal neoplasms in the petrous
bone, originating from inner ear structures.116 It was only recently recognised that
ELST is also a manifestation of VHL disease.117-121 Interestingly, the first patient de-
scribed by Von Hippel had a tumour of the petrous bone.13 An assessment after MRI
screening revealed the prevalence of ELST in 121 VHL patients to be 11%. This
figure may be an underestimate since 65% of these patients had pure tone threshold
abnormalities on audiometry, of whom 54% of those affected showed bilateral abnor-
malities.120
Macroscopically, the ELST presents itself as a reddish blue tumour from the
labyrinthal compartment of the temporal bone, resembling a haemangioma.121 Heffner
qualified the tumour as a low-grade adenocarcinoma of probable endolymphatic ori-
gin.122 These findings have been questioned by Pollak et al.121, who found in a VHL
patient that this tumour originated from the mucosa of the pneumatic spaces surrounding
the jugular bulb and that it was a benign tumour, i.e. papillary adenoma on histopatho-
logical examination.
Clinical findings in ELST patients include hearing loss, tinnitus and vertigo.120
Hearing loss may in fact represent one of the first clinical findings of VHL. ELST
may also show symptoms that are related to structures in the cerebello-pontine angle.
Involvement of the nervus facialis, causing facial paresis and ataxia or disequilibrium
have been reported.120,123
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Middle ear adenomas (MEA) are the principle tumours in differential diagnosis.
ELST and MEA share several features, including histological appearance.116 How-
ever, MEA are restricted to the middle ear and do not normally erode the bone, which
makes it possible to distinguish them radiologically.120,123 Both MRI and CT are used
in identifying ELSTs.120,121
Although, ELST are not known to metastasise and tumour growth is slow, clinical
(audiological tests) and radiological monitoring is indicated.120 Early detection is cru-
cial because early surgical therapy may prevent hearing deficits from progressing.116
1.3.7 Epididymal cysts and cystadenoma
In the epididymis simple cysts and cystadenoma may be encountered, although papil-
lary cystadenoma are thought to represent the VHL specific component. Epididymal
cysts, closely resembling renal cell carcinomas were first described by Lindau in
1927.124 Epididymal tumours have been observed in up to 50% of the males in one
VHL family,5 and bilateral epididymal cystadenoma have been reported in some fami-
lies.5,125-128 However, epididymal cysts are relatively common in the normal popula-
tion, 29% of 40 healthy volunteers had one or more lesions on high-resolution scrotal
sonography.129
Epididymal lesions are comprised of cuboidal and columnar cells with clear
cytoplasm lining tubular and cystic spaces and the intervening stroma is highly vascu-
lar.130 Histopathologically, epididymal cystadenoma resemble metastases from renal
cell carcinoma and can be distinguished by immunohistochemistry studies. 130,131 The
probable origin of these lesions is from epididymal duct epithelium,131 that arises from
the embryonic mesonephric duct (see also section 1.3.8). A somatic VHL mutation
was observed in an epididymal cystadenoma of a non-VHL patient, indicating that
VHL gene mutations play a role in the initiation of tumourigenesis.130 High levels of
VEGF mRNA are expressed in the clear cells of epididymal cystadenoma. Leung et
al.132 postulated that elevated VEGF levels may account for cyst formation and also
for the vascularised stroma in these lesions.
The lesions may be detected by manual examination or ultrasound. Choyke et
al.133 demonstrated by sonography that 54% of male patients with VHL had a unilat-
eral (33%) or bilateral (67%) solid abnormality in the head of the epididymis sugges-
tive of epididymal cystadenoma. Sonographic appearances ranged from a solid mass
with multiple tiny cysts to an almost completely solid mass. Bilateral tumours may
lead to oligozoospermia, low ejaculate volume,128 and may even impair fertility by
obstructing the seminiferous ducts.125,127 Surgery is not known to improve fertility in
affected patients.88 Close clinical monitoring is therefore indicated to enable
presymptomatic treatment.
1.3.8 Adnexal papillary tumour of probable mesonephric origin (APMO)
APMO is regarded as the female counterpart of the cystadenoma of the epididymis. In
men, the mesonephric duct stays intact and functional, whereas in women, the duct
system is a remnant (Fig. 7). APMOs arise from mesonephric (Wolffian) remnants in
women and may persist within the broad ligament (epoophoron and paroophoron) or
along the wall of the uterus (Gartner’s duct) or posterior vagina (Gartner’s duct cysts).134
The APMO is histologically similar to epididymal cystadenoma in VHL disease.135
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So far, APMO has been reported only as case reports,31,135-138 including one Dutch
patient.81. In 1997, a comprehensive study of the literature showed that all cases with
APMO described thus far arose in patients with VHL.135 This association indicates
that the APMO may represent a pathognomic visceral manifestation of VHL disease.
Patients with APMO may present with pain in the lower abdomen.138 When asymp-
tomatic, the tumour can be detected either during a routine physical exam,135 as an
incidental finding during surgery137, or using radiological tools.
1.3.9 Other lesions
Many other lesions have been reported in VHL patients (see table 1). Typical VHL-
related lesions include cysts, cystadenoma, angioma, haemangioma and haemangiob-
lastoma and they have been reported in liver, spleen, adrenal gland, lungs, skin and
bones.3,21,139,140 Haemangioblastoma of the optical nerve has been reported relatively
frequently141-145, and also in further supratentorial locations.146-149
In addition, various atypical, non-VHL-related tumours have been reported in
VHL patients. Among these lesions are: naevi, café au lait spots, parotid carcinoma,
thyroid carcinoma, pituitary adenoma, carcinoid, and testicular germ cell tumour.4,21,150-
155 In the central nervous system epidermoid, ependymoma, astrocytoma, choroid plexus
papilloma and neuroblastoma have been reported.3,42,148,156-159
One can argue whether all these lesions should indeed be associated with VHL
disease. On one hand, the VHL protein is widely expressed in normal human tis-
sues,160-162 even in organs not at risk for the disease (see 1.6). On the other hand, these
lesions may have risen from embryonic VHL-associated residual tissues, or represent
metastases.88 In our opinion, most lesions mentioned in table 1 probably represent
coincidental findings.
Fig. 7 Ventral view of the female reproductive organs (left) and embryonic tissues (right). The
adnexal papillary tumour of probable mesonephric origin (APMO) arises from mesonephric or
Gardner’s duct remnants and may occur within the broad ligament, along the wall of the uterus or
posterior vagina. O, ovary; T, uterine tube; U, uterus; UC, uterine cervix; V, vagina. The drawings
were made by Frank W. James and kindly provided by Gale James from the VHL Family Alliance.
The figures are based on:
(left) Figure 5.14 in Berek, J.S. et al. (eds) Novak’s Gynaecology, Twelfth edition. Baltimore, Williams
& Wilkins, 1996: p.100.
(right) Figure 13-16 C in Moore, K.L. (ed.) The Developing Human: Clinically Oriented Embryol-
ogy, Second edition. Philadelphia, WB Saunders Co., 1977: p.234 and Figure 22.13 in Skandalakis,
J.E. & Gray, S.W. (eds.) Embryology for Surgeons, Second edition. Baltimore, Williams & Wilkins,
1994: p.826.
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Table 1 A list of tumours rare in VHL patients
Origin Type Reference
Lesions of the CNS ependymoma 3,4
astrocytoma 4,157
meningeoma 4,21
choroid plexus carcinoma 4,158,163
neuroblastoma 4,148,159
syringomyelia 4,164-167
pituitary haemangioblastoma 152
epidermoid 156
neuroectodermal tumour 168
Parotis carcinoma 150
Lung cysts 3,4,21
angioma 3,4
haemangioblastoma 139
oat cell carcinoma 165
Kidney angioma 3
Bladder haemangioblastoma 21
Adrenal gland cortical angioma 3
cortical adenoma 3,21
cortical hyperplasia 3
Liver cysts 3,4,21,81
angioma (haemangioma) 3,4,21
haemangioblastoma 139,140,169
carcinoma 4
adenoma 3,4,21
hepatocellular carcinoma 165
Spleen cysts 3,4
angioma (haemangioma) 4,21
Ovaria angioma 3
Testes germ cell tumour 154,155
Endocrine tumours adenoma of the pituitary gland 4
thyroid medullary carcinoma 4,151,165
pancreatic islet cell carcinoma 4
carcinoid 4,153
Bone haemangioma 3,21
cysts 21
Skin angioma (angioblastoma) 4
nevus 21
café au lait spots 21
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1.4 Diagnostic criteria in VHL disease
Diagnostic criteria for VHL disease has long been based on the classic review of
Melmon and Rosen, published in 1964.21 These criteria were later modified by vari-
ous authors.2,4,7,170 By 1998, VHL disease was considered to be a complex of diag-
noses occurring in: (1) typical families with VHL germline mutations; (2) typical fami-
lies without detectable germline mutations; (3) sporadic cases of VHL disease with-
out germline mutations; (4) sporadic cases of VHL disease and germline mutations;
(5) atypical VHL families with germline mutations; (6) patients with a solitary VHL
tumour and a germline mutation.171
The disease as documented by Lindau in 1926 was defined as an association of
cerebellar haemangioblastoma with one or more of the following lesions: retinal hae-
mangioblastoma, spinal cord haemangioblastoma, pancreatic cysts, renal or epididy-
mal abnormalities. However, Melmon and Rosen considered this definition to be in-
complete since it failed to consider the hereditary character of the disease. They fa-
voured enlarging the diagnosis of Lindau’s disease by including patients with a single
lesion of the Lindau complex (haemangioblastoma, pancreatic cysts, renal or epididy-
mal abnormalities), with at least one other family member with a CNS haemangiob-
lastoma.21 Neumann et al. modified Melmon and Rosen’s criteria in 19874 such that
minimal diagnostic criteria would consist of retinal or CNS haemangioblastoma in a
patient and at least one typical VHL lesion in another immediate family member.88
Eventually, a clear family history was increasingly valued as an important clini-
cal criterium for diagnosing the disease. Certainly influenced by the rising success
rate of detecting VHL gene germline mutations in clinically well-defined VHL fami-
lies, a shift in clinical diagnosis has taken place in recent decades towards cases with
a definite or positive family history. It was therefore suggested that diagnosis of VHL
disease can be made in any patient with a single retinal or cerebellar haemangioblas-
toma, renal cell carcinoma, phaeochromocytoma, or multiple pancreatic cysts, when-
ever a positive family history is present.7 However, Maher et al. noted that apparently
sporadic cases of VHL disease may be under-ascertained as a result of this require-
ment.2 Therefore, a diagnosis can also be made for isolated cases of VHL disease
when two or more haemangioblastoma, or a single haemangioblastoma in association
with a visceral manifestation, are present in a sporadic patient.7
The definition of pathognomic VHL lesions forms another pillar upon which the
clinical diagnosis of the disease is based. Which tumours may be regarded as typical
VHL lesions? Glenn et al. defined a list of clinical situations leading to suspicion of
VHL disease and a evaluation of typical VHL-related tumours (Fig. 1).170 Recently,
bilateral ELSTs and the APMO were added to this list.7,31
In conclusion, VHL disease can be diagnosed in an at-risk family member with
a typical VHL lesion in combination with a positive family history. However, no un-
equivocal consensus has been reached for clinical diagnostic criteria in VHL disease.
These criteria are discussed in chapter 4.
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1.5 Genetics
In 1929, Möller was the first to suggest that VHL disease has an autosomal dominant
pattern of inheritance.25 This means that children of a parent who is a carrier of a
mutated VHL gene have a 50% chance of inheriting the disease. Since the disease has
a high penetrance,1,2 a dominant pattern of inheritance can be recognised in the vast
majority of VHL families of significant size. However, there are also VHL patients
without a family history. These sporadic patients probably represent de novo  muta-
tions, somatic mosaicism or non-penetrance in one of the parents. A de novo mutation
is found in 4-15% of the total identified VHL germline mutations.30,172 Data in the
literature on non-penetrance and mosaicism are scarce. Mosaicism has so far been
described in two VHL families,173 and non-penetrance on elder age (> 60 years) is
rare.1,2
1.5.1 The VHL gene
Genes associated with a particular disease are most commonly found by testing af-
fected family members with DNA markers. This technique is based on the concept
that certain chromosomal regions lying in the vicinity of the disease-causing gene
segregate in affected family members. This method is called positional cloning, or
reverse genetics, in contrast to the candidate gene strategy. In positional cloning the
location of the gene in the genome is established on its anticipated function. Using
genetic linkage analysis in large VHL families, the VHL gene was localised in 1988,
and mapped to chromosome region 3p25-26.29 Family linkage studies did not show
any evidence of genetic heterogeneity.29,174 Seizinger’s group was inspired by Zbar et
al.175, who had found loss of alleles of loci on the short arm of chromosome 3 in renal
cell carcinoma, a common manifestation of VHL disease.
Subsequently, tightly linked polymorphic markers in the region 3p25 were iden-
tified.176-179 A decisive step in finding the gene was the identification of large germline
deletions in VHL families. Probes from this region were used for pulsed field gel
electrophoresis.180,181 With one specific probe, Richards et al. found germline dele-
tions of 120 en 50 kb in 2 of 91 probands of VHL families.182 These deletions further
refined the localisation of the VHL disease gene to a small region of chromosome
3p25. Latif et al.30 isolated two genes (called g6 and g7) from the minimally deleted
region of 50 kb. They detected mutations in the g7 open reading frame that followed
transmission of the disease in VHL families and consequently identified g7 as the
VHL disease gene.
The VHL gene covers approximately 14,500 basepairs (bp) of genomic DNA.
The full-length messenger RNA is 4,700 bp.30 The open reading frame is 852 bp long
and contains two intragenic start codons (Met1 and Met54). The protein-coding re-
gion translated from the first start codon (Met1, nucleotides 214-216) encompasses
639 bp, and is divided into three exons of 340, 123, and 179 bp (Fig. 8). The protein
translated from Met54 contains 160 amino acid residues. The two protein products of
the VHL mRNA are described in more detail in section 1.6.1. The promoter of the
gene was identified in 1995.183 With the isolation of the 3' untranslated region in 1996,
together with the known promoter area, exons and introns, the complete sequence of
the human VHL gene was finally identified.184
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Fig. 8 Overview of the VHL gene, showing the three separate exons, the promoter region and the 3’
untranslated region (UTR). The numbers above the exons refer to the numbering of the nucleotides,
measured along the open reading frame. The numbers below refer to the codons. The two arrows
depict the two start codons (Met1 and Met54). The introns 1 (4.4 kb) and 2 (3.2 kb) are shown (not
to scale).
1.5.2 Two-stage mutation model in VHL tumours
The VHL gene is a tumour suppressor gene according to Knudson’s ‘two-hit’ hypoth-
esis: inactivation of both copies of the VHL gene is required for a normal cell to
develop into a tumour cell (Fig. 9).185 In VHL families, germline mutations at the VHL
gene are transmitted from affected individuals to their offspring. Patients inherit a
mutated germline copy of the VHL gene (the ‘first hit’) from the affected parent: they
are heterozygous for the VHL germline defect. The remaining (normal) copy of the
VHL gene is affected by an inactivating event (the ‘second hit’) at the somatic level:
in such a cell, the lack of normal VHL gene product is thought to drive tumourigenesis.
The occurrence of the second hit cannot be predicted and may occur at any age. In
conclusion, whereas VHL manifests as an autosomal dominant trait, it can be consid-
ered as being inherited as a recessive trait at the cellular level.
Evidence for a two-stage model in VHL disease was first delivered by Maher et
al. by statistical analysis of single VHL-related tumours and in tumours in VHL pa-
tients.186 They found that the age incidence curves for cerebellar haemangioblastoma
and renal cell carcinoma in VHL patients were compatible with a single mutation
model in VHL disease, whereas the age incidence curves for patients with either a
single cerebellar haemangioblastoma or renal cell carcinoma suggested a two-stage
mutation process. The mean age at diagnosis of VHL-related tumours was signifi-
cantly younger in VHL patients than in sporadic patients. VHL patients with cerebel-
lar haemangioblastoma were diagnosed at a mean age of 29 years and sporadic pa-
tients at a mean age of 48 years; similarly patients with renal cell carcinoma were
diagnosed at 45 years (VHL patients) and 62 years (sporadic). In 1998, the two-stage
model was also confirmed in retinal haemangioblastoma.187 It was demonstrated that
retinal haemangioblastoma not associated with VHL disease occurred at a later age
than in VHL patients (48 years vs. 25 years). In addition, the age incidence curve for
retinal haemangioblastoma in VHL patients fitted a first-order equation (indicating a
single somatic mutation), whereas solitary haemangioblastoma found in sporadic pa-
tients fitted a second-order equation, suggesting two separate somatic mutations.
For other tumour suppressor genes (for example APC),188 it is generally accepted
that the second mutation arises independently in many sites. This is also illustrated by
studies of genetic changes between primary renal cell carcinoma and metastases. Re-
nal cell carcinoma progression from non-metastatic primary tumours to metastasis is
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driven by an accumulation of genetic changes.189 An evaluation of the clonal relation-
ship between primary and metastatic renal cell carcinoma by comparative genomic
hybridisation revealed losses of chromosome regions 3p, 4q, 6q, 8p and 9p.190 The
most common gains were detected for chromosome regions 17q and Xq. 32% of the
metastases were genetically almost completely different from the primary tumour.
Loss of 3p was detected in 63% of the primary renal cell carcinoma, but in only 25%
of the metastases. It was hypothesised that a second copy of 3p can be regained as a
result of mitotic reduplication of the remaining allele of 3p.191 Such a duplication
could provide a growth advantage by an elevated expression of a putative oncogene
on 3p.
Similar to other tumour suppressor genes, the genotype of each typical VHL
tumour in a VHL patient should arise by a loss of the wild-type VHL allele, while
maintaining the mutated allele.192 Since 1993, VHL-associated tumours could also be
studied on the molecular genetic level. Loss of heterozygosity (LOH, caused by dele-
tion, non-disjunction, somatic recombination, etc.) at the chromosomal VHL locus
(3p) has been demonstrated in: cerebellar and retinal haemangioblastoma,38,47,193 renal
cell carcinoma,70,175 phaeochromocytoma,194 pancreatic microcystic adenoma,195 pan-
creatic (neuroendocrine) islet cell tumours,112 and endolymphatic sac tumours.196
Tumour types that display frequent chromosome 3 allele loss, but which do not
occur in VHL disease (e.g. lung, ovarian, testicular, head and neck, and breast can-
cers), do not have VHL gene mutations.197-199 This suggests that several tumour sup-
pressor genes map to chromosome 3p. So far, no other genes apart from the VHL
gene, have been isolated from this region.200
Fig. 9 The two hit model of the VHL tumour suppressor gene. In cells from carriers of a VHL
germline mutation one additional somatic hit is required for the initiation of tumourigenesis. In a
tumour cell from sporadic patients with a VHL-related tumour two separate somatic hits are in-
volved.
Normal (active) tumour 
suppressor gene 
First “hit” Second “hit” 
Normal cell Tumour cell
Mutant (inactive) tumour 
suppressor gene 
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1.5.3 Detection of mutations in the VHL gene
Methods of detecting germline mutations in VHL patients most commonly include
direct sequencing of the coding region of the VHL gene, Southern blot analysis, and
fluorescence in situ hybridisation (FISH). It was shown that Southern blot analysis
using a control probe was a sensitive method of detecting deletions encompassing the
entire VHL gene (see section 3.2). No point mutations, micro deletions or -insertions
were found in the first 54 or the last 13 codons of the VHL gene (see also Fig. 12). A
hot spot for VHL germline mutations is readily visible in the beginning of exon 3, or
more specifically at nucleotide 712/713 (codon 167). The promoter region and 3’
UTR have been investigated (also in Dutch VHL families, unpublished data), but
failed to reveal any further germline mutations.201,202
In VHL families where the above techniques fail to identify a germline muta-
tion, genetic linkage studies with polymorphic markers and intragenic polymorphisms
may be of help in diagnosing the disease in at-risk family members. The most in-
formative microsatellite markers are D3S1317, D3S1038, D3S587 and D3S1435, which
lie within a 500 kb region of the VHL gene.172 Intragenic polymorphisms lie at the 5’
end of the gene (VHL19A/G),203 and at the 3’UTR region (VHL1149A/G).204 A TaqI
or PstI polymorphism can be identified with Southern blot analysis.205 Olschwang et
al.206 demonstrated that six microsatellite markers surrounding the VHL gene resulted
in an accuracy of risk assessment in 90 of 99 (91%) asymptomatic individuals from
26 VHL families. However, linkage studies cannot be applied in confirming the diag-
nosis in relatives of sporadic cases or in families where the necessary samples are not
available.8
1.5.4 Germline mutations in VHL families
Since the identification of the VHL gene in 1993, the success rate of detecting germline
mutations has gradually risen to 80% in VHL families in 1996.86,202,203,207 By the end of
1998 VHL germline mutation analysis in well-defined families had reached a virtu-
ally 100% success rate in a study performed by the National Cancer Institute and the
University of Pennsylvania in the USA.173 Several groups reported VHL families where
mutation detection failed to identify the disease-causing mutation. However, improve-
ment in mutation detection approaches detected germline mutations in 10 remaining
families from Germany and 14 from Italy. In the Netherlands we have also identified
VHL germline mutations in all the large - with more than two patients - VHL families
(see section 3.1). This supports the concept that VHL is a genetically homogenous
disease with clinically well-defined VHL families.
Many different intragenic VHL germline mutations have been detected (Fig. 10
and 12). Most VHL germline mutations are unique to a small number (one or two) of
families, suggesting that most of these mutations are of recent origin.86 Several recur-
rent VHL mutations were found to occur in multiple, unrelated families (i.e. the pos-
sibility of a founder effect was ruled out).172 Missense mutations are found in 40% of
the families with an identified VHL germline mutation, i.e. a mutation that leads to an
amino acid substitution in the VHL protein product. Large deletions account for one-
third of the germline mutations, of which approximately 30% (or some 10% of all
VHL germline mutations) are deletions encompassing the entire gene. Microdeletions
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(1-18 bp), insertions (1-8 bp), splice site and nonsense mutations predicted to lead to
a truncated protein are found in the rest (i.e. some 27%) of the families.
Fig. 10 Graphical presentation of the
difference between germline mutations
(left) in the VHL gene and somatic mu-
tations (right) found in renal cell carci-
noma from sporadic patients. Please
note that partial and entire deletions of
the VHL gene are not included in these
figures.
A Division of 241 germline mutations
and 181 somatic mutations over the in-
dividual exons (1-3).
B Comparison of germline mutations
with somatic mutations per 100
basepairs (bp) for the three VHL gene
exons. This illustrates a relatively high
frequency of germline mutations in
exon 3 and a hot spot for somatic muta-
tions at exon 2.
C Distribution of type of VHL muta-
tion. Missense mutations form the ma-
jority of germline mutations, whereas a
large proportion of somatic mutations
concern micro-deletions.
1.5.5 Somatic mutation spectrum
In non-familial cancers, tumourigenesis is thought to be initiated by independent so-
matic alteration of both alleles of a tumour suppressor gene (Fig. 9).192 Somatic VHL
gene mutations (57%) and allele loss (98%) are frequent events in clear cell renal cell
carcinoma from sporadic patients198,208,209, but also in central nervous system haeman-
gioblastoma,210-212 suggesting that the VHL tumour suppressor gene plays a role in
their tumourigenesis. Different mutational mechanisms lead to the inactivation of the
VHL gene in renal cell carcinoma, including loss of heterozygosity, small intragenic
mutations, or hypermethylation.213-215 However, somatic VHL mutations are uncom-
mon in phaeochromocytoma.198,216
The distribution of somatic mutations in the VHL gene differs from the distribu-
tion of germline mutations (Fig. 10). In contrast to the germline mutations that are
mainly concentrated in exons 1 and 3,86 a relatively large proportion of the somatic
mutations is clustered in exon 2.198,208,209,217-219 Missense mutations represent 60% of
the germline mutations and 29% of the somatic mutations in the VHL gene (note that
partial and entire deletions of the VHL gene are not included in these figures). Conse-
quently, a relative higher frequency of mutations predicted to result in a truncated
protein are found in somatic mutations (71%) compared to germline mutations (40%).
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1.5.6 Genotype-phenotype correlations in VHL disease
VHL disease exhibits allelic variation, in that many types of mutations, known as
allelic variants, are scattered throughout the VHL gene. From a clinical point of view,
VHL disease is also a variable disorder: inter- as well as intrafamilial variability in the
clinical expression of the disease is common. A clinical classification of four VHL
phenotypes has been proposed, based on the presence or absence of renal carcinoma
and phaeochromocytoma (see table 2).86,203
Table 2 Classification of VHL disease
Type CNS Retinal Renal cell Phaeochromocytoma
haemangioblastoma haemangioblastoma carcinoma
I present present present absent
IIA present present absent present
IIB present present present present
IIC absent absent absent present
There is evidence of relationship, to a limited extent, between the specific VHL
germline mutation (the ‘genotype’) and the clinical manifestation of the disease (the
‘phenotype’). Accordingly, some interfamilial clinical variability in VHL disease can
be explained by differences between the respective VHL germline mutation. In 1996,
Zbar et al. noted that 96% of the VHL families with deletions, microdeletions/inser-
tions, splice site, or nonsense mutations did not manifest phaeochromocytoma (VHL
type I), while 92% of VHL families with phaeochromocytoma (VHL type II) carried
missense mutations in the VHL gene (Fig. 11).86 However, the recent (1998) improve-
ment in methods detecting deletions of the VHL gene using quantitative Southern blot
analysis has revealed that the differences between germline mutations found in VHL
types I and II are not that distinct, but still significant (Fig. 11). Missense mutations
were found in 69% of the VHL type II families and in 27% of the VHL type I fami-
lies.173
VHL type II is divided into three subtypes (A, B and C, see table 2) Most fami-
lies have type IIB, a phenotype with renal cell carcinoma. A few specific missense
mutations lead either to VHL type IIA, a phenotype without renal cell carcinoma;203,207,220
or to IIC, a phenotype with only phaeochromocytoma.82,90,221-227 The monitoring and
management of patients may be adjusted based on knowledge of the specific VHL
mutation. These genotype-phenotype correlations may have not only clinical signifi-
cance, but may also indicate functional domain differences within the VHL gene.
In 1999, the three-dimensional structure of the VHL protein was published (see
section 1.6.1 for more details).228 This study provided structural and functional insights
into the mechanism by which certain missense mutations lead to a phenotype with
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Fig. 11 Mutations found in families
with phaeochromocytoma (left) and
without phaeochromocytoma
(right). The upper pie charts depict
the germline mutation spectrum of
the VHL gene as reported in 1996;86
the lower pie charts show an altered
mutation spectrum after quantitative
Southern blot analysis improved the
detection rate of deletions in the
VHL gene. 173  Families with
phaeochromocytoma have predomi-
nantly (specific) missense muta-
tions, whereas families with all types
of germline mutations (including
missense mutations) have no
phaeochromocytoma.
phaeochromocytoma and others to a phenotype without phaeochromocytoma. VHL
type I (not associated with phaeochromocytoma) missense mutations frequently map
to the beta domain hydrophobic core (Fig. 12), and are thought to cause a complete
unravelling of the VHL protein structure.228 VHL type II (associated with phaeochromo-
cytoma) missense mutations map either to residues that contact Elongin C or to an
area that forms the putative substrate for the ubiquitination binding site (see 1.6.2.2).228
Accordingly, type II mutations are thought to cause mostly local defects and not a
total loss of function. For example, the alpha domain contains the most frequently
mutated amino acid (Arginine 167), which in most families carrying this mutation
results in a phenotype with phaeochromocytoma.86
92%
0% 0%
3%3%
2%
27%
16%
12%3%
3%
39%
69%
8%
4%
0%
0%
19%
35%
14%
6%
15%
5%
25%
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One hypothesis is that the development of phaeochromocytoma may involve a
dominant negative effect of the mutant VHL protein. Since VHL has two protein binding
sites, a mutant having a defect in only one site (for example, binding to Elongin C)
may isolate key components of the biochemical pathway (substrates for ubiquitination)
in which VHL is involved.228 Alternatively, tumourigenesis may be induced by a gain
of VHL function in particular cell types.229 Mutations that lead to a partial loss of
function may ensure the viability of certain cell types, due to a residual function of
VHL. However, if these explanations were true, then the germline mutation in the
VHL gene would be sufficient to cause phaeochromocytoma and a second hit would
not be required for tumourigenesis. Apparently, the product of the VHL gene must
have multiple and tissue-specific functions (see section 1.6.2).200
Nevertheless, patients with identical VHL germline mutations may display dif-
ferent phenotypes, indicating that the issue of genotype-phenotype correlations in VHL
is complex. In 1998, evidence was provided that genetic factors (so called modifier
genes) and environmental influences play an additional role in the clinical expression
of VHL germline mutations, including the occurrence of retinal haemangioblastoma.230
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First-degree family members (sharing half the genome) showed a significant correla-
tion with regard to the number of ocular haemangioblastoma, in contrast to more
distant family members. This suggests that modifying factors are more likely to be
shared between closely related family members than between more distant family
members. Moreover, individuals with ocular haemangioblastoma had a significantly
increased incidence of cerebellar haemangioblastoma and renal cell carcinoma (haz-
ard ratios 2.3 and 4.0, respectively), suggesting that the same modifying factors ap-
pear to influence susceptibility to three of these major VHL manifestations.230
Environmental factors may also influence genotype-phenotype correlations. A
current opinion is that smoking (particularly in males) is correlated with the develop-
ment of renal cell carcinoma.231-233 In addition, there is an increased incidence of renal
cell carcinoma in certain professions (e.g. among workers exposed to asbestos,234
trichloroethene,235 leather workers,236 fire fighters and painters,237) and a correlation
has also been found with obesity and hypertension.232,233Further evidence for the influ-
ence of toxic factors was provided by comparing missense mutations occurring as a
germline mutation in the VHL gene and those occurring as somatic mutations in renal
cell carcinoma from sporadic patients (Fig. 10). In the latter group 68% of the mis-
sense mutations corresponded to transversions, versus 35% for the VHL germline
mutations.219 Since transitions are more common nucleotide substitutions, transversions
may indicate the influence of external factors. These findings support the hypothesis
of the involvement of environmental factors in the aetiology of sporadic renal cell
carcinoma in industrial countries.231,232,236
1.5.7 Germline mutations in sporadic patients with VHL-related tumours
In addition to VHL families a diagnosis of VHL disease should also be considered in
sporadic patients with a VHL-related tumour (see sections 3.3 and 3.4). The diagnosis
of VHL disease is often delayed because patients do not fulfil diagnostic criteria, and
the family history may be cryptic or uninformative. In particular, in patients with
VHL-related tumours that manifest multiply, bilaterally, familial, or at a young age, a
VHL germline mutation may be anticipated.
VHL germline mutations are found in approximately 3% of patients with phaeo-
chromocytoma without family history, and hence isolated tumours.238 A higher per-
centage of VHL germline mutation was found in familial phaeochromocytoma (45%)
and bilateral tumours.239 In patients with a single cerebellar haemangioblastoma ap-
proximately 10% (2 out of 20) of the patients carried a VHL germline mutation.211,240
Germline mutations were identified in 3 of 189 (1.6%) unselected renal cell carci-
noma patients. Once again, the risk was higher in the following clinical situations of
renal cell carcinoma: familial 3 out of 3 (100%); 1 out of 10 patients with bilateral
tumours (10%); and patients younger than 50 years old, 1 out of 33 (3%).241
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1.6 VHL protein (pVHL)
The VHL protein (pVHL) is widely expressed in normal human tissues.160-162 The
pVHL is even expressed in organs not at risk for the disease, suggesting a role for
pVHL that goes beyond the organs involved in the disease. Endothelial cells grown in
various angiogenic conditions (atherosclerotic lesions, tumour metastasis and inflam-
matory processes) strongly express pVHL; however, normal endothelial cells do not.162
In human embryos pVHL was expressed in all three germ layers, with strong expres-
sion noted in the central nervous system, kidneys, testis and lung.242
The intracellular localisation of the pVHL appears to be related to a novel physi-
ological control mechanism: cell density.243,244 In sparse cultures, pVHL is mainly
found in the nucleus, whereas it can be found in the cytoplasm of more confluent
cells. In addition, the subcellular localisation of pVHL is cell-cycle dependent.245 In
G1/G0-phase, pVHL is localised exclusively in the nucleus, whereas the majority of
cells in the S-phase show a diffuse cytoplasmatic staining. It was hypothesised that
pVHL may need to traffic between the nucleus and the cytoplasm to perform its func-
tions.246 Lee et al. found that the trafficking between the two cellular components is
lost with a deletion of exon 2, but not with deletion of other parts of the VHL gene.
1.6.1 Structure of pVHL
The open reading frame of the VHL gene is unlike that of any known gene. In the N-
terminus of this open reading frame there is an acidic pentameric repeat that is some-
what similar to a region of the Trypanosoma brucei membrane protein.30 The corre-
sponding region of the VHL gene is not frequently mutated in VHL families and is not
highly conserved between human and rodents.243,247 In contrast, the C-terminus (down-
stream) part of pVHL is very similar in human and rodents. Many germline mutations
that are thought to lead to a truncated protein occur in the C-terminal part of pVHL,86
and may therefore impair tumour suppression function. This is supported by the find-
ing that VHL proteins mutated in this C-terminus region, in contrast to wild-type
pVHL, are unable to suppress tumour formation when introduced in renal carcinoma
cells lacking both copies of the VHL gene.248,249
The VHL gene encodes a 213 amino acid protein with a molecular weight of
about 28-30 kiloDalton (pVHL30).248 A second VHL gene product, with an apparent
molecular weight of 18 kiloDalton (pVHL18), arises from alternate translation initia-
tion at a second start codon (Met54) within the VHL open reading frame.250-252 It was
ruled out that the VHL18 was a proteolytic fragment of pVHL30, or that pVHL18
arises because of alternative splicing.251 pVHL30 is predominantly found in the cy-
tosol and to a lesser extent in the nucleus or at the cell membranes.160,161,248,253 In con-
trast, pVHL18 is equally distributed between nucleus and cytosol.251 Both VHL gene
products are biologically active. They both bind to the Elongin proteins and they both
inhibit the production of hypoxia-inducible proteins, such as vascular endothelial
growth factor and glucose transporter-1, when introduced into renal carcinoma cells
lacking the wild-type VHL allele.251 Reintroduction of either pVHL30 or pVHL18
into renal carcinoma cells lacking the wild-type VHL allele suppresses their ability to
form tumours in nude mice. This brings us to the function of the VHL protein: why
does loss of function of the VHL gene give rise to tumours?
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1.6.2 Possible functions of pVHL
Based upon its direct role in the initiation of both familial and isolated renal tumours
(see 1.5.2), VHL is considered to be a ‘gatekeeper’ gene in renal cells.254 According to
Kinzler and Vogelstein, gatekeepers are genes that directly regulate the growth of
tumours by inhibiting growth or death.254 Each cell type has only one (or a few) gate-
keepers. Inactivation of a given gatekeeper leads to a the very specific tissue distribu-
tion of cancer. By microdissecting material from individual lesions it has been shown
that loss of the wild-type allele and retention of the inherited, mutated VHL allele
occurs in both cystic lesions and renal cell carcinoma from VHL patients.70
Several studies have addressed the identification of the normal physiological
functions of the VHL gene and its protein product by investigating proteins that are
capable of binding to pVHL.
1.6.2.1 pVHL and transcription elongation
The interaction of pVHL with the Elongins C and B has provided a possible clue
about the normal function of the VHL protein. Based on in vitro studies, it has been
postulated that pVHL plays a role in regulating the transcription elongation.243,255-258
Transcription (the process of reading off DNA sequence by a polymerase and creating
a corresponding RNA) elongation is mediated by the initiation factor RNA polymer-
ase II. When normal pVHL is present in the cell, binding of pVHL to Elongins C and
B (VCB complex), causes RNA polymerase to pause during transcription at several
sites along a gene. Most of the tumour-derived mutations destabilise the VCB com-
plex.255,256,259,260 Failure by pVHL to sequester Elongins C and B may result in interfer-
ence with elongation control mechanisms, leading to upregulation of specific target
genes. At this stage in 1995, it was unknown which gene products where regulated at
the transcription level by this mechanism, or how the absence of functional pVHL
may have influenced other proteins.
By transfecting rat phaeochromocytoma cells with either wild-type or mutant
human pVHL it was demonstrated, for the first time in vivo, that regulation of tran-
script elongation is pVHL-dependent.261 These two VHL proteins have an opposite
effect on regulating the expression of the tyrosine hydroxylase (TH) gene, that is a
rate-limiting enzyme in catecholamine synthesis. Whereas the wild-type pVHL leads
to a five-fold repression of levels of TH mRNA and protein, a truncated (1-115) pVHL
induced a three-fold accumulation of TH mRNA and protein.261 The investigators dem-
onstrated that in the presence of wild-type pVHL, the TH gene is repressed by inhibi-
tion of RNA elongation. During this elongation pause the pVHL is sequestered by the
Elongins B and C. In contrast, the mutant pVHL stimulates TH gene expression by
increasing the efficiency of TH transcript elongation. Moreover, this study confirmed
the anticipated dominant negative activity of pVHL mutants in phaeochromocytoma
cells.261
1.6.2.2 pVHL and ubiquitination
In 1999 Stebbins et al. studied the three-dimensional structure of the VCB complex
by co-expressing the three proteins in Escherichia coli.228 In the structure of this ter-
nary complex, Elongin C binds Elongin B and VHL on two separate binding sites,
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whereas Elongin B and VHL do not interact (Fig. 13). The VCB complex binds, in its
turn, to Cullin2 (Cul2).253,260 Elongin C and Cul2 are similar to two yeast proteins, Skp
1 and Cdc53, respectively.228,253,262 These latter proteins form multi-protein complexes
with adapter subunits called F-box proteins that recognise different substrates through
specific protein-protein interaction domains.263 These SCF (i.e. Skp1-Cdc53/Cul1-
Fbox) complexes target other proteins in the cell for degradation via a process called
ubiquitination. In this process the target is bound by a protein called ubiquitin, that
labels a protein to be degraded. The destruction itself takes place inside a proteasome,
a protein-digesting complex. Interestingly, Elongin B proved also to harbour an
ubiquitin-like structure.260,264 So far, no other proteins than Elongin C have been found
that bind Elongin B.265
Fig. 12 Spectra of VHL gene mutations (deletions are not shown) related to functional domains. The
sequence of the amino acids is depicted (between the lines) with germline mutations (top) and so-
matic mutations (bottom) in the VHL gene. The germline mutation data derive from VHL families
reported by Zbar et al.86, the somatic mutations derive from various studies on renal cell carcinoma
found in sporadic patients.198,208,209,217-219 The position of each mutation in the coding region is de-
picted by a symbol representing the specific mutation (see legend). The mutations are pooled per 10
nucleotides. Mutations that are located close to the intron-exon boundaries, for example splice site
mutations, are placed in their exon of origin.
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The VCB complex targets substrates for degradation. Boxes around the amino
acids indicate residues that make contact with Elongin C (Fig. 12). The VHL gene has
two functional domains: a domain rich in beta-sheets (beta-domain) and a smaller
alpha-helical domain (alpha-domain). The beta domain harbours a spot that binds a,
so far unknown, substrate of the VCB complex. A large portion of the alpha-domain
and a small portion of the beta-domain interact with Elongin C. Mutations in exon 1
and 2 may affect the binding to substrates by the VCB complex, which are conjugated
to ubiquitin for degradation. Mutations in exon 3 would disassemble the VCB com-
plex. In either case, the substrates would no longer be targeted for degradation.262
The pVHL has two domains: a ~100 amino acids long beta-sheet domain and a
~35 amino acids long alpha-helical domain (Fig. 12).228 The so-called SOCS-box (a
sequence motif identified in the suppressor of cytokine signaling-1 (SOCS-1) protein
sequence motif) in the alpha domain is the key contact to Elongin C.266 Thus, the alpha
domain binds to Elongin C which, in turn, binds to Elongin B and Cul2. The beta
domain is thought to be the place where the target protein binds. About half of the
mutations found in tumours map to the alpha domain and its specific residues that
contact Elongin C, while other mutations affect mainly the beta domain.
Kamura et al. presented further evidence for the role of pVHL in ubiquitination.267
It was shown that endogenous VHL complex in rat liver also includes Rbx1, an evolu-
tionary conserved protein that interacts with Cullins. Rbx1 regulates SCF to degrade
proteins.
However, the substrate that would be degraded by the VCB-Cul2-complex is not
yet known. Since VHL disease is characterised by the development of extremely vas-
cularised tumours, factors that are involved in angiogenesis are suitable candidates.
1.6.2.3 Ubiquitination and hypoxia-inducible mRNAs
Possible substrates that are targets for ubiquitination by the VCB complex include
mRNA-binding proteins that regulate the stability of hypoxia-inducible factors, such
as: vascular endothelial growth factor (VEGF), platelet-derived growth factor-beta,
and glucose transporter-1, or the hypoxia-inducible transcription factor HIF-1alpha
regulated by ubiquitin-dependent degradation.262
In VHL patients, not only haemangioblastoma but also renal cell carcinoma show
an abundance of blood vessels. The well-vascularised phenotype of these VHL tu-
mours suggests that inactivation of the VHL gene induces either upregulation of an
angiogenic factor or downregulation of an inhibitor of angiogenesis.268 In 1995, evi-
dence was found that VEGF was upregulated in VHL-associated haemangioblastoma269
Benjamin and Keshet demonstrated that expression of VEGF in a mouse brain causes
blood vessels to proliferate and form a haemangioblastoma-like structure.270 Overpro-
duction of VEGF mRNA is a feature of many human cancers and has been primarily
linked to hypoxia. However, renal cell carcinoma lacking functional pVHL produce
high levels of hypoxia-inducible mRNAs, such as the mRNA encoding VEGF, under
hypoxic as well as normoxic conditions.249,271,272 This means that cells lacking pVHL
act as though they are deprived of oxygen, whether they are or not.265
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Hence, the highly vascular nature of VHL-associated neoplasms may be due, in
part, to dysregulation of hypoxia-inducible mRNAs following loss of function of the
VHL protein. A paradoxical finding in this respect was that a ‘knock-out’ (with two
inactive VHL alleles) mouse model died in utero between 10.5 and 12.5 days of ges-
tation, most likely due to an impairment of placental vasculogenesis.273
Maxwell and co-workers showed that pVHL binds to two transcription factors,
hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha, and targets them for destruc-
tion.274 These proteins are transcription factors that regulate production of mRNAs for
hypoxia-inducible factors as VEGF.275 The alpha-subunits of HIF are rapidly degraded
by the proteasome under normal conditions, but are stabilised by hypoxia.276 In VHL-
defective cells, HIF-alpha-subunits are stabilised (i.e. not degraded) in well-oxygen-
ated conditions. When normal pVHL is introduced, oxygen-dependent instability is
again restored, leading to degradation of HIF. Maxwell et al. concluded that constitu-
tive HIF activation may underlie the angiogenic phenotype of VHL-related tumours.274
Fig. 13 Molecular basis of VHL disease (Dr. W.G. Kaelin, Jr.), reprinted with permission from
Nature265 copyright (1999) Macmillan Magazines Ltd.
pVHL binds to Elongin C, Elongin B, Cullin2, Rbx1 and E2 (an unknown ubiquitin-conjugating
enzyme), and forms a VCB complex. This complex degrades alpha subunits of hypoxia-inducible
factor (HIF) in an oxygen-dependent manner. So far, it is unknown whether VCB complex directly
or indirectly binds to HIF. Degradation takes place in a proteasome via ubiquitination. Cells that
lack pVHL do not degrade HIF in response to oxygen. Normally HIF controls the production of
factors that promote formation of blood vessels. In the presence of a defective VCB complex, HIF is
not degraded and results in uncontrolled proliferation of blood vessels.
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1.6.2.4 Interaction with fibronectin
Ohh et al. showed that pVHL also interacts with fibronectin.277 Fibronectin is nor-
mally found in the extracellular matrix of cells where it can interact with the surface
receptors of other cells. Cancer cells characteristically produce low levels of fibronectin
and fibronectin matrix involvement in contact inhibition and metastasis has been sug-
gested.278-280 Fibroblasts from both VHL knock-out mice as wells as tumour cells missing
both VHL alleles failed to assemble a fibronectin matrix.277 Reintroduction of the
wild-type pVHL partially corrected this defect. This observation would suggest that
the fibronectin interaction of pVHL might also be related to its tumour suppressor
activity.200
1.6.2.5 Other pVHL-binding proteins
In addition, other proteins have been found that bind or are associated with pVHL, but
to which no functional significance could be attributed. These include: VHL binding
protein 1 (VBP-1)281, transcription factor Sp1282, and protein kinase C (PKC).283,284 It
remains to be elucidated whether these observations indeed represent biologically
significant interactions.
1.6.2.6 Other downstream targets of pVHL
pVHL regulates, at least indirectly, the levels of variety of mRNAs other than hy-
poxia-inducible ones such as VEGF. These include: a glucose transporter (GLUT1),
transforming growth factor alpha (TGF alpha), platelet-derived growth factor B
(PDGFb) and carbonic anhydrases (CA 9 and 12).229,271,285 CA9 and CA12 might affect
peritumoural pH and thereby indirectly influence tumour growth.
1.6.3 Anticancer therapy
Neovascularisation appears to be one of the crucial steps in a tumour’s transition from
a small, harmless cluster of mutated cells to a large, malignant growth, capable of
spreading to other organs throughout the body.286,287 Antiangiogenic drugs are being
developed that aim to stop new growth and should, in theory, do no harm to blood
vessels serving normal tissue in which the vascularisation has stabilised. However, an
important disadvantage of antiangiogenic therapy is that it is likely to impact physi-
ological angiogenesis, occurring in processes such as in wound healing and menstrua-
tion. Overproduction of VEGF mRNA is a feature of many human cancers and
vasculogenesis and is vital for the majority of cancers to thrive.288,289 Accordingly,
manipulation of pVHL and its associated proteins is a potentially productive area for
developing anticancer therapies. Although pVHL may be directly responsible for a
So the simplest model would be one in which pVHL, through its association
with Elongin B, Elongin C and Cul2, regulates the stability of HIF-1 and -2265 (Fig.
13). If these proteins are not degraded, the result is excessive formation of blood
vessels. However, important questions remain. Is HIF the substrate of pVHL and does
the VCB complex thereby ubiquitinate HIF? Does pVHL bind HIF directly or indi-
rectly and does the VCB complex also bind other proteins? Moreover, how can the
VEGF-hypothesis account for the occurrence of cystic lesions in carriers of a VHL
germline mutation?
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rare disease occurring in only ~ 1:40,000 persons, a fundamental understanding of its
function may lead to it playing a significant role in the treatment of a much larger
group of cancer disorders.
Besides pVHL and its associated binding proteins, other compounds have been
proposed for their ability to suppress angiogenesis, particularly in VHL disease.
Angiostatin is a potent inhibitor angiogenesis, it reduces tumours to microscopic size
and holds them in a dormant state. Angiostatin is a fragment of a larger protein plas-
minogen, which is not itself antiangiogenic. Thus, when physiological angiogenesis
has to be stopped plasminogen is degraded in order to make angiostatin available.286,287
Additionally, there are two studies being carried out at present on the medical treat-
ment of VHL-related tumours. A team under Dr. William Kaelin of the Dana Farber
Cancer Research Institute is proposing to conduct a clinical trial of a new drug de-
signed to inhibit VEGF (see www.vhl.org). Dr. Gross in Jerusalem, Israel, has demon-
strated that treatment of mice grafted with paraganglioma from a VHL patient with
linomide (quinoline-3-carboxamide) reduced tumour size and weight.31 Histological
examination of the tumours showed marked avascularity and indicated an
antiangiogenic effect of the drug. Safe doses of these drugs still have to be determined
to enable clinical trials with VHL patients.
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Abstract
Von Hippel-Lindau (VHL) disease is a hereditary syndrome characterised by a pre-
disposition for bilateral and multicentric retinal haemangioblastoma, haemangioblas-
toma in the central nervous system, renal cell carcinoma, phaeochromocytoma, islet
cell tumours of the pancreas, and endolymphatic sac tumours, as well as cysts in the
kidney, pancreas and epididymis. This review focuses on developments in the imaging
of renal, adrenal and pancreatic masses in VHL disease. Radiology still has a central
place in managing of VHL disease. Radiologists should therefore be aware of the
importances of magnetic resonance imaging, computed tomography and ultrasound
compared to other radiodiagnostic tools for these three organs. Since a conservative
approach to the treatment of VHL lesions is now becoming more widely accepted,
ongoing follow-up by careful radiological monitoring with ultrasound and especially
magnetic resonance imaging, will play a central role in managing the disease. We also
give an overview of recent advances in the molecular biology of VHL disease because
the combination of imaging with (presymptomatic) DNA analysis has made early
detection and monitoring of lesions possible and led to a reduction of morbidity and
mortality.
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Introduction
Von Hippel-Lindau (VHL) disease is a hereditary syndrome characterised by predis-
position for bilateral and multicentric retinal haemangioblastoma, haemangioblastoma
in the central nervous system, renal cell carcinoma, phaeochromocytoma, islet cell
tumours of the pancreas, and endolymphatic sac tumours, as well as cysts in the kid-
ney, pancreas and epididymis. VHL disease is a relatively rare disease, with an esti-
mated incidence of between 1:31,000 to 1:53,000 in South Baden (Germany) and East
Anglia (Great Britain), respectively.1-3 The disease is inherited as an autosomal domi-
nant trait with a high penetrance (almost complete by 60 years of age) and variable
expression. The basis of familial inheritance of VHL disease is a germline mutation in
a tumour suppressor gene, first identified in 1993.4
Most tumours in VHL patients show typical hereditary features. The tumours
are often multiple or bilateral, and manifest at a young age. The median life expect-
ancy is reduced to 49 years of age. At present, metastasis from renal cell carcinoma
and neurological complications from cerebellar haemangioblastoma are the most com-
mon causes of death in VHL disease.5-8 However, the life expectancy has strongly
improved over the last years. Intensive radiological and clinical monitoring and ad-
vanced operation techniques have contributed to the reduction of both morbidity and
mortality.
History
The German ophthalmologist Eugen von Hippel (1867-1938) is usually credited with
the first full description of a retinal vascular abnormality.9 In 1911 he named this
abnormality angiomatosis retinae.10 This condition was already reported in 1879,11
and the microscopic appearance was described in a brother and sister in 1894.12 The
pathologist Arvid Lindau  published a paper in 1926 describing 40 cases with cystic
cerebellar tumours.13 He associated angiomatosis retinae with cerebellar and spinal
haemangioblastoma, and cysts of the kidneys, pancreas and epididymis. Lindau named
this syndrome central nervous system angiomatosis. In 1951 Streif noted that in 1864
French physicians had reported the first probable VHL patient who died with brain
and retinal tumours.14 The initial reports on adrenal involvement in VHL disease ap-
peared in 1953 and 1959 15,16 Melmon and Rosen published the first major VHL litera-
ture review in 1964.17 They stressed the importance of careful monitoring of the fam-
ily and gave criteria for the clinical diagnosis of VHL disease.
Richards et al. diagnosed renal carcinoma with intravenous urography and angi-
ography in two asymptomatic members of a VHL family in 1973,18 and descriptions
appeared of radiographic manifestations in various VHL families.19,20 In 1977 Lee et
al. advocated selective renal angiography for all VHL patients.21 The technique of
computed tomography (CT) was introduced in 1972 as head scanner and revolution-
ised diagnostic medicine of the whole body. Clinical imaging applications of nuclear
magnetic resonance increased in the mid 1980’s and is known as magnetic resonance
imaging or MRI. Filling-Katz et al. reported in 1989 that Gadopentetate dimeglumine
(Gd-DTPA) enhanced MRI gave the best results for assessing CNS lesions.22
A second revolution in the diagnosis of VHL disease was the identification of the
VHL gene in 1993.4 Presymptomatic DNA analysis and identification of carriers of
Clinical investigations 2.1
Genetics
In 1988, the VHL gene was localised and mapped to chromosome region 3p25-26
using genetic linkage analysis in large VHL families.23 A positional cloning strategy
subsequently led to the isolation and identification of the VHL gene in 1993.4 The
VHL gene covers approximately 14,500 basepairs (bp) of genomic DNA on chromo-
some 3. The full-length VHL messenger RNA is a 4,700 bp molecule; an additional
mRNA isoform is generated by alternative splicing involving exon 2.24,25 The open
reading frame is 852 bp long and contains two intragenic start codons. The protein-
coding region translated from the first start codon (nucleotides 214-216) encompasses
639 bp, and is divided into three exons of 340, 123, and 179 bp (Fig. 1a). The pro-
moter of the gene was identified in 1995.26 With the isolation of the 3' untranslated
region in 1996, together with the known promoter area, exons and introns, the com-
plete sequence of the human VHL gene was identified. 27
The VHL gene is a tumour suppressor gene according to Knudson’s ‘two-hit’
hypothesis:28 inactivation of both copies of the VHL gene is required for a normal cell
to develop into a tumour cell. Different mutational mechanisms may lead to the inac-
tivation of the VHL gene, including small intragenic mutations, loss of heterozygosity
(i.e. deletion of a large part of the gene, or even of the entire VHL gene), or
hypermethylation.29,30
In VHL families, germline mutations of the VHL gene are transmitted from af-
fected individuals to their offspring. VHL disease has an autosomal dominant pattern
of inheritance: children of a parent who is a carrier of a mutated VHL gene, have a
50% chance of inheriting the disease.  Patients inherit a mutated germline copy of the
VHL gene (the ‘first hit’) from the affected parent: they are heterozygous for the VHL
germline defect. The remaining (normal) copy of the VHL gene is affected by an
inactivating event (the ‘second hit’) at the somatic level: in such a cell, the complete
lack of normal VHL gene product is thought to drive tumourigenesis. The moment of
the second hit cannot be predicted and may occur at any age. Generally, tumour devel-
opment in VHL patients occurs between the age of 20 and 40 years.
Structure and possible functions of the VHL protein product
The VHL gene encodes a 213 amino acid protein (pVHL) with a molecular weight of
about 30 kiloDalton,31 of which the normal function is not precisely known. The ob-
servation that inactivation of the VHL gene leads to tumour initiation suggests that
pVHL plays a crucial role in the control of cellular proliferation in specific tissues,
such as the kidney, retina, and adrenal gland.
In addition to the germline mutations identified in families with VHL disease,
somatic mutations and/or loss of the VHL gene are frequently observed in sporadic
(i.e. non-familial) tumours, including  haemangioblastomas and renal cell carcino-
mas.25,32 Based upon its direct role in the initiation of both familial and sporadic renal
tumours, VHL is considered to be a ‘gatekeeper’ gene in renal cells.33 According to
VHL germline mutations in families permits the progress of tumour development to
be followed from a relatively early age, and optimises the time in which treatment is
carried out.
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Kinzler and Vogelstein,33 gatekeepers are genes that directly regulate the growth of
tumours by inhibiting growth or inhibiting death. Each cell type has only one (or a
few) gatekeepers. Inactivation of a given gatekeeper leads to a very specific tissue
distribution of cancer.  Several studies have addressed the identification of the normal
physiological functions of the VHL gene and its protein product. The VHL protein has
been shown to associate with at least five other proteins, namely CUL-2,34 VBP1,35,36
fibronectin (W.G. Kaelin, personal communication 1997) and the Elongins B and C.
The interaction of pVHL with the Elongins has provided a possible clue about the
normal function of pVHL. Based on these in vitro studies, it has been postulated that
pVHL plays a role in regulating the transcription elongation.37-41 Transcription (the
process of converting DNA sequence into corresponding RNA) elongation is medi-
ated by the initiation factor RNA polymerase II. When normal pVHL is present in the
cell, binding of pVHL to Elongins B and C causes RNA polymerase to pause during
transcription at several sites along a gene. Mutations of the VHL gene lead to absence
of normal pVHL. Failure by pVHL to sequester Elongins B and C may result in an
ongoing transcription activity. When genes involved in cell cycle control are regu-
lated at the transcription level by this mechanism, the absence of functional pVHL
may lead to abnormal cell proliferation.
Interestingly, the region of the VHL gene that encodes the Elongin binding do-
main (nucleotide 682-781)39,42 is a hot spot for missense mutations: approximately
70% of VHL families have mutations predicted to disrupt VHL binding to Elongin
(Fig. 1a).43 This suggests that this region is critical for the normal functioning of the
VHL protein. However, mutations leading to VHL disease are also found outside the
Elongin binding domain, indicating that other regions of the VHL gene encode pro-
teins that have another function.
The VHL protein is widely expressed in normal human tissues.43a,44 The pVHL is
even expressed in organs not at risk for the disease, suggesting a role for pVHL that
goes beyond the organs involved in the disease. In human embryos pVHL was ex-
pressed in all three germ layers, with strong expression noted in the central nervous
system, kidney, testis and lung.45 The intracellular localisation of pVHL appears to
depend on a novel physiological control mechanism: cell density.41,46 In sparse cul-
tures, pVHL is predominantly present in the nucleus, whereas it can be found in the
cytoplasm of more confluent cells. The putative role of the pVHL in transcription
elongation (as discussed above) and its ability to localise based on culture conditions
suggests an ability to control cellular growth in response to environmental signals.47
Recently,  it was shown that the wild-type (normal) pVHL inhibits the production of
hypoxia-inducible mRNAs, such as the vascular endothelial growth factor (VEGF)
mRNA, under normoxic conditions.31,48 In renal tumour-derived cell lines which lack
normal pVHL, VEGF mRNA expression is increased.48 Thus, the highly vascular na-
ture of VHL-associated neoplasms may be due, at least in part, to dysregulation of
hypoxia-inducible mRNAs following loss of function of pVHL.
In addition to these biochemical studies, a mouse model has been developed to
analyse the function of the VHL gene.49 Using targeted homologous recombination in
murine embryonal stem cells, a so called ‘knock-out’ mouse model was generated for
VHL carrying an inactivating mutation at the Vhl gene (the murine homologue of the
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VHL gene). Heterozygous Vhl (+/-) mice survived beyond 15 months of age without
evidence of spontaneous disease. However, homozygosity for the Vhl  ‘knock- out’
allele leads to embryonic lethality. Apparently, the Vhl gene is required for normal
embryonic development in the mouse. Vhl (-/-) embryos die in utero between 10.5
and 12.5 days of gestation, most likely due to an impairment of placental
vasculogenesis.49 This is in contrast to the observations that the wild-type VHL gene
results in decreased VEGF levels and that mutations in the VHL gene are associated
with richly vascularised VHL lesions.
VHL mutations
Germline mutations in the VHL gene are found in up to 80% of  the VHL families.50 In
families with an identified VHL germline mutation, almost 60% have a missense
mutation, i.e. a mutation that leads to an amino acid substitution in the VHL protein
product. Large deletions account for 20%, and microdeletions, insertions and non-
sense mutations are found in another 20%.43,51 (Note: updated summaries of VHL
germline mutations can be found on the World Wide Web at http//www.ncifcrf.gov/
kidney and at http://www.uwcm.ac.uk/uwcm/mg/search/120488.html).
A large number of different intragenic (i.e. missense and  nonsense mutations, splice
defects, micro deletions and insertions) VHL germline mutations has been detected.
Most VHL germline mutations are unique to a small number (one or two) of families,
suggesting that most of these mutations are of recent origin.43 However, several recur-
rent VHL mutations, which occur in multiple, unrelated families, have also been ob-
served (Fig. 1a).
Fig. 1a Germline mutations identified in VHL patients from North America, Japan and Europe
(including the Netherlands) are shown. Information was obtained from the World Wide Web page of
the National Cancer Institute in Bethesda, USA (www.ncifrcf.gov/kidney) and the Clinical Genetics
Centre in Utrecht, the Netherlands (unpublished data). The numbers of the nucleotides are shown
along the X-axis, starting at the first start codon (nucleotide 214) and ending at the stop codon
(nucleotide 852). VHL germline mutations were found between nucleotides 376 and 811. The number
of families with a particular VHL germline mutation are shown along the Y-axis. Each symbol
represents one family. Mutations found in Dutch VHL families are shown in black.
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Genotype-phenotype correlations in VHL
As illustrated above, VHL disease is heterogeneous at the molecular level: mutations
of all types are found, and they are scattered throughout the VHL gene. From a clini-
cal point of view, VHL disease is also a heterogeneous disorder: inter- as well as
intrafamilial variability in the clinical expression of the disease is common. Based on
the presence or absence of renal carcinoma and phaeochromocytoma in VHL disease,
a classification of three VHL phenotypes has been proposed: (1) renal carcinoma with-
out phaeochromocytoma, (2) renal carcinoma with phaeochromocytoma, (3)
phaeochromocytoma alone.43
There is evidence that, to a certain extent, a relationship exists between the spe-
cific VHL germline mutation (the ‘genotype’) and the clinical manifestation of the
disease (the ‘phenotype’). Such genotype-phenotype correlations may not only indi-
cate important functional domains of the VHL protein, but may also have clinical
significance. Based on the knowledge of the specific VHL mutation, surveillance and
management of patients may be adjusted.
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Fig. 1b Genotype-phenotype
correlations in VHL disease.
The pie charts show the total
mutational spectrum and the as-
sociation of mutations with
phaeochromocytoma (based on
Zbar et al. 43).
Interfamilial clinical variability in VHL disease can partly be explained by dif-
ferences in the family-specific VHL germline mutation. As shown in Figure 1b, al-
most all families (92%) with phaeochromocytoma (types 2 and 3) have missense
mutations in the VHL gene.43 In VHL families without phaeochromocytoma (type 1),
most mutations (65%) are predicted to lead to either constitutional deletion of a VHL
allele or synthesis of a truncated VHL protein (Fig. 1b). Zbar et al (1996) identified
germline mutations in 300 of 469 VHL families and noted that 96% of the families
with either deletions, microdeletions/insertions, splice site, or nonsense mutations were
affected by VHL disease without phaeochromocytoma.43 A few specific missense
mutations lead to VHL phenotype with phaeochromocytoma, retinal and CNS hae-
mangioblastoma without renal carcinoma.52,53
However, patients with identical VHL germline mutations may display different
phenotypes, indicating that the issue of genotype-phenotype correlations in VHL dis-
ease is complex. It is likely that other genetic  (‘modifier’ genes) and/or environmen-
tal factors (lifestyle, diet, smoking) may play a role in the clinical manifestation of
VHL germline mutations.
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Renal masses
In VHL patients, renal lesions can be divided into three different forms with cystic,
combined cystic-solid and solid renal cell carcinoma (RCC) lesions.54 Cystic lesions
which can be single or multiple, can occur unilaterally but are mostly bilateral. They
can grow either slowly or rapidly, but can also involute. The combined cystic-solid
lesion, in which the solid (malignant) component gradually increases, may lead in
turn to a solid RCC lesion.
RCC may present with haematuria or with back pain. However, most renal tu-
mours are detected as an incidental finding in radiological screening performed for
other reasons, while a growing number of renal lesions in patients is found by periodi-
cal monitoring of VHL families. If not identified by monitoring, VHL patients with
RCC have a shortened life expectancy. At present, RCC is the cause of death in 15-
50% of VHL patients,5-7 and 30-50% of symptomatic RCCs have already metastasised
to lymph nodes, liver, bone, lung or brain.17,55-57 Fortunately, RCC does not occur in
every VHL patient (in different VHL families incidence varies between 3% and 63%
of the patients)5,53 nor in every kidney, and RCC does not always have a fatal outcome.
These features may be caused by differences in family-specific germline mutation,
the timing of origin and nature of the somatic mutation. The somatic mutations may
be induced by environmental factors. For example, current opinion is that smoking
(particularly in males) is correlated with the development of RCC.58-60 There is an
increased incidence of RCC in certain professions (e.g. among workers exposed to
asbestos,61 trichloroethene,62 leather workers,63 fire fighters and painters64) and a cor-
relation has been found with obesity and hypertension.59,60
The renal lesions have a typical hereditary character, i.e. the lesions occur mul-
tiply, bilaterally and at a relatively young age. While sporadic RCC occurs predomi-
nantly in the seventh and eighth decades of life,65 the mean age of presentation in VHL
patients is 30 to 36 years.66-69 However, there is a trend towards detection at younger
age, probably as a result of intensification of monitoring. The youngest reported VHL
patients with a RCC are 15 and 16 years old.68,70 Poston et al.67 found a mean of
7.8  cystic and 3.0 solid renal lesions in VHL patients, which is in agreement with our
own observations (unpublished) and other studies.5,54
Most RCC in conjunction with VHL disease grow slowly. A radiological study
demonstrated that the average increase of diameter in cysts was 0.5 cm/year and that
solid lesions grew at an average of 1.6 cm/year.54 Complex lesions (with cystic and
solid parts) appeared to transform to a predominantly solid lesion that continued to
grow, while the cystic part of the lesion gradually regressed. More recently, the mean
growth rate of RCC in VHL disease was found to be between 0.3 cm (own unpub-
lished data) and 0.5 cm/year.71 This is comparable to the mean growth rate of sporadic
RCC, which was reported to be 0.36 to 0.5 cm/year.72,73
Pathologically, RCC is a malignant epithelial tumour of the renal parenchyma
and is often found in the renal cortex. The tumour tissue is frequently crowded with
recent and old haemorrhages, necrosis and inflammation, and is surrounded by a
pseudocapsule.74,75 The most common cellular pattern is clear cell carcinoma,76 aris-
ing from cells of the proximal tubuli.77
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Renal cysts in VHL disease can contain lining epithelium exhibiting atypia, and
are therefore considered to be premalignant.57,67,78-80 However, transformation into a
solid malignant tumour is rare,81 Kragel et al. demonstrated that simple cysts in VHL
disease arise more commonly from distal tubules, whereas the majority of RCC arises
from proximal tubules.81 Nevertheless, some renal carcinomas do arise from the distal
nephron and comparison of markers of tubular differentiation in atypical cysts and
RCC supports the progression of atypical cysts to carcinoma.81
Furthermore, by microdissecting material from individual lesions it has been
demonstrated that loss of the wildtype allele and retention of the inherited, mutated
VHL allele occurred both in cystic lesions and in RCC.82 This clearly demonstrates
that cysts are precursors for RCC and that loss of the VHL gene (the second hit in
Knudson’s theory28) occurs early in their development.
Fig. 2 CT images of the kidneys in the corticomedullary phase after intravenous contrast shows
small RCCs in the left kidney of a 30-year old VHL patient. a Lesion in the upper pole (arrow)
measures nearly  3 cm. b Smaller lesion (arrow) in lower pole of the kidney. Both lesions appear to
be encapsulated. Right kidney shows a small cortical cyst. c Oblique reconstruction and d coronal
3D surface rendering show the exophytic lesions emanating from the medial aspect of the kidney,
free from the main renal vessels. In the upper pole the renal parenchyma has been partly cut away.
The right kidney shows cortical defects caused by cysts (see b). Elective surgery could be performed
on the left kidney. Encapsulated cystic tumours of 1.8 and 2.6 cm in diameter were removed radi-
cally. The larger tumour showed infiltration into the pseudocapsule, but did not penetrate it. Radio-
logical follow-up (four years) showed enlarging cysts in right kidney, but no tumour in left kidney.
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Over the past years the treatment of renal lesions in VHL disease has been dis-
cussed by many authors.67,68,71,83-87 Recommendations range from bilateral nephrec-
tomy to follow-up investigations only. If both kidneys are affected with multiple cysts
and tumours, a difficult decision has to be made between radical nephrectomy or
nephron sparing surgery. If a patient progresses to having a large number of tumours
and/or large individual tumours, nephrectomy followed by renal transplantation may
be the first option. Bilateral nephrectomy followed by transplantation shortens life
expectancy and diminishes the quality of life, although this quality has been improved
over the past decade by the use of immunosuppressive therapy.88,89 Graft 5- year sur-
vival rates of 80%, and up to 90% for living donors, have been reported.88,89 In gen-
eral, haemodialysis has a less favourable outcome, but this is most likely influenced
by selection of patients.88 Apart from a diminished life expectancy, the quality of life
is reduced for dialysis and transplantation patients. Moreover, it has been suggested
that immunosuppression accelerates (pre-existing) neoplastic growth.90
Nephron sparing surgery is based on maintaining renal function as long as pos-
sible, while reducing the risk of metastases 86 The most serious complication is renal
atrophy and this has been reported in 11% of nephron sparing surgery.86 In VHL dis-
ease, operative removal of solid RCC and those RCC larger than 3 cm which are still
growing has been advocated by several authors.54,71,72,86 Tumours under this size are
more likely to be low grade and less frequently associated with metastases. Cancer
specific five- and ten-year survival rates from nephron sparing surgery have been
reported to be 100% and 81%, respectively.68 These results indicate that nephron spar-
ing surgery can provide effective initial- and preventive treatment for VHL patients
with RCC.
With the advent of ultrasonography (US) and computed tomography (CT), there
has been an increase in detection of small renal masses91 and monitoring of VHL
patients is likely to yield a correspondingly high number of such masses.  CT scan-
ning is found to be more reliable than ultrasound in detecting renal masses. Jamis-
Dow et al. concluded that CT was more sensitive than US for the detection of small
renal masses (particularly those smaller than 1.5 cm).92 However, a substantial pro-
portion of lesions under 1 cm were not detected with either technique. Nonetheless,
US is a critical tool in helping to determine whether a lesion is principally cystic or
solid.93
Intraoperative colour Doppler US is helpful in characterising deep parenchymal
cystic lesions and evaluating larger deep or hilar tumours. 94 This technique minimises
blood and renal parenchymal loss and allows safe removal of renal lesions. In particu-
lar, patients with many renal lesions benefit from a thorough inspection of the kidney
with this technique, before closing.94
Thin-section (3 to 5 mm), intravenous contrast-enhanced CT is mandatory, and a
helical technique is necessary to ensure that small lesions are not missed.95 The recent
introduction and use of helical or spiral CTscanners offers volumetric imaging of the
kidneys in a single breath-hold and can therefore eliminate respiratory misregistration.
These  scanners can detect and discriminate lesions smaller than 1.0 cm by using
overlapping intervals and thin collimation.96 Bosniak and Rofsky claim that in the
general population a normal contrast CT scan of the kidneys using 5 mm sections
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rules out a clinically significant renal parenchymal neoplasm.97 Moreover, CT can
exactly localize postoperative defects in patients after nephron sparing surgery.98 In
patients with reduced functioning renal tissue and patients with only one kidney, as
often seen in VHL disease, tumour enhancement may be problematic because tissue
enhancement is directly related to the level of contrast material in the blood.97 In such
cases gadolinium-enhanced (gd-DTPA) MRI can be of great value, because it pro-
vides critical information about lesion vascularity without the risks of intravascular
iodinated contrast material.
Fig. 3 Comparison of CT and MRI of a RCC in a 27-year old woman with VHL disease. Monitoring
was started two years before these imaging results. US showed a left-sided tumour of 3 cm in diam-
eter. a CT shows a large cystic tumour in the left kidney (arrow). b MRI (TR/TE = 2475/100 ms)
shows the pseudocapsule (arrow) better than CT. Note the cortical cysts in the right kidney. Despite
the tumour size of 5x5x3 cm, nephron sparing surgery was able to be performed. During operation,
major haemorrhage of the wound bed of the left kidney could be treated. A small cystic part of the
tumour reached the rim of resection, but enucleation was performed radically. The right kidney
shows a more central cystic tumour on CT in c and MRI in d, which should be removed in the near
future. Note the pancreatic cyst in the tail (small arrows) in c.
Imaging of renal masses is also possible with radio-labelled octreotide, which
binds to somatostatin receptors of a wide variety of tumours including RCC.99 An in
vivo study  demonstrated binding of 111In-octreotide to RCC in 43% (3 out of 7 pa-
tients). In these three patients 20 of 23 known tumour localisations, predominantly
metastases, were clearly visualised. This method may not only provide valuable infor-
mation on the secondary spread of the tumour but it may also be used to select those
patients who could benefit from treatment with somatastatin receptor analogues.99
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Typically, RCC possess a pseudocapsule,100 which may play a critical role in the
success of nephron sparing surgery. Various imaging techniques have been described
to reveal a pseudocapsule of the RCC (Fig. 3). A surrounding radiolucent rim is ob-
served with angiography, a low or high density rim with CT, and a low intensity rim
with MRI.74,75 The sensitivity of CT in detecting pseudocapsules was lower than that
of angiography and statistically significant. T2-weighted MRI is superior for visualis-
ing a pseudocapsule of RCC and also for providing reliable selection criteria for tu-
mour enucleation.75,100 The appearance on T2-weighted MRI is related to the fibrous
element and compressed renal parenchyma. The inner margins of most pseudocapsules
are composed of compressed parenchyma, whereas the outer margins contain reactive
hyperplasia of the renal capsule as well as compressed parenchyma.74 The low-inten-
sity band or rim appears on MRI when the pseudocapsule is thicker than 2 mm.
Takahashi et al. mentioned three limitations of the detection of a pseudocapsule by
MRI.75 First, pseudocapsular invasion tends to be observed near the renal hilum, where
there are abundant blood vessels. Second, if the tumour is small and located at the
upper pole, partial volume averaging may obscure the pseudocapsule. A chemical
shift artifact, observed at the interface between the tumour and the perinephric fat,
forms a third limitation.75,100
Table 1. VHL monitoring recommendations
Test NIH Netherlands
Ophthalmoscopy From infancy, yearly From age 5 years
Fluorescein angiography Not routine When indicated
Physical examination From age 2 years, yearly From age 10 years, yearly
and neurological assessment
Urinary/blood catecholamines From age 2 years, From age 10 years, yearly
every 1-2 years
US abdomen From age 11 years, yearly From age 10 years, yearly
CT abdomen From age 20 years, -
yearly or every other year
MRI abdomen (MIBG) When indicated When indicated
MRI with gadolinium of From age 11 years, every two years; From age 15 years, every two years
cerebellum and myelum after age 60 years, every 3-5 years
MRI petrous bones; If hearing loss, If hearing loss,
Audiometry tinnitus and/or vertigo* tinnitus and/or  vertigo*
Information was obtained from Choyke et al.93 and  completed with information kindly provided by
Dr. G.M. Glenn from the National Institutes of Health (NIH), Bethesda, Maryland, USA.
* These symptoms may be caused by an endolymphatic sac tumour (ELST) which is associated with
VHL disease.142
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regime should be complemented by a MRI once every three years. If renal monitoring
is performed by CT, spiral 3-D geometry is preferred. Small masses are less likely to
be missed by this method. In our opinion, careful cross-sectional monitoring with
alternate MRI and US gives the best protection for aggressive RCC in most VHL
patients. Both US and MRI can distinguish between solid and cystic masses, but the
quality and reliability of MRI is equal or even superior to US in the detection and
characterisation of renal masses. The best results are obtained by breath-hold T2-
weighted MR images. Others use T1-weighted gadolinium-enhanced MRI with fat
suppression,101 which is useful for the characterisation of renal lesions. Angiography
is inadequate for detecting renal lesions,102 but was predominantly used as preoperative
‘road mapping’, to identify the renal vascular supply.
Some monitoring protocols recommend yearly alternate CT and US examina-
tions to reduce both costs and radiation (see Table 1).93 Other institutes advise that this
Fig. 4 Schematic diagrams of the kidneys used for monitoring renal lesions. The radiologists are
requested
1.  to draw lesions on coronal picture and number them. The same number for the same lesion in all
following reports should be used and new lesions should be numbered consecutively; 2. to draw
lesions on the transversal pictures (1-3) as well and use the same number for each lesion consist-
ently; 3. to give nature of lesions: uncomplicated cyst (c), combined cystic/solid lesion (c/s), solid
(s) and indicate whether lesions have a pseudocapsule (pc); 4. to give size of lesions in millimeters
and, if possible, growth rate in millimeters per year.
We advise careful radiological monitoring at least once a year, preferably with MRI.
Renal lesions can be adequately monitored by documenting the number, size and na-
ture of lesions in a schematic figure of the kidneys (Fig. 4). Examples of cases are
shown in Fig. 2, 3, 5 and 6.
Clinical investigations 2.1
Fig. 6 CT scan of extensive disease of the kidneys in a 45-year old male who was diagnosed in 1966
with retinal haemangioblastoma in another clinic but who unfortunately did not receive periodical
monitoring. When he presented with symptoms of back pain in 1996, he already had advanced renal
cell carcinoma with metastases in regional lymph nodes, bones and lungs. The kidneys have a poly-
cystic aspect but contain large solid tumours (arrows). This patient could only be treated by pallia-
tive radiotherapy on ossal metastasis in the spine and died six months after onset of symptoms.
Adrenal masses
VHL-associated phaeochromocytoma differs from isolated phaeochromocytoma in
having younger age of onset (19 years earlier), multiple lesions, and a very low pro-
portion of malignant tumours 103 The mean age at phaeochromocytoma diagnosis is
27-29 years,5,103,104 with youngest reported patient of five years old.104 Phaeochromo-
cytoma may cause palpitations, sweating attacks, hypertension or paroxysmal unsta-
ble blood pressure, and headache. In VHL patients, phaeochromocytoma often re-
main quiescent or produce few symptoms, and investigation may show normal bio-
chemical tests. However, the behaviour of phaeochromocytoma remains unpredict-
able; biologically inactive lesions may suddenly become dangerous. Benign phaeo-
chromocytoma may also become malignant.83 About 5% of VHL patients die from
phaeochromocytoma-induced endogenous catecholamine intoxication, which has also
caused fatal pregnancy outcome.66,105,106
Fig. 5 Transverse MRI of a 27-year old VHL patient and bilateral small renal tumours (arrows). T2-
weighted images (a TR/TE = 2436/50 and b TR/TE = 2436/100) show two combined solid/cystic
lesions (arrows) in the right kidney. The one near the hilum is not suited for nephron sparing surgery.
Recently, the lesion in the left kidney (arrow) was removed nephron sparingly. Histopathological
examination showed a cystic tumour, measuring 2 cm at closer examination, surrounded by an intact
pseudocapsule of 1-2 mm thick.
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VHL germline mutations are found in approximately 3% of patients with
phaeochromocytoma without family history, thus sporadic tumours.108 A higher per-
centage of VHL germline mutation was found in familial phaeochromocytoma (45%)
and bilateral tumours.109 This raises the possibility that some VHL mutations might
predispose to phaeochromocytoma but be associated with a low risk of other typical
VHL lesions.104,110-115
Diagnosis is based on biochemical tests and radiology.103 Laboratory test may
include evaluation of serum and urinary norepinephrine, epinephrine, and
vanillylmandelic acid. Measurement of 24 hour urinary epinephrine excretion is the
most sensitive of the biochemical tests.103
Phaeochromocytoma occur in 0-58% of patients in VHL families.5,20,43,54,66,105,107
There is strong evidence that the presence or absence of phaeochromocytoma is cor-
related with the type of VHL germline mutations (vide supra genotype-phenotype
correlations). Beside this clear interfamilial difference, also intrafamilial differences
have been observed.
Radiology testing may include US, CT, MRI and metaiodobenzylguanidine
(MIBG) scintigraphy. A low sensitivity for US was reported by Neumann (40% vs 90-
95% in other reports).103 In CT scanning, phaeochromocytomas typically enhance af-
ter administration of a contrast medium and CT is considered useful for evaluating the
adrenal glands and organ of Zuckerkandl, but it is less accurate for investigating ec-
topic sites.93 Sensitivity of abdominal CT in VHL disease was reported to be 76%.103
T2-weighted MRI demonstrates high signal intensity for phaeochromocytoma (Fig.
7) in 95-100% of the cases. 103,116 Most phaeochromocytoma appear markedly
hyperintensive to the liver on T2-weighted images, but occasionally phaeo-
chromocytoma may be iso- or hypointense to the liver.103 One of the new techniques
for MRI of the adrenal gland is fat suppression, it reduces cardiac and respiratory
motion-induced artifacts, accentuates small differences in tissue contrast, and elimi-
nates chemical shift artifacts.117 MIBG is about 75-95% sensitive for phaeo-
chromocytoma and is 100% specific, but it may not depict very small lesions.93,103,116
Preoperative MIBG scintigraphy is also important in localising extra-adrenal
phaeochromocytoma.118 It has been demonstrated that phaeochromocytoma in VHL
disease can also occur in the thorax.118a
Fig. 7 T2-weighted pre-operative MRI of asymp-
tomatic bilateral phaeochromocytoma  (arrows)
in a 37-year old male with VHL disease. Both
kidneys are affected with multiple cysts and slow
growing tumours, mostly occurring in places in
which surgery is not possible without consider-
able loss of renal tissue. The largest solid lesion
grew from 1.8 cm in 1980 to 2.5 cm in 1996. A
difficult decision has to be made between ne-
phrectomy and nephron sparing surgery. If he
progresses to having a larger number of tumours,
renal transplantation may be the first option, or
one could decide to operate nephron sparingly
on feasible tumours.
Clinical investigations 2.1
Operative treatment can be considered if a growing mass in the adrenal gland is
established. Recently, satisfactory results have been reported from laparoscopic re-
moval of adrenal tumours,119-121 and in VHL disease (G. Janetschek, personal commu-
nication 1997). Enucleation rather than adrenalectomy is recommended by an increasing
number of surgeons.106
Pancreatic cystic masses
The pancreatic manifestations of VHL disease include simple cysts, diffuse cystosis,
cystadenoma, and rarely adenocarcinoma. 83,122 Islet cell tumours are considered sepa-
rately.93 The incidence of pancreatic involvement in VHL disease varied from 0-
56%.5,56,122-124 In a review of 275 reported cases,125 69 (25%) patients had cysts, 4
(1.5%) of which proved to be serous cystadenoma, 14 (5%) cases had islet cell tu-
mour, two (0.7%) adenocarcinoma, and one patient had an haemangioendothelioma.
Pancreatic lesions may be the only abdominal manifestation in VHL disease (12%)
and may precede any other manifestation.122 The earliest age of discovery reported is
15 years.107
Cyst formation is found in 70-72% of patients at autopsy studies.56,126 The cysts,
which are lined with a single layer of epithelial cells, are filled with serous fluid and
may be haemorrhagic.127 They can range from several millimeters to 10 cm in diam-
eter (Fig. 3c and 8a).93 Cysts are often multiple and enlarge the pancreas,123 or may
eventually replace the entire gland.127 Complications can arise from space-occupying
effects (local pain, bile duct obstruction, pancreatitis), but the cysts are mostly asymp-
tomatic, while exocrine and endocrine hormonal insufficiency have been reported in a
few cases.17,93,123-125,128-131  The pancreas may become so replaced with multiple cysts
that it becomes nonfunctional, which results in steatorrhea and diarrhea.93 Insulin-
dependent diabetes mellitus has been reported as a complication.129,130
Cystadenoma, like cysts, contain serous fluid and are benign in VHL disease.93,123
Serous cystadenoma is a grape-like cluster of multiple microscopic and macroscopic
cysts, separated by thickened walls of stroma.93,122,129,132 Calcification or a central stellate
scar may be seen.122
The differential diagnosis of cystic pancreatic lesions in VHL disease includes
pseudocysts (Fig. 8b) caused by pancreatitis, pancreatic involvement in polycystic
kidney disease and echinococcosis.123,133 Metastasis from renal cell carcinoma has been
described,134 and has to be considered in the differential diagnosis of solid pancreatic
masses. Adenocarcinoma in VHL disease is rare and was first detected by CT in 1979.5,20
Different imaging techniques, such as US, MRI and CT, have  comparable diag-
nostic value.132 US is therefore the method of choice for monitoring programs.123 How-
ever, in finding a small lesion, or identifying a solid lesion, CT scanning or MRI may
be superior to US.54,132 Serous adenoma may appear solid in US because of the multi-
ple acoustic interfaces caused by multiple microscopic cysts.93 Also, a cystadenoma
may be indistinguishable from a cluster of simple cysts, but this has no clinical impli-
cations since both are benign lesions122 (Fig. 8b).
Pancreatic cystadenoma and the long T2 of the serous contents of cysts both result in
high signal intensity on T2-weighted images. Gadolinium enhancement may be help-
ful because of high signal intensity in serous microcystic neoplasm, but it is absent in
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Fig. 8 Pancreatic lesions in VHL disease. a T2-weighted image (TR/TE = 2323/100) shows a small
pancreatic cyst (arrow) in a 40-year old male with renal cell carcinoma (not shown). b CT in a 31
years old female with multiple pancreatic cystic lesions in corpus and tail of the pancreas with soft
tissue parts, most probably serous cystadenoma (white arrow). On MRI one year before, the lesions
had high signal intensity on the T2-weighted images. Despite some mass effect these lesions do not
require resection. Moreover, she developed a pseudocystic mass (black arrow) due to a
ventriculoperitoneal catheter in this region, inserted after surgery of a cerebellar haemangioblas-
toma.
 cystic lesions. The signal intensity on T1-weighted images is usually low but can
vary depending on the presence of haemorrhage.127
Asymptomatic pancreas lesions may represent an important feature that may be
useful in detecting early expression of the disease. Because the disease is usually
asymptomatic, conservative measures are considered adequate for cystic lesions.123,125
However, aggressive resection is mandatory for a solid pancreatic lesion in VHL dis-
ease.125 Patients with space-occupying cysts have been treated with percutaneous drain-
age and hypertonic saline sclerosis.93 Cholestatic jaundice may be treated by endo-
scopic implantation of a biliary stent,135 or a biliary bypass.125
Pancreatic islet cell tumours
Familial islet cell tumours in VHL disease were first reported in 1979.124 Solid islet
cell tumours may occur in 5-17% of the patients125,136 and may be unrelated to pancre-
atic cystic disease.93 Many islet cell tumours are slow-growing, asymptomatic and
non-functional.93,124,136 The functional ones most commonly secrete various peptides
such as insulin, glucagon and somatostatin.137 The frequency of malignant islet cell
tumours is very low, only case reports have been published,5,122-126,128,129,136,138 some
with metastasis.123,138
Pancreatic islet cell tumours occur more frequently in patients with phaeochromo-
cytoma and may be considered as an additional form of the multiple endocrine
neoplastic syndromes.93,124,136 Islet cell tumours arise either from pancreatic islet cells,
which are believed to be derived from the neural crest,139 or from a single neuroendo-
crine-programmed ectoblast.137 This might indicate that islet cell tumours share a com-
mon origin with phaeochromocytoma.
Clinical investigations 2.1
The VHL gene does not play a pathogenetic role in the development of non-
VHL (sporadic) pancreatic endocrine tumours.140 This is in contrast to some other
tumours of the VHL-spectrum (vide supra: Structure and possible functions of the
VHL protein product). A locus at chromosome 3p25 centromeric of VHL is frequently
lost in these tumours and may harbour a novel pancreatic endocrine tumour suppres-
sor gene. Allelic loss at chromosome 3p25 is thought to be correlated with more clini-
cally advanced disease.140
With US, benign islet cell tumours are usually seen to be well demarcated, round
or oval, and hypoechoic relative to pancreatic parenchyma. Success rates for insulinoma
localisation range from 25-60%, with those for gastrinomas at about 20%.137 Intra-
operative US may be useful in identifying focal masses when pancreas-sparing sur-
gery is being considered, but detection of small lesions is difficult. Most islet cell
tumours larger than 2 cm can be visualised by any technique, while those smaller than
2 cm are best seen with bolus-enhanced, contrast medium-enhanced, thin-section dy-
namic CT.137 Islet cell tumours show intense enhancement on CT and may contain
calcification.93 As the tumour enlarges, areas of necrosis may be seen. The character-
istic arteriographic feature of islet cell tumours is a dense, homogeneous, circum-
scribed parenchymal blush. Angiography was useful in the past in localising pancre-
atic islet cell tumours,93 but has been replaced by CT and MRI. Fat-suppressed and
dynamic gadolinium-enhanced MRI are superior to CT in depicting islet cell tumours.141
Small insulinoma (less than 1.5 cm in diameter) were revealed well on dynamic gado-
linium-enhanced, fast low-angle shot (FLASH) images.141 However, others believe
that CT and US are superior to MRI in detecting small islet cell tumours.137
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Abstract
Objective To evaluate nephron sparing surgery (NSS) or radical nephrectomy (RN)
for treating renal cell carcinoma (RCC) in patients with Von Hippel-Lindau (VHL)
disease.
Patients and methods Between 1976 and 1997 ten patients with RCC from four
VHL families, of whom seven were from one family, were studied by clinical and
histopathological examination. Prior to 1991 three patients were treated using RN,
and thereafter five patients were treated using NSS. Two patients were not operated
on.
Results RCCs in our patients showed a slow growth rate (on average 0.3 cm/year)
and asymptomatic patients presented with tumours of low-grade malignancy. In all
patients, tumours were surrounded by a fibrous pseudocapsule. In five out of seven-
teen tumours pseudocapsular invasion was observed and three of these five tumours
broke through the pseudocapsule. So far, these patients have not shown a less favour-
able outcome than those without pseudocapsular involvement by tumour growth.
Multicentricity of RCC was relatively low (4.6 lesions per kidney). In two of the three
RN patients only a single satellite lesion, in the direct vicinity of a RCC, was found in
one kidney. Six tumours (1.8-5.5 cm) were enucleated by NSS. During a mean fol-
low-up of 30 months, renal function in these patients was well preserved.
Conclusions In our patients, RCCs grew slowly, were of low grade, had a dense fi-
brous pseudocapsule and were thus good candidates for NSS.
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Introduction
Von Hippel-Lindau (VHL) disease is a hereditary syndrome characterised by predis-
position to bilateral and multicentric renal cell carcinomas (RCC), retinal haeman-
gioblastoma, haemangioblastoma in the central nervous system and phaeochromo-
cytoma, as well as cysts in the kidneys, pancreas and epididymis. VHL is a relatively
rare disease, with an estimated incidence of between 1:31,000 to 1:53,000 in South
Baden (Germany) and East Anglia (Great Britain), respectively.1-3 The basis of famil-
ial inheritance of VHL disease are germline mutations in a tumour suppressor gene,
identified in 1993 and located in chromosome region 3p25-26.4 The disease is inher-
ited as an autosomal dominant trait with a high penetrance and a variable expression.
This is well illustrated by RCC, which occurs in different VHL families in between
3% and 63% of the patients.5,6
In VHL patients, renal involvement can be divided into three different forms
with cystic, combined cystic-solid, and solid RCC lesions.7 Pathologically, RCC is a
malignant epithelial tumour of the renal parenchyma and is often found in the renal
cortex. The tumour tissue is often observed to be crowded with recent and old haem-
orrhages, necrosis and inflammation, and is surrounded by a pseudocapsule. The most
common cellular pattern is clear cell carcinoma,8 which arises from cells of the proxi-
mal tubuli.9
Presymptomatic identification of carriers of a germline mutation in the VHL
gene enables periodic examination. This permits the progress of tumour development
to be followed from a relatively early age, and optimises the time in which treatment
is carried out. Recommendations for treatment of RCC in VHL patients range from
radical nephrectomy (RN), nephron sparing surgery (NSS), to follow-up investiga-
tions only.10-16
In this study, we report on ten VHL patients with RCC. The treatment of other
VHL lesions is not described in this article. Patients operated on before 1991 under-
went RN, and those operated on thereafter underwent NSS. The study provides a
retrospective analysis of the clinical data of these patients and histopathological pat-
tern of their renal lesions, and how these relate to the surgical treatment used.
Patients and methods
Patients
Between 1976 and 1997, nine RCC patients from three VHL families, were evaluated
and treated in the University Hospital of Utrecht. Patients 1-7 were from one large
family (Fig. 1, pedigree A), patients 8 and 9 were from two other families (B and C).
All these patients underwent an annual monitoring program performed by a
multidisciplinary team.10 An additional patient (10) had been diagnosed with retinal
haemangioblastoma in 1966 at another clinic, but unfortunately had not had periodi-
cal monitoring. When the patient presented with symptoms of pain in the back in
1996, he already had advanced RCC in both kidneys and metastases in lymph nodes,
bones and lungs. He died six months after onset of symptoms. None of the other nine
patients studied had metastases of RCC.
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All ten patients had a definite VHL family history and fulfilled the VHL crite-
ria.17,18 Only the patient with metastases (10) presented with symptoms or signs that
could be directly associated with RCC. The clinical records of first presentation were
not available for one patient (1). Eight other patients (2-9) were asymptomatic and
were identified by ultrasound monitoring, with the diagnosis being confirmed by com-
puterised tomography (CT) or magnetic resonance imaging (MRI). Pre-operative an-
giography was performed in five patients (1, 2, 6, 8 and 9) and spiral CT in two
patients (5 and 6) to determine the optimal surgical strategy.
Surgery
Three patients were operated on prior to 1991 and underwent RN (1, 2 and 3), five
patients were operated on after 1991 and underwent NSS (4, 5, 6, 8 and 9). Two
patients were not operated on (7 and 10). In NSS the tumours were enucleated accord-
ing to the technique described by Novick.19 After careful radiographic assessment of
the size, complexity and progression of the tumour, and following discussion in a
multidisciplinary team (general physician, nephrologist, surgeon/urologist and radi-
ologist), renal lesions were electively removed. After median or flank incision, renal
artery occlusion was performed with a tourniquet. Intra-operative renal hypothermia
was used when clinically indicated; ultrasound examination of the kidney was not
applied.
Pathology
Surgical specimens were macroscopically examined, and grossly abnormal tissue as
well as random samples were histologically investigated conforming to standard sur-
gical-pathological procedures. Each lesion was characterised as a cystic, solid or com-
bined lesion, and further classified by cell type and architecture (tubular, trabecular,
cystic or papillary). Lesions were evaluated for pseudocapsule invasion or breakthrough
by tumour tissue and staged according to UICC guidelines.20
Fig. 1 Pedigree of family A.
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cording to established procedures. Exons 1, 2 and 3 of the VHL gene and their flank-
ing sequences were amplified using the polymerase chain reaction.21 The amplified
DNA was purified by ultra-low melting point agarose gel electrophoresis. The ex-
cised fragments were directly sequenced by the dideoxy-chain termination reaction
with a pUC-sequencing kit (Boehringer Mannheim, Mannheim, Germany), using
[alpha-35S] dATP (600 Ci/mmol). The amplification primers were used as primer in
the sequencing reactions.
Screening for large gene abnormalities was performed by Southern blot analy-
sis. DNA was digested with either HindIII or EcoRI. After gel electrophoresis and
transfer to Hybond-N filters, the genomic DNA was hybridised with a VHL cDNA
probe,4 (kindly provided by I. Kuzmin) according to the manufacturer’s instruction,
and subsequently rehybridised with PCR products of the respective VHL exons.
Follow-up
Mean follow-up was 30 months (range 21-52 months) for the NSS group and 171
months (97-259 months) for the RN group. Yearly follow-up included physical ex-
amination, abdominal radiology (ultrasonography and MRI) and biochemical analy-
sis of blood (including serum creatinine assessment) and urine. Complete follow-up
data have been obtained for all patients up to December 1997.
Results
DNA analysis
The results obtained from probands and other patients from families A, B, and C are
shown in Table 1 (patients 1-9). A VHL gene mutation has not yet been identified in
the proband from family D (patient 10).
Clinical
RCC was detected at a mean age of 32 years (range 24-45 years). Patients included in
the presymptomatic monitoring protocol were all diagnosed at a relatively young age
(Table 1); five patients from family A (3-7) were diagnosed at a mean age of 25 years
(range 24-28 years). Radiologically, lesions showed a mean growth of 0.3 cm a year
(range 0.04-0.5 cm). The pre-operative serum creatinine level of five patients (2, 4, 5,
6 and 9) ranged from 0.68-0.89 mg/dl (mean = 0.78 mg/dl). Post-operative serum
creatinine levels after one month, ranged from 0.66-1.46 mg/dl (mean = 0.94 mg/dl).
Surgery
Of the ten patients, two were not operated on: patient 10 was not operated on because
of advanced RCC with multiple metastases; patient 7 is currently being discussed by
the multidisciplinary team and a decision was made recently to enucleate a subcapsu-
lar cortical lesion of approximately 3.0 cm in his left kidney (Table 1). This operation
DNA analysis
High molecular weight DNA of the probands was isolated from peripheral blood ac-
has not yet been performed.
Clinical investigations 2.2
and 5.5 cm, respectively. In both these patients perirenal fat was also excised, as radi-
ology had demonstrated infiltration into the perirenal tissue. Complications devel-
oped only in patient 5 with post-operative urinary tract infection and intra-operative
bleeding from the crateriform lesion (haemoglobin concentration dropped from 12.4
to 6.0 g/dl, post-operatively).
Pathology
All lesions had the same appearance (Fig. 2). The tumour cells had slightly pleiomor-
phic nuclei surrounded by a clear cytoplasm. Mitoses were scarce. The cells formed
Table 1 VHL disease and RCC, surgery
Patient In Mutation Age AOD RCC Surgery Largest lesion Compl. Creat. pre/
pedigree post op.
1 A-II-5 V170D 64 42 (1976) RN  L+R 14.0 + 2.5 no unknown /n.a.
2 A-II-7 “ 58 40 (1979) RN  L 2.6 no 0.79/1.46
3 A-III-11 “ 35 26 (1988) RN  L+R 2.1 + 1.4 *1 1.36/n.a.
4 A-III-12 “ 33 28 (1992) NSS  L 2.6 no 0.86/1.08
5 A-III-8 “ 30 24 (1991) NSS  L 5 *2 0.89/0.66
6 A-III-13 “ 30 24 (1991) NSS  L 2 no 0.68/0.75
7 A-III-4 “ 41 24 (1980) no na na na
8 B, na R167Q 42 38 (1993) NSS  L 5.5 no unknown
9 C, na deletion 35 31 (1993) NSS  L 2 no 0.70/0.75
exon 1+2
10 D, na unknown 45 (=) 45 (1996) no 5 *3 na
Na, not applicable; Age, in December 1997; (=), died; AOD, age (and year) of diagnosis of RCC
(renal cell carcinoma); RN, radical nephrectomy; NSS, nephron sparing surgery; L, left; R, right;
Diameter of largest lesion in cm; Compl., complication: *1, interstitial cellular rejection and retro-
peritoneal abcess, *2, haemorrhage and urinary tract infection; Creat. pre/post op., creatinine levels
in mg/dl pre- and post-operative *3, metastases.
Three patients underwent RN and were all treated differently. Patient 1 had a
bilateral nephrectomy and has been treated by haemodialysis since 1976. Patient 2
underwent nephrectomy of her left kidney in 1985. During follow-up, only a very
small cyst was discovered recently by MRI, but so far she developed no RCC in the
contralateral kidney. Patient 3 underwent a left-sided nephrectomy. Six weeks later,
he underwent the second nephrectomy and was transplanted in the same session with
a cadaveric kidney. Patient 3 was the only patient in the RN group with complications.
He developed interstitial cellular rejection in the graft and abundant retroperitoneal
inflammatory infiltrate, which had to be drained three times.
Five patients (4, 5, 6, 8 and 9) were operated on using the NSS procedure and a
total of six tumours were enucleated, with two tumours being removed from patient 4.
In two patients (5 and 8) the enucleated lesions were larger than 3 cm, measuring 5.0
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regularly monitored patients (family A) were small and mostly staged as T1 or T2
(Table 2).
Autopsy of patient 10 revealed that the left kidney contained three peripheral
RCC measuring 3-5 cm, with both pseudocapsular breakthrough and renal capsular
invasion. The right kidney contained two peripheral and one hilar RCC, with an
intrarenal size of 4 cm and vena cava/iliaca communis involvement. Moreover, both
kidneys contained multiple cysts lined by clear cells similar to those observed in solid
RCCs.
Table 2 VHL disease and RCC, clinical-pathological features
Patient Number Cysts Invasion Break- Stage Satellite lesions
(size) (size) through
1 L: 2 (7.0 - 14.0) L: 10 (0.6-3.3) L: 0/2 0/2 L: T3 L: 1, near RCC
R: 3 (2.5) R: 5 R: 0/3 R: 0/3 R: T2 + several cysts
2 L: 1 (2.6) L: 1 (1.0) 1/1 1/1 T3 no
3 L: 4 (0.3 - 2.1) L: 2 L: 1/4 (1.3) L: 1/4 L: T1 L: 1, near RCC
R: 1 (1.4) R: 3 (0.6-1.5) R: 0/1 R: 0/1 R: T1
4 L: 2 (1.8 -2.6) no 2/2 0/2 T1+2 no
5 L: 1 (5.0) no 0/1 0/1 T2/3 no
6 L: 1 (2.0) no 0/1 0/1 T1 no
8 L: 1 (5.5) no 1/1 1/1 T3 no
9 L: 1 (2.0) no 0/1 0/1 T1 no
Number and size of RCC, in cm; L, left; R, right; Cysts, number and size of cysts; Invasion, invasion
of tumour tissue in the pseudocapsule; Breakthrough, tumour tissue breaking through the
pseudocapasule; Stage, TNM20
Most lesions were surrounded by a fibrous pseudocapsule of varying thickness.
Five out of seventeen lesions had pseudocapsular invasion, and four of these tumours
were smaller than 3 cm. Three tumours, measuring 1.3-5.5 cm (in patients 2, 3 and 8),
invaded surrounding tissue by breaking through the pseudocapsule (Fig. 2c and Table
2). In two patients (1 and 3) some macroscopically invisible cysts and combined le-
sions were found elsewhere in the removed tissue specimens by microscopic investi-
gation (Fig. 2a and b). These lesions had the same appearance as the larger cysts and
solid parts of the grossly visible tumours. Tumours detected in asymptomatic and
solid areas consisting of lobuli with an intervening, fibrovascular lattice-like stroma.
Cystic spaces were lined by uni- or multilayered clear cells, identical to those found in
the solid parts. Necrosis, haemorrhages and fibrosis also formed part of the lesions.
No sarcomatoid, chromophobe, tubulopapillary, medullary or oncocytic lesions were
encountered. Due to minimal atypia and scarcity of mitoses, all lesions were consid-
ered to be of low grade malignancy. No further grading was done due to the uniform
histopathology of the lesions amongst all patients.
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Fig. 2 a Photomicrograph show-
ing a RCC (left) as well as normal
renal tissue (right) in patient 1. An
intervening fibrous capsule is
clearly visible. The adjacent renal
tissue shows a satellite lesion (ar-
row). The tumour shows a
microcystic pattern. Most lesions
contain erythrocytes, indicating
intratumoural haemorrhage and no
surgical effects, as the adjacent re-
nal tissue does not contain eryth-
rocytes. H&E, x40.
b Magnification of the satellite le-
sion show a cyst, lined by multi-
layered clear cells. H&E, x600.
c Photomicrograph of a RCC from
patient 2 showing tumour tissue
(right) breaking through the
pseudocapsule (arrow). The adja-
cent renal tissue (left) shows no ab-
normalities. H&E, x240.
Follow-up
Lesions remaining after removal of the tumour are reported in Table 3. In patients that
experienced NSS and in the patient that underwent an unilateral nephrectomy, renal
function was well maintained. During the total follow-up time (range 21-259 months),
we found an average number of 4.6 tumours per kidney (range 0-14 tumours). Pa-
tients with involvement of the pseudocapsule by either invasion or breakthrough did
not exhibit a less favourable course than those with tumours entirely surrounded by an
intact pseudocapsule.
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Discussion
Mutation analysis in the VHL families revealed three different genotypes. Regarding
RCC, no clear interfamilial differences in phenotypes were found, although this ob-
servation is limited by the number of families and patients per family. However, in
family A (with the rare V170D mutation), from which seven patients were available
for study, considerable variation in both multicentricity and bilaterality of tumours
was observed. It is essential to collect material from many more families and patients
to be able to form an opinion on genotype/phenotype correlations.
Natural history
If not identified by monitoring, patients with VHL may have a shortened life expect-
ancy, as illustrated by patient I:1 (Fig. 1) from family A and patient 10. At present,
RCC is the cause of death in 15-50% of VHL patients.6,22,23 In symptomatic RCC, 30-
50% of the lesions metastasise to lymph nodes, liver, bone, lung or brain.17,24-26
Some cysts with lining epithelium show focally irregular hyperplastic features,10
however transformation into a solid lesion is rare.7,27,28 Fortunately, RCC does not
occur in every VHL patient, nor in every kidney, and RCC does not always have a
fatal outcome. We speculate that these features are caused by differences in family-
specific VHL germline mutation, and the timing of origin and nature of somatic
mutation(s). Such somatic mutations may be induced by environmental factors. In
this respect, it is noteworthy that five of the ten patients were smokers, of whom
patient 10 was a heavy smoker (Table 3). The current opinion is that smoking is corre-
lated with the development of RCC.29-31
Clinical
Most RCC in conjunction with VHL met the criteria of hereditary tumours (multicen-
tric, bilateral and young age of onset) and showed a slow growth rate. Radiological
studies demonstrated that the average increase of diameter in cysts was 0.5 cm/year
and 0.5-1.6 cm/year in solid lesions.7,11 Complex lesions (with cystic and solid parts)
appeared to transform to a predominantly solid lesion that continued to grow, while
the cystic part of lesions gradually regressed.7
Pathology
In our cases, most tumours were found to be of low grade malignancy. This may
account for the reasonably benign course of the disease. The presence of a
pseudocapsule did not necessarily guarantee a favourable course of disease, since
invasion and perforation of the capsule was observed in some of our cases. Whether
all VHL-associated RCCs are of low grade malignancy cannot be answered by the
limited number of cases we have studied to date. A higher grade of malignancy may
be present in VHL cases with RCCs showing more progressive growth. In the litera-
ture, most RCCs in VHL patients are staged as T1 (75%) or T2 (9-17%).12,32
Close microscopical examination of five kidneys removed from our patients
only revealed incidental small lesions, mainly in the direct vicinity of the macro-
scopic visible tumours. Controversially, Walther estimated, by extrapolation of tissue
surrounding renal lesions, that the number of microscopic clear cell lesions in an avarage
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Surgical treatment
If both kidneys are affected with multiple cysts and tumours (as in patients 5 and 7), a
difficult decision has to be made between RN or repeated NSS. If further progression
of a large number of tumours occurs, RN followed by renal transplantation may be the
first option. If a restricted number of lesions is present, NSS is indicated for tumours
larger than 3 cm including a rim of normal tissue,35 since the close surrounding tissue
may contain satellite lesions. To determine the surgical strategy, pre-operative angi-
ography for vascular mapping of tumour vessels has a limited role,36 but spiral CT for
locating renal lesions exactly is helpful.
In retrospect, the right kidney of patient 3 would have been an excellent candi-
date for NSS, with one small, well-encapsulated lesion and three subcapsular cortical
cysts (0.6-1.5 cm). Transplantation with a cadaveric kidney was undertaken in the
same session because of the patient’s fear for dialysis based on his uncle’s (patient 1)
bad experiences.
Bilateral nephrectomy followed by transplantation shortens life expectancy and
diminishes the quality of life, although it has been improved over the past decade by
the use of immunosuppressive therapy. Graft 5-year survival rates of between 80% to
90% for kidneys from living donors are reported.37,38 However, it is suggested that
immunosuppression favours the growth of pre-existing cancers.39 Goldfarb et al. stud-
ied the results of renal transplantation after bilateral nephrectomy in 32 VHL patients.40
Three patients died due to metastatic disease. Their data suggested that for limited
disease transplantation can be performed safely soon after nephrectomy, whereas in
more advanced cases (pT3 and above) a waiting period of at least two years should be
considered, to avoid transplantation in subjects with dormant lesions. In general, haemo-
dialysis has a less favourable outcome than transplantation, but it is greatly influenced
by the general health of the patient.37
The results with five patients treated by NSS are promising and renal function
was preserved in all patients. Large tumours represent more risk at enucleation (as in
patient 5) which emphasises the need for periodical examination and excision of tu-
mours before they become too large. For VHL patients, operative removal of solid
RCC (larger than 3 cm) showing progressive growth has been advocated by several
authors.7,11,16,41 It was shown that smaller tumours are more likely to be low grade and
are less likely to be associated with metastasis. Five- and ten-year cancer-specific
survival rates from NSS have been reported to be 100% and 81%, respectively.12 Our
results support the conclusion that NSS can indeed provide effective initial and pre-
ventive treatment for VHL patients with RCC.
VHL kidney was 1100 cysts (benign and atypical) with clear cell lining and 600 clear
cell neoplasms.33 However, in the following editorial comment it was questioned
whether the normal tissue in the area immediately surrounding a lesion is representa-
tive of the entire kidney.33 Extensive tumour formation may occur when inadequate
control and treatment is given, as in patient 10. But our general finding of a relatively
low number of renal lesions confirms the low frequency reported in other studies.7,13,15,34
In addition, mild manifestation of renal involvement in VHL is also illustrated by the
absence of RCC during long-term follow-up in patient II-13 (Fig. 1), as well as the left
kidney of patient 2 and also in three younger patients from family A.
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Conclusions
With a cautious note that seven of the ten patients studied came from the same family,
we conclude that RCC in VHL grows slowly and that multicentricity per kidney is
relatively low. The majority of tumours had a pseudocapsule and showed little evi-
dence of metastasis. Tumours measuring 1.8-5.5 cm can be safely removed by NSS.
However, since smaller tumours may grow progressively and break through the
pseudocapsule, we advise removing tumours measuring 2-3 cm, as well as a rim of
normal renal tissue. In all affected family members, ongoing follow-up by careful
radiological monitoring is required at least once a year.
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Abstract
Von Hippel-Lindau (VHL) disease is an autosomal dominant tumour syndrome caused
by germline mutations of the VHL tumour suppressor gene located on chromosome
3p25-26. In VHL disease tumours may occur in fourteen different target organs, in-
cluding the eye. Retinal angiomas are considered the first manifestation of VHL dis-
ease in 43% of cases, and the cumulative probability of developing a retinal angioma
in one or both eyes rises during each decade of life, reaching 80% for patients over 80
years old.
Since 1976 patients with VHL disease at the University Medical Centre Utrecht
and their at-risk relatives have been screened periodically by a multidisciplinary team.
Long term follow-up ophthalmological data were analysed with special attention to
natural course and results of treatment. In addition, we looked for a genotype-pheno-
type correlation. Retinal angiomas were found in all families. In one large family with
a missense mutation (V170D) of the VHL gene, in which the complete spectrum of
visceral- and CNS features of VHL disease is present, macular-, parapapillary-, optic
disc- and ora serrata-angiomas were also found. In general, however, a clear-cut geno-
type-phenotype correlation could not be found.
Only early detection and treatment of peripheral retinal angiomas can be ex-
pected to decrease the percentage of patients with decreased visual acuity. Therefore,
early detection and treatment of these tumours is of paramount importance. Ophthal-
mological monitoring of patients and persons at risk should start as early as possible.
In patients with apparently sporadic retinal angiomas it is advisable to perform germline
DNA analysis, since the risk of developing VHL disease is high, especially if the
angiomas are bilateral, or unilateral and multicentric, or if the patient is young, or if
there is a family history suggestive of VHL disease.
Ocular haemangioblastoma
Introduction
Von Hippel-Lindau (VHL) disease is an autosomal dominant tumour syndrome, caused
by germline mutations of the VHL tumour suppressor gene located on chromosome
3p25-26.1,2 In VHL disease tumours may occur in fourteen different target organs,
including the eye.
In the eye the typical lesion is the so-called peripheral retinal angioma, a globular
reddish tumour with a dilated tortuous feeding artery leading from the optic disc to the
tumour and a similar draining vein leading back to the disc. It is usually located in the
temporal periphery of the retina. Less frequently, the tumour is located elsewhere in
the retina, next to or on the optic disc, and even in the orbital portion of the optic
nerve.3
In the ophthalmic literature, the eponym Von Hippel’s disease is used when only
the eye is affected. If systemic abnormalities are present the disease is called Von
Hippel-Lindau disease,3,4 after Von Hippel who established retinal angiomatosis as a
clinical entity5 and Lindau who noted the association between retinal angiomatosis,
haemangiomatous cysts of the cerebellum and the visceral components of the dis-
ease.6 Von Hippel’s disease is considered the first manifestation of VHL disease in
43% of cases, and the cumulative probability of developing a retinal angioma in one
or both eyes rises during each decade of life, reaching 80% for patients over 80 years
old.7 On histopathologic examination, the ocular tumours are seen to be composed of
a proliferation of capillaries and glial cells, and are identical to the cerebellar haeman-
gioblastoma. Therefore, they should actually be called haemangioblastoma.8,9
The natural history of peripheral retinal angiomas is not fully understood; un-
treated, however, they may eventually cause blindness and loss of the eye.3 Peripheral
retinal angiomas generally become symptomatic during the third decade of life when
they cause decrease of visual acuity or a visual field defect as a result of retinal exuda-
tion, haemorrhages in the vicinity of the tumour, retinal detachment or macular pucker.10
Spontaneous regression can also occur.11 The onset and natural course of angiomas
located elsewhere in the eye is not clear and treatment is often unsatisfactory.3
Many different modes of therapy have been used to treat peripheral retinal angi-
omas: diathermic-, xenon-, laser- and cryocoagulation. All have been reported effec-
tive depending on the location, size and number of the tumours.3 However, despite
seemingly successful treatment, tumour recurrences are sometimes seen, even after
many years, probably because the tumour was only destroyed superficially.12
Since 1976 in the University Medical Centre Utrecht VHL patients and their at-
risk relatives are screened periodically by a multidisciplinary team. Long term fol-
low-up ophthalmological data were analysed with special attention to the natural course
of ophthalmological signs of the disease and results of treatment. In addition, we
looked for a correlation between the VHL germline mutations and the ophthalmologi-
cal manifestations.
Patients and methods
Data of 20 patients from six families were collected from the files. All patients had an
annual routine ophthalmological examination consisting of measurement of visual
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acuity, slit lamp examination and fundoscopy. If angiomas were present or suspected
in the far periphery of the retina, inspection with a Goldmann three-mirror lens was
performed. Additional fluorescein angiography was done if micro angiomas were sus-
pected to secure the ophthalmoscopic diagnosis, and usually before treatment of large
angiomas, in order to observe the blood supply of the tumour. Peripheral retinal angi-
omas were treated by xenon- and, later on, by laser coagulation. For small tumours,
up to one disc diameter in size, a single treatment of the surface was performed with
burns of large size (500 mm), low intensity, and long duration (0.2-0.5 sec). Larger
tumours were treated in multiple sessions, starting with treatment of the surrounding
retina, avoiding coagulation of the feeder vessels. Retinal detachment caused by reti-
nal angiomas was treated by cryotherapy of the tumours, followed by a scleral buck-
ling procedure. Recurrent retinal detachment was treated by vitrectomy and endolaser
coagulation.
Results
The six families with VHL disease are A, B, C, D, E and F. A deletion was found in
one family (F) and different missense mutations were found in five families, confirm-
ing the diagnosis of VHL disease. In four of the six probands the presenting symptom
was cerebellar haemangioblastoma. Age at presentation was between 30 - 44 years. In
one of these four probands retinal angiomas were also found. In two probands (C, D)
the presenting sign was retinal angioma. Their ages at presentation were 26 and 28
years, respectively. In one of these (D) a cerebellar haemangioblastoma was found;
the other proband (C) has the VHL germline mutation, but no other signs of the dis-
ease up till now.
In family A one person is suffering from the disease. She has secondary optic
atrophy caused by occlusive hydrocephalus because of a cerebellar haemangioblas-
toma, but no retinal angiomas or other signs of the disease.
In family B two patients have been identified. Four other members of this family
have already died because of a CNS tumour. Renal cell carcinoma, medullary hae-
mangioblastoma and pancreas cysts are also present in this family. Follow-up is 12
years. Both patients suffer from cerebellar haemangioblastoma, but only one of them
has one angioma in one eye. This was treated successfully with xenon coagulation.
In family C one person is known to suffer from the disease. She was adopted as
a baby from Korea. She suffers from a congenital motor nystagmus. At the age of 26
years she experienced a decrease of visual acuity to finger counting in the right eye, in
which she appeared to have multiple angiomas with an exudative retinal detachment.
After vitrectomy, cryotherapy and scleral buckling procedure, the tumours became
fibrotic and the retina was reattached; visual acuity, however, did not recover. Follow-
up is three years.
In family D two persons have retinal and cerebellar haemangioblastomas, but no
other signs of the disease. Follow-up is 19 years. The retinal angiomas were treated
successfully with xenon- and laser therapy. Visual acuity remained normal.
In family E twelve patients suffer from the disease (Fig. 1). Follow-up is 23
years. Another three patients had died before the start of the monitoring program.
From the records of the family doctor it appeared that they died of renal cell carci-
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noma (patient I-1) at the age of 55 years, and obstructive hydrocephalus caused by a
cerebellar haemangioblastoma at the age of 33 and 39 years (patients II-2+4) respec-
tively; no ophthalmological data were recorded. A number of ophthalmological signs
and symptoms are seen in patients of family E. The proband (patient II-7), who pre-
sented with obstructive hydrocephalus caused by a cerebellar haemangioblastoma,
has secondary optic atrophy, but no retinal angiomas at the age of 55 years. He also
has pancreas and adrenal cysts. His elder brother (patient II-3) has a small angioma on
one optic disc, which has remained unchanged for more than 20 years. Visual acuity is
near to normal in this eye. He had bilateral renal carcinomas, and cysts in cerebellum,
adrenals and pancreas. His elder sister (patient II-5) has pale optic discs. She was
operated for an intra medullary haemangioblastoma Th6-Th7, but has never had signs
of raised intracranial pressure. In addition, she has had a unilateral renal carcinoma,
bilateral phaeochromocytomas and a unilateral mamma carcinoma.
In the next generation, in patient III-4, a small parapapillary angioma and an ora
serrata angioma with a dilated feeder artery and draining vein is present in one eye.
The angiomas have never been treated and have not changed for more than 17 years.
No new ocular angiomas have developed. He also has cerebellar haemangioblasto-
mas, bilateral phaeochromocytomas, renal carcinomas, pancreatic cysts, liver cysts
and medullary haemangioblastomas. Patient III-6 has pale optic discs. She suffers
from a small cerebellar haemangioblastoma. Patient III-7 has no ophthalmological
signs. She had bilateral phaeochromocytomas. Patient III-8 developed a very small
angioma in one eye at the age of 28 years. She also has bilateral renal carcinomas.
Fig 1. Family tree of family E with VHL disease (missense mutation: V170D)
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Patient III-10 has retinal angiomas in both eyes. One of the tumours originating at the
ora serrata was floating in the vitreous cavity. After five years of uneventful follow-
up, a retinal detachment developed, that was treated successfully with a scleral buck-
ling procedure and cryotherapy of the tumour. A second retinal detachment was treated
successfully by vitrectomy, retinotomy and silicon oil implantation. Visual acuity,
however, dropped from 0.8 to finger counting and did not recover. This patient also
suffers from bilateral renal carcinomas, phaeochromocytoma and medullary haeman-
gioblastomas. Patient III-11 has no ophthalmological signs. He suffers from a unilat-
eral renal carcinoma and cerebellar haemangioblastoma. Patient III-12 has optic atro-
phy secondary to obstructive hydrocephalus because of a cerebellar haemangioblas-
toma and a macular retinal angioma that detached from the retina and is now floating
in the vitreous cavity, still attached to the optic disc. The angioma was already de-
tached from the retina when we examined her for the first time. At the age of 27 years
new angiomas started to develop in both retinas, including a recurrent angioma in the
left macula with exudation in the posterior pole (Fig. 2). After laser coagulation the
exudation disappeared. The other angiomas were treated successfully with laser co-
agulation. This patient also suffered from a haemangioblastoma of the medulla oblon-
gata and bilateral renal carcinomas. Patient III-13 developed retinal angiomas in one
eye at the age of 32 years. Family member III-14 has pale optic discs with a normal
neurological examination.
Fig. 2 Posterior pole of left eye of patient
E III-12. Angioma attached to optic disc and
floating in the vitreous cavity (black arrow).
Second angioma in macular area (white ar-
row), causing exudation along the vascular
arcade (arrow heads).
In family F eight patients are suffering from the disease; six patients live in
Turkey; two patients are seen more or less regularly in our hospital. Both patients
suffer from cerebellar haemangioblastomas and retinal angiomas. In one patient the
retinal angiomas caused an exudative retinal detachment that was treated in Turkey.
Discussion
Four of the six probands of the Utrecht families presented with symptomatic cerebel-
lar haemangioblastoma, the other two with retinal angioma. In the literature, cerebel-
lar haemangioblastoma and retinal angioma are given equally frequently as the most
common presenting feature of VHL disease.4,13-16 Symptomatic cerebellar haeman-
gioblastomas usually present in the fourth decade and symptomatic retinal angiomas
in the third decade. In monitoring examinations of documented VHL families, how-
ever, retinal angioma is the earliest and most frequent manifestation detected.13,17
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Although most retinal angiomas, both symptomatic and asymptomatic, start to
develop in the third decade, which we also found in our patients, it is not unusual to
find small lesions in teenagers from affected families, and some lesions have even
been documented from birth.17
Our patients’ case histories clearly reveal the natural course of development of ocular
angiomas. A peripheral retinal angioma starts as a small pink or grey spot, the size of
a diabetic micro aneurysm. There are no feeder vessels and no well-formed vascular
channels within the tumour. Fluorescein angiography therefore gives a picture of a
lack of perfusion. This stage 1 tumour can remain unaltered for years. Usually, how-
ever, it grows slowly until in stage 2 it shows a small, slightly elevated, red nodule. At
this point only the draining vein is prominent. On fluorescein angiography, perfusion
and profuse leakage is seen at the site of the angioma (Fig. 3). In stage 3 the angioma
attains its classic appearance: an elevated red nodule with prominent feeder vessels
(Fig. 4). Exudate can be seen on the angioma and in the macular area. Neovasculari-
sation on the surface causes haemorrhage into the vitreous body. Fluorescein angio-
graphy shows profuse leakage, micro aneurysms and capillary dropout in the sur-
rounding capillary bed (Fig. 5) because of ischaemia, caused by the shunting of circu-
lation to the angioma. In addition hyper fluorescence is seen up to several hours after
angiography. In stage 4 exudative detachment of part of the retina is seen. In stage 5
total exudative retinal detachment is seen.18
Fig. 3 Fluorescein angiographic picture of stage
2 angioma with prominent draining vein (arrow).
Fig. 4 Composite picture of classical stage 3 an-
giomas (arrows) in the temporal periphery with
prominent feeder vessels, leading from and to the
optic disc.
Stage 1 carries no risk of immediate exudation or haemorrhage. The only risk
lies in its potential for progression to stage 2, but decades may elapse between the two
stages. Stage 2 also poses no immediate threat of exudation or haemorrhage, but there
is a great risk of progression to stage 3, which may occur within months. Stage 3 is the
earliest stage in which exudation and haemorrhage pose a clinical problem. Progres-
sion to stage 4 is almost certain to occur within months and there is almost no possi-
bility of stopping the progression to the terminal stage 5. If it is not possible to destroy
the tumour(s) and reattach the retina uveitis, cataract and secondary, usually untreatable,
glaucoma will eventually develop, necessitating enucleation of the globe.18
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Fig. 5 Fluorescein angiographic picture of clas-
sical stage 3 angioma. Profuse leakage from the
angioma, micro aneurysms and capillary drop-
out in the surrounding capillary bed (arrows).
Most angiomas are present in the temporal periphery. They can, however, also
occur in the nasal periphery, in the posterior pole, at the ora serrata, next to or on the
optic disc and in the optic nerve.3,19 In family E, macular-, (Fig. 2), parapapillary-,
optic disc- and ora serrata angiomas were found (4 patients) as well as peripheral
retinal angiomas. From 1975 to 1987 only 55 cases of optic disc angiomas have been
reported, of which 24% were considered part of VHL disease.4 Angiomas originating
at the ora serrata are even more rare. In the series reported by Moore et al. in 1991,
however, 11 peripheral retinal angiomas were detected together with five angiomas
on the optic disc and one at the ora serrata in 11 patients.19
Angiomas of the optic disc appear as well-circumscribed, reddish-orange, round
or oval elevated lesions obscuring part of the optic disc, usually on the temporal side.
Less commonly, the lesion is flatter and greyish with poorly defined margins extend-
ing from the disc into the retina. Fluorescein angiography reveals that the mass con-
sists of small caliber vessels that fill early during the retinal arterial phase and leak.
The most common symptom is visual loss resulting from macular oedema, with or
without serous retinal detachment.15 Intra retinal juxta papillary angiomas appear as a
diffuse greyish thickening that obscures the border of the optic disc, often without
prominent vascular channels. They are dispersed within the retinal tissue and are not
confined to a single layer; they have communication with both choroidal and retinal
circulations. They may be confused with papilloedema, papillitis, chorioiditis, choroidal
neovascularisation, or choroidal haemangioma.18 Data concerning age of onset and
natural course are lacking. Regarding the findings in our families and in those of
Moore et al. in 1991,19 optic disc-, juxta papillary and ora serrata angiomas may occur
more commonly than previously reported. In our series these lesions, together with
retinal detachment caused by large peripheral angiomas, are responsible for the de-
creased visual acuity.
In family E pale optic discs are also found, some are secondary after obstructive
hydrocephalus caused by a cerebellar haemangioma, but some are primary in patients
without CNS lesions and with no signs of raised intracranial pressure. Up till now no
clear explanation could be given for this phenomenon. Since pale optic discs also
appeared to occur in a family member without the germline mutation, there is prob-
ably no causal relationship with VHL disease. Visual acuity is normal in the persons
with pale optic discs.
Ocular haemangioblastoma
Regarding the natural history of peripheral retinal angiomas, treatment is indi-
cated from stage 3 on.3,18 The result of treatment of small stage 3 peripheral angiomas
up to 1 disc diameter in size is usually good; tumours of 1 to 1.5 disc diameter in size
respond satisfactorily to treatment, but may require repeated treatments and they may
recur; large lesions (> 2 disc diameters in size) respond poorly and treatment may
result in further tractional detachment of the retina.18 Histopathologic examination of
moderate-sized angiomas following what appeared clinically to be successful laser
photo coagulation has revealed residual viable tumour to be present in some cases
beneath areas of superficial tissue destruction.3
Since the start of our monitoring program, peripheral angiomas were treated
with xenon- and, later on, with laser coagulation. No complications of these treat-
ments were seen and visual acuity remained normal. There have been no recurrences
in any of our patients thus far.
Ocular angiomas that usually cause a decrease of visual acuity and that are diffi-
cult to treat because treatment itself inevitably causes a decrease of visual acuity, are
optic disc-, juxta papillary-, macular- and paramacular angiomas. In our families large
peripheral, posterior pole and ora serrata angiomas were the cause of decreased visual
acuity in 20% of our patients. Coagulation therapy of papillary, juxta papillary and
macular angiomas is so unsatisfactory that treatment is not advised before visual acu-
ity drops because of exudation, and even then treatment can be more hazardous than
the subsequent natural course.10 Thus, only early detection and treatment of peripheral
angiomas can be expected to reduce the percentage of patients with decreased visual
acuity. Early detection and treatment of these peripheral angiomas is therefore of para-
mount importance. Although it will never be possible to prevent visual loss in all VHL
patients, earlier detection of asymptomatic peripheral retinal angiomas should lead to
improved visual outcome and, at any rate, a better outcome than that reported in the
series in which 36% of patients had visual acuity of less than 0.1 and 11% had enu-
cleation of the globe.4
Ocular monitoring of patients and persons at risk should start as early as possi-
ble. For ophthalmologists used to examining children, it poses no problem to examine
a child annually, starting from birth. For practical purposes, however, and since most
retinal angiomas start to develop later in life, ophthalmological examinations may
start at the age of five when the child is sufficiently cooperative to detect small periph-
eral angiomas.
In patients with apparently sporadic retinal angiomas it is advisable to perform
germline DNA analysis, since the risk of developing VHL disease is more than 40%,7
especially if the angiomas are bilateral, or unilateral and multicentric, or if the patient
is young, or if the family history is suggestive of VHL disease.
Four different clinical types of VHL disease are distinguished at the moment
(Table 1).20-22 Families A to D and F suffer from the clinical type 1. Family E suffers
from the clinical type 2B. Although clinical types of VHL disease can be distinguished,
a relation to a specific genotype has not yet been found. A clear-cut genotype-pheno-
type correlation is not very likely, because in addition to the germline mutation also
somatic mutations in the homologous allele, which can be manifold, are necessary to
bring out the ophthalmological spectrum of signs of VHL disease.
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 Patients in all our families developed peripheral retinal angiomas. In one family
with the missense mutation V170D optic disc-, juxta papillary-, macular- and ora
serrata tumours were also found. In general, however, no clear-cut genotype-pheno-
type correlation could be determined in our families with VHL disease.
Table 1. Classification of VHL disease
Type CNS Retinal Renal cell Phaeo-
haemangioblastoma haemangioblastoma carcinoma chromocytoma
I present present present absent
IIA present present absent present
IIB present present present present
IIC absent absent absent present
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Abstract
Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited syndrome pre-
senting with tumours in various organs. The Dutch VHL Working Group presents
guidelines for DNA testing and clinical monitoring, to enhance early detection and
treatment of VHL patients in the Netherlands.
Diagnosis of VHL disease is justified in patients presenting with a typical VHL tu-
mour and a positive family history. In addition, patients with a VHL-related tumour
and a negative family history may have VHL disease. Diagnosis of VHL disease can
be confirmed by molecular genetic analysis of the VHL gene and is informative in
virtually all VHL families. A patient with confirmed or suspected VHL disease should
be referred for genetic counselling.
A protocol for clinical monitoring of VHL disease is presented and is recommended
for: carriers of a VHL germline mutation; members of VHL families with an unknown
familial mutation; members of VHL families who decline testing of the familial muta-
tion; patients suspected of having VHL disease, but who do not have a VHL mutation.
Guidelines for diagnosis and monitoring
Introduction
Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited disorder with a
high penetrance and is characterised by tumours occurring in various organs. The
most frequent lesions are haemangioblastoma in retina and central nervous system
(CNS), renal cell carcinoma, phaeochromocytoma, cyst and cystadenoma in kidneys,
pancreas and epididymis, and the endolymphatic sac tumour (ELST) in the inner ear.1,2
The minimal birth incidence has been estimated at 1:36,000.3
In order to support early detection and treatment of VHL patients in the Netherlands,
these recommendations, based on international guidelines, for DNA diagnosis and
periodic, clinical monitoring have been proposed by the National VHL Working
Group.4,5 We expect early detection and treatment of complications of VHL disease,
especially from haemangioblastoma and renal cell carcinoma, will reduce morbidity
and mortality in VHL patients.
Diagnostic criteria
Clinical For diagnosing VHL disease in a patient, both clinical manifestations and
family history are important. Typical tumours that are associated with VHL disease
are: haemangioblastoma (retinal or CNS), phaeochromocytoma, renal cell carcinoma,
ELST and multiple pancreatic cysts.1,6 Multiple pancreatic cysts are specific for VHL
disease because they are rare in the normal population.7 In contrast, renal or epididy-
mal cysts occur more often in the normal population. In the presence of a positive
family history, VHL disease can be diagnosed in a patient with a typical VHL tu-
mour.1,8 In the absence of a VHL family history, two or more haemangioblastoma, or
a haemangioblastoma combined with a further typical VHL tumour are required.1
Molecular genetics The gene that, in mutated form, is responsible for the disease was
identified in 1993.9 The gene is located on chromosome 3 (3p25-26) and is a tumour
suppressor gene accordingly to Knudson’s two hit theory.10 Inactivation (mutation) of
both alleles is thought to drive a normal cell into a tumour cell. In all cells of VHL
patients a germline (inherited) mutation is present in one allele (the first hit). The
second hit is a somatic mutation in the remaining allele.
With molecular genetic analysis of DNA obtained from lymphocytes from peripheral
blood, a germline mutation is detected in virtually all well-defined VHL families.11
Many different mutations are found in the VHL gene. Between 60-70% of these mu-
tations are point mutations, or micro-deletions and -insertions in the coding region of
the VHL gene. In the other families, the VHL gene is partially or fully deleted. Muta-
tion analysis comprises direct sequencing, Southern blotting and Fluorescence In Situ
Hybridisation (FISH).11 In addition, VHL germline mutations are found in patients
with apparently sporadic haemangioblastoma (10%),12,13 renal cell carcinoma (1.6%),14
and phaeochromocytoma (3-9%).15,16
Natural history
VHL disease is characterised by inter- and intrafamilial variation in expression of the
disease. This means that both manifestations and the age at which symptoms occur
may differ not only between families but also within a family. Two phenotypes are
distinguished in VHL disease: families without phaeochromocytoma (VHL type I)
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Fig. 1 A survey of the most frequent tumours in patients with VHL disease. The percentages are
derived from studies in large populations of VHL patients (n= 43-554).1,4,6,17-21
and those with (VHL type II). Mutations that are associated with a loss of function
VHL protein are correlated with a phenotype without phaeochromocytoma. In con-
trast, families with phaeochromocytoma have predominantly specific missense muta-
tions.22 In view of the variability of expression of the disease, it was suggested that, as
well as the family-specific VHL gene mutation, external factors (environment and
lifestyle) and modifier genes also play a role.23
Penetrance of the disease is high, almost all carriers of VHL germline mutation de-
velop one or more VHL-related tumours at an age of 60 years.4 The mean prevalences
of the various tumours are depicted in Figure 1.1,4,6,17-21 Generally, tumours occur at a
relative young age in VHL patients. This age is however dependent on the intensity of
clinical monitoring of asymptomatic lesions. The mean age at diagnosis of the sepa-
rate tumours are: retinal haemangioblastoma 25 years (range 1-68 years),
phaeochromocytoma 28 years (10-56 years), cerebellar haemangioblastoma 30 years
(11-78 years) and renal cell carcinoma 36 years (15-69 years).4,5,17,24 Most VHL pa-
tients die from the consequences of cerebellar haemangioblastoma or renal cell carci-
noma.4,17
Guidelines for diagnosis and monitoring
Dutch guidelines
DNA diagnosis
Clinical monitoring (Table 1) and DNA analysis are indicated for any patient sus-
pected of having VHL disease (Figure 2). DNA analysis in minors is only possible
after consulting a clinical geneticist. The assessment of a VHL germline mutation has
consequences for confirmation of the clinical diagnosis or presymptomatic diagnosis
in family members. Diagnosis is confined to presymptomatic DNA analysis only for
persons from families with an identified VHL gene mutation.
DNA analysis for VHL disease is carried out by the Department of Medical
Genetics at the UMC Utrecht and the Department of Clinical Genetics in the Univer-
sity Hospital Rotterdam. An application for DNA testing should meet the following
requirements: 1) an informed consent procedure should proceed any application; 2) a
completed application form (including clinical data and family tree); 3) three heparine-
tubes with 10 ml blood each (two tubes for DNA-diagnostics and one for FISH).
Table 1 VHL protocol for periodic clinical monitoring
Investigation Age Frequency
Obtaining patient’s history From 10 years old annually
Physical examination, blood pressure “ “
Biochemical blood tests2,5 “ “
24 h-urine tests (catecholamines and  metanefrines) a “ “
Ophthalmological examination From 5 years old annually
Upper abdominal ultrasound From 10 years old annually
MRI (with gadolinium) cerebellum en myelum From 15 years old biannuallyb
MRI upper abdomen When indicatedc
MRI inner ear When indicatedd
Audiogram When indicatedd
Neurological examination When indicated
a Assess separately
b Radiosurgical techniques are being developed that enable presymptomatic treatment of solid cer-
ebellar haemangioblastoma, which may justify more frequent monitoring for these tumours.
c When an MRI of the myelum is made every two years, it is recommended the upper abdominal
organs be imaged simultaneously. In this way the upper abdomen is monitored with ultrasound and
MRI in alternate years.
d When an Endolymphatic Sac tumour (ELST) is suspected; i.e. hearing loss/deafness, tinnitus, or
vertigo.
A presymptomatic DNA test can only be requested by a clinical geneticist. A test
to confirm the clinical (symptomatic) diagnosis can be requested by a clinical geneti-
cist or the attending physician. It is recommended that a clinical geneticist be con-
sulted before requesting a DNA test. Firstly, a genetic diagnosis not only has conse-
quences for the applicant, but also for his family members. Secondly, since a mutation
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* At the moment, a VHL germline mutation is found in virtually all families that meet clinical
diagnostic criteria. If no germline mutation is found in the presence of a positive family history,
patients and first- and second-degree family members should be monitored according to the proto-
col. In patients who meet clinical diagnostic criteria and in patients persistently suspected of having
VHL disease, we advocate submitting the patients and their first-degree relatives to regular monitor-
ing. In the absence of a VHL family history, a once-only investigation following the protocol is
recommended. If this investigation reveals no further typical VHL tumours, the diagnosis of VHL
disease is unlikely.
Fig. 2 Guidelines for DNA diagnosis and periodic monitoring of patients with a VHL tumour.
Periodic clinical monitoring (Table 1): Who are eligible?
1. carriers of a VHL germline mutation;
2. first- and second-degree family members in a VHL family without an
identified germline mutation;
3. first- and second-degree family members that decline a DNA test;
4. patients (and first-degree family members) with a typical VHL tumour and
features that suggest the presence of a germline mutation (i.e.: young age at
diagnosis, bilateral or multiple tumours).
is not found in all VHL families, proper interpretation of the test result requires con-
sultation between the attending physician and clinical geneticist. This has particular
consequences for a patient in which the diagnosis of VHL disease is considered, but
no mutation is detected.
Assuming that early detection, periodic monitoring and treatment of VHL patients
lead to a better prognosis, giving information to family members is of utmost impor-
tance. Family members of VHL patients may not be contacted directly. An informa-
tive brochure (distributed via the patient or informed family members) can provide
information to persons at risk for VHL disease and they can be advised to seek genetic
counselling for themselves. In this way they can choose whether they (or their off-
spring) want to be tested. Patients can turn to the Dutch VHL support group for infor-
mation and advice on social issues (see: www.vhl.org).
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Abstract
Introduction Von Hippel-Lindau (VHL) disease is a complex, autosomal, dominant
inherited disorder, variably presenting with retinal and cerebellar haemangioblastoma,
renal cell carcinoma, phaeochromocytoma and endolymphatic sac tumours. Cysts and
cystadenoma may develop in kidney, pancreas and epididymis. Germline mutations
in the VHL tumour suppressor gene are found in most of the families fulfilling the
clinical diagnostic criteria of VHL disease.
Objective To summarise the results of mutation analysis of the VHL gene in familial
and sporadic cases of VHL disease diagnosed in the Netherlands.
Patients and methods Familial (n=25) and sporadic (n=7) VHL patients, as well as
sporadic patients (n=2) with VHL-related tumours, not fulfilling current diagnostic
criteria for VHL disease, were investigated by direct sequencing of the coding region,
quantitative Southern blot analysis and Fluorescence in Situ Hybridisation (FISH) of
the VHL gene.
Results We report 34 VHL germline mutations, including eight novel germline muta-
tions in the open reading frame of the VHL gene. Analyses of genotype-phenotype
correlations were consistent with previous reports. In nine sporadic patients with a
VHL germline mutation we could identify four de novo VHL gene mutations. In four
of the nine sporadic patients the parents were not available for testing. One of the nine
patients shared a VHL germline mutation with a clinically unaffected parent (age 77
years) suggesting non-penetrance of VHL disease. Family histories of VHL in two
other families were suggestive for reduced penetrance of VHL germline mutations.
Conclusions These results indicate that at least 12% of the germline mutations in the
VHL gene occur de novo.  Germline mutations are found in patients not fulfilling the
currently accepted diagnostic criteria for VHL disease. Absence of VHL symptoms in
carriers of VHL germline mutations indicate reduced penetrance and has implications
for genetic counselling.
VHL germline mutations in the Netherlands
Introduction
Von Hippel-Lindau (VHL) disease is an autosomal, dominantly inherited disorder.
Current estimates of the prevalence of VHL germline mutation carriers range between
two and three per 100.000 persons.1-3 A germline mutation in the VHL gene predis-
poses carriers for haemangioblastoma in the central nervous system and retina, and
for renal cell carcinoma, phaeochromocytoma, endolymphatic sac tumours, and cysts
and cystadenoma in kidney, pancreas and epididymis.4,5 VHL disease is characterised
by multiple, richly vascularised tumours that may occur at a young age, i.e. between
20 and 40 years.6,7 The penetrance of the disease appears almost complete by the age
of 60 years and the median expected survival is 49 years.2,7 However, early detection
of tumours by intensive radiological and clinical screening, together with advanced
operation techniques are likely to reduce both morbidity and mortality in VHL dis-
ease.5,8-10 Early identification is now facilitated by presymptomatic detection of VHL
germline mutations.
With a positive family history, VHL disease can be diagnosed in a patient with at
least one typical VHL-related tumour.5,11 Typical VHL-related tumours include retinal
and cerebellar haemangioblastoma, renal cell carcinoma, and phaeochromocytoma.5
Endolymphatic sac tumours and multiple pancreatic cysts suggest a positive carrier
status (in the presence of a positive VHL family history), since they are uncommon in
the general population.5,12 In contrast, renal and epididymal cysts occur more frequently
in the general population and alone they are unreliable indicators of the carrier sta-
tus.13 Without a family history, VHL disease can be diagnosed when two or more
retinal or cerebellar haemangioblastomas or a single haemangioblastoma in combina-
tion with a typical visceral lesion are present in a sporadic patient.5
A genetic locus for the disease was mapped to the short arm of chromosome 3 by
linkage studies,14 and the VHL tumour suppressor gene was identified in 1993 by
positional cloning.4 Subsequently, more than 300 VHL germline mutations have been
reported world-wide.15,16 Using direct sequencing of the coding region and quantita-
tive Southern blot analysis, a detection rate of 100% was reported in well-defined
VHL families.17 VHL germline mutations of all types are scattered over the VHL gene
and also include entire gene deletions.
Recently, it was demonstrated that the VHL protein (pVHL) plays a role in the
degradation (via a process called ubiquitination) of hypoxia-inducible proteins, possi-
bly including vascular endothelial growth factor (VEGF).18-20 Excessive blood vessel
formation may occur when these proteins are not properly degraded.21 pVHL fulfils
its function by binding to other proteins called Elongin C, Elongin B, and Cullin2.18
Analysis of the structure of pVHL also enables the study of genotype-phenotype
correlations. The disease has been divided in two phenotypes: families without (VHL
type I) and with phaeochromocytoma (VHL type II).15,17 Mutations in patients with
VHL type I group are most commonly found in the beta domain of the pVHL and are
predicted to lead to a loss of function. This beta domain probably binds the target
proteins for ubiquitination.18 In contrast, most mutations in patients with VHL type II
(i.e. specific missense mutations) are located in the alpha domain and allow a residual
ability to bind Elongin C.18 It was suggested that specific missense mutations would
have a dominant negative effect by sequestering key components of the ubiquitin
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pathway. Missense mutations are present in 69% of VHL type II families and 27% of
VHL type I families.17 Most VHL type II families have renal cell carcinoma (type
IIB), but some do not (type IIA).22 A phaeochromocytoma-only phenotype (type IIC)
is associated with specific missense mutations.23 Intrafamilial variability indicates that
other genetic (‘modifier’ genes) and/or environmental factors are involved in the clinical
manifestations of VHL gene germline mutations.24.
We report a survey of VHL germline mutations and their associated phenotypes
found in families and sporadic patients with VHL disease, as well as sporadic patients
with a VHL-related tumour (but not fulfilling the current diagnostic criteria for VHL
disease) diagnosed in the Netherlands.
Patients and methods
Patients
Familial VHL patients and patients with at least one VHL-related tumour were re-
ferred for DNA testing by clinical geneticists, internists, neurologists, neurosurgeons,
and ophthalmologists between January 1985 and August 1999. Detailed family histo-
ries were obtained for all carriers of a VHL germline mutation as well as clinical
information from medical and pathological reports.
The patient population consisted of 25 VHL patients with well-documented family
histories and seven VHL patients (4, 9, 16, 17, 21, 23 and 32) without a family history
but who met the diagnostic criteria of sporadic VHL disease. We also included two
patients (6 and 10) with a VHL germline mutation who do not fulfil the current VHL
diagnostic criteria. The success rates of finding germline mutations in such sporadic
patients with VHL-related tumours, e.g. central nervous system haemangioblastoma,25
renal cell carcinoma 26, and phaeochromocytoma 27 are reported elsewhere. Most of
these patients presented with a young age of onset, and/or with multicentric or bilat-
eral manifestations.
DNA analysis
DNA of probands was extracted from 10 ml peripheral blood samples according to
established procedures. Exons 1, 2 and 3 of the VHL gene and their flanking sequences
were amplified using PCR, using oligonucleotides according to Gnarra et al.28 The
flanking sequences included 90 nucleotides upstream of the start codon (the first nu-
cleotide of the coding region is 214) and 45 nucleotides downstream of the stop codon.
The nucleotides are numbered according to Latif et al. (Genbank accession number
L15409).4 PCR products were purified and subjected to sequence analysis using an
ABI 377 automated sequencer. When a missense mutation was found, DNAs of 50
non-VHL patients were used as control samples to investigate the possibility of a
polymorphism. Probands with the same germline mutation were haplotyped with a
panel of polymorphic markers linked to the VHL gene (D3S651, D3S656, D3S1038,
D3S1304, D3S1317, and D3S1537) to study common ancestry.
Screening for structural rearrangements, including deletions, was performed by
Southern blot analysis. DNA was digested with Eco RI,4 and with an Eco RI / Ase I
double digest.17 After gel electrophoresis and transfer to Hybond-N filters, the ge-
nomic DNA was hybridised with the VHL g7-cDNA probe.4 After detection of aber-
rant fragments the DNA was digested with at least two other restriction enzymes to
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exclude the possibility of polymorphisms affecting an Eco RI or Ase I site. A human
beta globin gene probe was used as an internal control to enable comparison of signal
intensities in the case of apparently normal hybridisation patterns.29 Additionally, exon-
specific probes generated by PCR amplification of exons 1, 2, and 3 were hybridised
to the same filters, for further delineation of the abnormalities.
Deletions encompassing the entire VHL gene were confirmed by FISH analysis
on lymphocytes from affected individuals. FISH analysis was carried out on met-
aphase chromosome spreads according to established procedures 30. The VHL cosmid-
11 probe was labelled by nick translation with biotin-14-dATP. After precipitation of
the labelled probe in the presence of Cot-1 DNA, pre-annealing was performed to
block repetitive sequences. The final concentration of the probe was 15 ng/ml. Hy-
bridisation of the denatured probe onto the denatured metaphase chromosomes was
carried out overnight at 37˚C. Each slide was mounted with 15 ml antifade medium
(Vectashield, Brunschwig) containing DAPI. Microscopic analysis of images was
performed using a CytoVision, Applied Imaging.
Fig.1 Southern blot analysis of eight patients with a partial VHL gene deletion.
Numbers of the probands are depicted above the lanes and correspond with the numbers of Table 1.
Genomic DNA (7 mg) was digested with an Eco RI and Ase I double digest and hybridised with 32P
labelled probes specific for the VHL gene (g7 cDNA, upper band). The lower band represents a
VHL pseudogene ( y ), located on chromosome 1.34
Samples with a rearrangement in the VHL gene exhibit a less intense g7 band and an abnormal
migrating band. The abnormal migrating band shows different lengths for all patients with a partial
deletion, except for lane 2 and 9 (both members from family 26). Patient 9 is a carrier of a missense
mutation and can be regarded as a normal control in this analysis.
25
- g7 (9.7 kb)
26 27 9 28 29 30 31 26
- y  (4.4 kb) 
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Results
Mutation analysis of the VHL gene revealed a total of 34 variants. Sequence analysis
revealed 13 missense mutations, three nonsense mutations, four microdeletions, three
insertions, and one splice site mutation (Table 1). None of the missense mutations was
found in a control panel of 50 non-VHL patients. Quantitative Southern blot analysis
showed eight gene rearrangements (Fig. 1), and two entire VHL gene deletions (five
of these ten are described in more detail in a manuscript in preparation). Since the
gene rearrangements showed unique banding patterns on Southern blot analysis, no
further investigation for shared haplotypes was undertaken. FISH analysis in patients
with deletions encompassing the entire VHL gene showed a single fluorescent signal,
whereas two signals at 3p were present on the chromosomal pairs of healthy family
members.
32 of the 34 germline mutations in the VHL gene were found in patients with
familial or sporadic VHL disease. The remaining mutations were identified in two
sporadic patients (6 and 10) with a VHL-related tumour, but who did not meet the
diagnostic criteria for VHL disease. A missense mutation (P81S) was found in a 47-
year old woman (6) with a solitary cerebellar haemangioblastoma (diagnosed at 44
years). The P81S mutation was not identified in four relatives (father, son, sister and
aunt; aged 77, 17, 43 and 64 years respectively), who were without signs of VHL-
related lesions when clinically screened. Another missense mutation (V166A) was
found in a 15-year old girl (10) with bilateral phaeochromocytoma diagnosed at age
11 years and a negative VHL family history.
In four (9, 10, 21 and 23) of the nine sporadic patients the VHL germline muta-
tion was not identified in either of their parents; while the father of patient 6 shared
the germline mutation with his daughter, but has no VHL-related tumours at the age
of 77 years. The parents of four other sporadic patients were not available for DNA
analysis. Patient 4 is an adopted child with bilateral retinal haemangioblastoma. Pa-
tient 16 (37 years old), has a negative family history for VHL disease; neither parents
(~70 years old) nor seven sibs (25-50 years old) were reported to have VHL-related
tumours. Patient 17 (59 years old) has a negative family history; his parents are de-
ceased and he has no children. Patient 32 (29 years old) has seven relatives (brother,
parents and great-parents) who underwent ophthalmological screening but were all
negative for VHL-related ophthalmological lesions.
Table 1 Genotypes and phenotypes of the reported patients and families.
Fam, family number; Code, unique family registration number; Mutation, VHL germline mutation
(consequence of point mutations); Origin: D, Dutch; B, Belgian; T, Turkish; K, Kosovarian;Prev.
reported, previously reported and reference; Pts, number of patients with an identified germline
mutation in the VHL gene; rHAB, retinal haemangioblastoma; cHAB, central nervous system hae-
mangioblastoma; RCC, renal cell carcinoma and (renal cysts); Phaeo, phaeochromocytoma; PC,
pancreatic cysts; ELST, patients suspected (deafness, tinnitius, or vertigo) for an endolymphatic sac
tumour; APMO, adnexal papillary tumour of probable mesonephric origin; other, (if in more than
one VHL mutation carrier, number of patients).
No, novel germline mutation in the VHL gene; sporadic, sporadic patient and parents not tested
(except for case 6, see text); de novo , sporadic patient and tested parents do not share the VHL
germline mutation; *, patients not fulfilling clinical diagnostic VHL criteria;  part. del, partial dele-
tion of the VHL gene that has not been precisely characterised; na, not applicable.
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Clinical manifestations corresponded with VHL type I (without phaeochromo-
cytoma) in 27 families. Different types of germline mutations were identified in these
families, including eight missense mutations (30%), three nonsense mutations, three
microdeletions, three insertions, one splice site mutation, seven partial deletions, and
two entire VHL gene deletions. Phaeochromocytoma were present (VHL type II) in
seven families, five of which had (specific) missense mutations (71%), one a
microdeletion, and one a partial deletion of the VHL gene. The frequency of missense
mutations was almost significantly different (Fisher’s exact test, p = 0.057) between
VHL types I and II. Renal cell carcinoma occurred in six of the seven families with
phaeochromocytoma (VHL type IIB). One sporadic 15-year old patient (number 10)
had only phaeochromocytoma diagnosed at age 11 (VHL type IIC).
In addition to the P81S carriers, other families in this study suggest a reduced
penetrance of VHL germline mutations. In family 1 with the R64P mutation, two
patients had bilateral phaeochromocytoma (14 and 29 years), one renal cell carci-
noma (48 years) and one a paraganglioma (29 years). Two other closely related carri-
ers (55 and 34 years) of the R64P mutation had no symptoms after clinical screening
so that the age of the first carrier would also suggest non-penetrance. Patient 4 (E70K),
aged 25 years, only has retinal haemangioblastoma. Patient 5 (S80N), aged 15 years,
only has retinal haemangioblastoma and his father, who died from cerebellar haeman-
gioblastoma aged 37 years, was his only relative with a VHL-related lesion.
Fig. 2 Comparison of germline mutations in the VHL gene reported in the USA 17 and in this study,
the Netherlands (NL).
USA NL
Discussion
We identified VHL germline mutations in 32 patients with familial and sporadic VHL
disease and in two sporadic patients with a VHL-related tumour not fulfilling the
currently accepted diagnostic VHL criteria. The mutation spectrum did not differ signifi-
cantly from that reported in a comparable study (Fig. 2).17 We identified two unrelated
families with the R167Q mutation. Codon 167 is a hotspot for mutations in the VHL
gene (Fig. 3) and has a structurally central role in the functional domain of the VHL
protein that binds Elongin C.18 In addition, we confirmed another recurrent VHL
germline mutation (440 del TCT), which has been decribed at least ten times world-
wide.15,17,32 Apparently, the presence of a tandem repeat (TCTTCT) renders this se-
quence susceptible to the deletion of a TCT triplet. Haplotype analysis with six poly-
morphic markers ruled out the possibility of common ancestry for both mutations.
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38%
Insertion
2%
Deletions
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This study identified eight novel germline mutations and 10 deletions (Table 1).
Since the exact breakpoints of the deletions were not investigated in either the litera-
ture or this study, it remains obscure whether the deletions resemble reported ones.
Recently, a new technique, ‘long PCR’, was developed that facilitates the detection of
deletion breakpoints.35 The authors successfully sequenced deletion breakpoints in
nine unrelated patients from VHL families, after a germline deletion was demon-
strated with long PCR.
Four of the six missense mutations identified in the 5’-end of exon 1 of the VHL
gene were associated with a mild phenotype or reduced penetrance (Table 1 and Fig.
3). In this study a P81S mutation presented in an apparently sporadic 44 year old
patient with a solitary cerebellar haemangioblastoma. Four other closely related carri-
ers (17, 43, 62 and 77 years) have no VHL-related tumours so far. Particularly, the
cases of two older patients suggest reduced penetrance of the P81S germline muta-
tion.
The P81S mutation has been reported four times previously: (1) in an isolated
German patient with a full-blown VHL tumour spectrum (i.e. cerebellar and spinal
HAB, renal cell carcinoma, and renal, pancreatic and epididymal cysts); (2) in a 34-
year-old American patient with HAB-only; (3) in 35-year-old American patient with
retinal haemangioblastoma and islet cell tumour of the pancreas, the father is the only
other relative with a VHL-related tumour and had a phaeochromocytoma; (4) in an
isolated Japanese patient with multiple HABs and a renal cell carcinoma.15,17,36 Con-
firmation of reduced penetrance will have implications for genetic counselling in these
families and contrasts with the previous observation that penetrance of the disease is
almost complete by the age of 60 years.2,7
In addition, the R64P, E70K and S80N mutations possibly predispose to reduced
penetrance. Since these missense mutations are present within the first part of the
translated area of the VHL gene, they could have a mild effect on the VHL protein. In
contrast, the two missense mutations in the Serine65 residue were associated with
more severe phenotypes. Serine65 is mutated more frequently and has so far been
described in seven families world-wide.32 This may indicate that this amino acid is
located within an important functional domain of the VHL gene.
We identified four VHL germline mutations as definitely de novo in nine spo-
radic patients. The families of three further sporadic VHL patients were suggestive for
de novo occurrence of the mutations. We estimate that de novo mutations in the VHL
gene in the Netherlands therefore occur in least 12% (4/34) to 21% (7/34) of the
identified cases of VHL disease. Data in the literature on de novo mutations are scarce.
VHL germline mutations are detected. In 4-15% of the identified VHL germline mu-
tations, the mutation was found in patients without a family history,4,37 and may repre-
sent de novo mutations or incomplete penetrance. Richards et al. studied 106 families
with known VHL gene mutations, of whom 23 families were presumed to have a de
novo mutation (22%). A de novo mutation in the VHL gene was identified in 16 spo-
radic patients (15%), while in the remaining seven cases the parents could not be
tested.37 It is conceivable that only a small proportion of de novo mutations are recog-
nised, since sporadic patients with a single VHL-related lesion are not routinely tested
for VHL germline mutations.
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VHL germline muations were detected both in sporadic patients with two or
more typical VHL lesions as well as in sporadic patients with a single VHL-related
lesion. An alternative explanation for the occurrence of sporadic patients with a single
VHL-related tumour may be that they represent mosaicism and therefore have a milder
phenotype. Mosaicism has so far been described in only two VHL families.17 More-
over, independent somatic mutations may occur by chance and cause a single typical
VHL-related lesion in a sporadic patient. The success rates of finding VHL germline
mutations in sporadic patients with a single VHL-related lesion, e.g central nervous
system haemangioblastoma, phaeochromocytoma and renal cell carcinoma, are re-
spectively 10%, 3% and 1.6%.25-27 Most of the sporadic patients with a VHL germline
mutation present with a young age of onset, and/or with multicentric or bilateral mani-
festations.
In conclusion, we recommend genetic screening for VHL germline mutations
not only for patients who meet the clinical diagnostic criteria, but also for sporadic
patients with a VHL-related tumour who do not meet the classic diagnostic VHL
criteria. These patients should be screened particularly when they present at a young
age of onset, or with multicentric or bilateral tumours. We have presented evidence
for non-penetrance of VHL germline mutations and found that a significant propor-
tion of germline mutations in the VHL gene concern de novo mutations. Because the
costs of DNA analysis are relatively low, the molecular genetic analysis of the VHL
gene is readily feasible, and the vast majority of VHL gene mutations can be detected,
we strongly recommend that sporadic patients should be analysed for VHL germline
mutations. Especially, since each identified proband enables genetic counselling and
clinical management for VHL disease of at risk family members.
Fig. 3 VHL germline mutations in the Netherlands (in black) and world-wide (deletions are not
shown).15,32 The position of each mutation in the coding region is depicted by a symbol representing
the specific mutation (see caption). The mutations are pooled per 10 nucleotides. Mutations that are
located close to the intron-exon boundaries, for example splice site mutations, are placed in their
exon of origin. A hotspot for VHL germline mutations is readily visible in the beginning of exon 3,
or more specific at nucleotide 712/713 (codon 167). Note that mutations in the VHL gene are re-
stricted to an area between nucleotide 376 (codon 55) and nucleotide 820 (codon 202). The solid
bars below represent genomic deletions found in probands 25-34, the dotted lines characterise the
possible extent of the deletions.
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Abstract
Von Hippel-Lindau (VHL) disease is a hereditary tumour syndrome characterised by
predisposition for bilateral and multi-centric haemangioblastoma in the retina and
central nervous system, phaeochromocytoma, renal cell carcinoma, as well as cysts in
the kidney, pancreas and epididymis.
We describe five families where direct sequencing of the coding region of the
VHL gene failed to identify the family-specific mutation. Further molecular analysis
revealed deletions involving the VHL gene in each of these families. In four families
partial deletions of one or more exons were detected by Southern blot analysis. In the
fifth family, FISH analysis demonstrated deletion of the entire VHL gene.
Our results show that (quantitative) Southern blot analysis is a sensitive method
for detecting germline deletions of the VHL gene that should be implemented in rou-
tine DNA diagnosis for VHL disease. In addition, our data support the previously
established observation that families with a germline deletion have a low risk for
phaeochromocytoma. Furthermore, families with a full or partial deletion of the VHL
gene display a phenotype with a preponderance of central nervous system haeman-
gioblastoma.
Five families with VHL germline deletions
Introduction
Von Hippel-Lindau (VHL) disease is a hereditary tumour syndrome characterised by
predisposition for bilateral and multi-centric haemangioblastoma in the retina and
central nervous system, phaeochromocytoma, renal cell carcinoma, as well as cysts in
the kidney, pancreas and epididymis, and endolymphatic sac tumours. VHL disease is
a relatively rare disorder, with an estimated birth incidence of 1/36,000.1 The basis of
familial inheritance of the disease is a germline mutation in the VHL tumour suppres-
sor gene, located in chromosome region 3p25-26 and identified in 1993.2 The disease
is inherited as an autosomal dominant trait with a high penetrance. A genotype-pheno-
type correlation has been described for the presence of phaeochromocytoma, but not
for other VHL-related tumours.3
Germline mutations are found in up to 100%.4 of the families fulfilling the clini-
cal VHL criteria.5,6 Missense, nonsense, splice site mutations, and microdeletions and
-insertions, are detected in approximately two-thirds of these families.3,4,7 In one-third
of the VHL families, large deletions (4 - 380 kb) are found.3,4,7 Such deletions are
demonstrated by Southern blot analysis,4 pulsed field gel electrophoresis,8,9 or fluo-
rescent in situ hybridisation (FISH).10,11
Detection of germline mutations in VHL families allows diagnosis of the dis-
ease, and also at an early or presymptomatic stage. Identification of carrier status
avoids the inconvenience of intensive clinical surveillance of non-carriers. Carriers of
the mutated VHL gene can be monitored closely and given the appropriate treatment.
We describe five families where direct sequencing of the coding region of the
VHL gene failed to identify the family specific mutation. However, further molecular
analysis revealed large deletions involving the VHL gene in each of these families.
Evaluation of clinical features in these families suggests that VHL gene deletions
result in a disease phenotype characterised by an absence of phaeochromocytoma and
a high incidence of haemangioblastoma.
Patients and methods
Patients
The five families (A, B, C, D and E) described here were referred to the Department
of Medical Genetics, UMC Utrecht, for germline mutation analysis in the VHL gene.
The patients were clinically examined in the university hospitals of Utrecht, Groningen,
Leuven and Gent, and in the Merwede Hospital, Dordrecht. (Table 1). Clinical moni-
toring included annual ophthalmoscopy, yearly alternate Magnetic Resonance Imaging
(MRI) and ultrasound of the abdomen, and - in variational frequencies - MRI of the
central nervous system (CNS).12 All probands fulfilled the clinical diagnostic criteria;
i.e. in the presence of a positive family history, a diagnosis of VHL disease can be
made by the identification of a single retinal or cerebellar haemangioblastoma, renal
cell carcinoma, or phaeochromocytoma, in an at-risk individual.5,6
DNA analysis
High molecular weight DNA was isolated from peripheral blood samples according
to established procedures. Exons 1, 2 and 3 of the VHL gene and their immediately
flanking sequences were amplified by PCR, using oligonucleotides according to Gnarra
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et al. 1994.13 The flanking sequences included 90 nucleotides upstream of the second
start codon in exon 1 and 45 nucleotides downstream of the stop codon in exon 3.
Amplification products were purified and subjected to automated sequence analysis
on an ABI 377. The amplification primers were used as primers in the sequencing
reactions.
Screening for structural rearrangements, including gross deletions, was performed
by Southern blot analysis. DNA was digested with Eco RI alone,2 and with an Eco RI
/ Ase I double digest.4 To confirm the results two other restriction enzymes, Hind III
en Stu I were used (see Fig. 1 for restriction map). After gel electrophoresis and trans-
fer to Hybond-N filters, the genomic DNA was hybridised with the VHL g7-cDNA
probe,2 according to the manufacturer’s instruction. The human beta globin gene was
used as an internal control.14 Additionally, exon-specific probes generated by PCR
amplification of exons 1, 2, and 3 were hybridised to the same filters.
Fig. 1 Genomic organisation of the VHL gene (to scale), including the 5'- and 3' untranslated regions
(UTR), the VHL g7 probe and a restriction map of enzymes used in this article. Numbers refer to
size of restriction fragments in kb (= 1000 base pairs). The solid bars below represent genomic
deletions found in families A-E, encompassing the exons indicated. The dotted lines characterise the
possible extent of the deletions.
FISH
FISH analysis was carried out on metaphase chromosome spreads according to estab-
lished procedures.10 The VHL cosmid-11 probe was labelled by nick translation with
biotin-14-dATP. After precipitation of the labelled probe in the presence of Cot-1
DNA, pre-annealing was performed to block repetitive sequences. The final concen-
tration of the probe was 15 ng/ml. Hybridisation of the denatured probe onto the dena-
tured metaphase chromosomes was carried out overnight at 37˚C. Each slide was
mounted with 15 ml antifade medium (Vectashield, Brunschwig) containing DAPI.
Microscopic analysis of images was performed using a CytoVision, Applied Imaging.
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Table 1.  Genotypes and phenotypes
Fam Age Origin Deletion Pts Number of patients with a VHL-related manifestation
(mean) Phaeo RCC cHAB rHAB Other
A (2) 16-37 Turkish exon 1+2 5 0 2 4 2 Pancreatic cysts (2 ),
(31) bilateral renal cysts (1 )
B (15) 20-80 Dutch exon 1 20 0 1 17 12 Pancreatic cysts (2),
(49) multiple ovarian cysts (1)
C (23) 47-72 Belgian exon 1-3 5 0 0 5 0 Pancreatic cysts (1),
(57) ovarian cyst and renal cyst (1 )
D (51) 46-? Belgian exon 1 2 0 0 2 1 Pancreatic cysts (1)
(46)
E (61) 31-60 Dutch exon 1 2 0 0 0 2 Neurofibromatosis (1)
 (46)
Total 16-80 (47) 34 0 3 28 17
Fam, family (unique identification number); Age, range of current age in years of affected family
members; Deletion, germline mutation; Pts, number of clinically affected family members; Phaeo,
phaeochromocytoma; RCC, renal cell carcinoma; cHAB, central nervous system haemangioblas-
toma; rHAB, retinal haemangioblastoma
Results
Clinical manifestations
No phaeochromocytoma occurred in any of the 34 clinically well-monitored patients
in the five families studied (Table 1). Other visceral VHL-related manifestations in-
cluded: three patients with renal cell carcinoma, two with renal cysts, six with pancre-
atic cysts and two with ovarian cysts. Five patients had symptoms associated with an
endolymphatic sac tumour (i.e. hearing loss, tinnitus or vertigo), however, magnetic
resonance imaging did not show tumours in the posterior fossa in these patients. One
patient in family E had neurofibromatosis.
CNS as well as retinal haemangioblastoma were found in four of the five fami-
lies: in the retina in 17 patients (50%), and in the central nervous system in 28 patients
(82%).
Germline mutations in the VHL gene
In family A direct sequencing did not reveal a germline mutation, neither was linkage
analysis with highly polymorphic markers informative (data not shown). Southern
blot analysis after Eco R1 digestion, with the g7 probe and an internal control probe,
demonstrated an extra band above the 20 kb normal fragment in the proband. To
further characterise the putative genetic alteration, Southern blot analysis was repeated
using a panel of restriction enzymes, of which Hind III showed an aberrant fragment
segregating with the disease (Fig. 2). Hybridisation of the Hind III blot with radio-
labelled PCR products of exons 1, 2 and 3 demonstrated a deletion of exon 1 and 2.
This deletion was confirmed by digesting DNA with the enzymes Bam HI, Ksp 632I
and Bgl II, that have restriction sites in exons 1, 2 and 3, respectively. Bam HI re-
vealed a diminished intensity of the exon 1 specific band, and Ksp 632I demonstrated
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an extra band, also suggesting loss of a restriction site. Bgl II showed a normal band-
ing pattern. This finding was also confirmed with Stu I restriction enzyme that yields
fragments of the three separate VHL exons. On Southern blot analysis diminished
band intensity was seen for exons 1 and 2, and a normal intensity for the fragment
containing exon 3 (data not shown).
Consequently, Southern blot analysis was also performed in four additional fami-
lies where no mutations in the VHL gene had been detected by direct sequencing. In
families B and D, Southern blot analysis using Eco RI and hybridisation with the g7
probe, generated an aberrant restriction fragment (Fig. 3). This aberrant restriction
fragment was recognised by probes representing exons 2 and 3. However, hybridisa-
tion with the exon 1 probe resulted in a normal banding pattern, indicating a deletion
encompassing exon 1.
In the proband from family C, six different restriction enzymes (Eco RI, Eco RI
/ Ase I double-digestion, Hind III, Stu I, Dra I and Pvu II) consistently revealed a
diminished band intensity of the VHL band compared to the beta globin control probe.
This indicated the presence of a deletion encompassing the entire VHL gene. Indeed,
FISH analysis with the cos-11 probe demonstrated loss of signal of one of the two
VHL alleles in three patients from this family, but not in an unaffected family member
(Fig. 4).
Fig. 2 Analysis of the segregation of an aberrant fragment with the disease.
Numbers of the persons tested of family A correspond with the Southern blot analysis lanes.
Genomic DNA of 11 family members and of three control persons was digested with Hind III and
revealed an aberrant banding pattern in three affected family members.
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Fig. 4 Detection of a
deletion encompassing
the entire VHL gene by
FISH analysis in family
C. A loss of signal from
one of the two VHL
alleles (short arrow) was
detected in a patient
from family C. The long
arrows represent the
centromeric probe of
chromosome 3.
Fig. 3 Constitutional VHL gene deletions identified by Southern blot analysis in five families.
Genomic DNA from family A-E and control (N) digested with Eco RI (lane 1-6) and with Eco RI /
Ase I (lane10-15) was hybridised with the g7 probe and a beta-globin control probe. The lambda-x-
Hind III marker (lane 8) shows fragment sizes in kb (= 1000 base pairs). Aberrant bands are indi-
cated with arrows. The bands marked with an asterisk (*) might represent a restriction site polymor-
phism or partially digested DNA.
In family E, we noticed that Eco RI, as well as Hind III and Stu I did not result in
abnormalities on Southern blots. As recently described by Stolle et al. (1998), the
resolution of Southern blot analysis for the VHL gene is improved by using an Eco RI
/ Ase I double-digestion. When we subjected all five families to the latter method,
aberrations could be seen, as expected, in families A, B, C and D (Fig. 3). Surpris-
ingly, the proband from family E showed an altered restriction fragment. Further analy-
sis revealed a deletion of exon 1.
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Discussion
Detection of VHL gene deletions
We describe five kindreds with germline deletions of the VHL gene. In four families
partial deletions removing one or more exons were readily detected by Southern blot
analysis. In a fifth family, FISH analysis demonstrated deletion of the entire VHL
gene We found that these deletions are involved in 28% (5/18) of the VHL families
that were referred to our department (unpublished data). Although in three families
(B, D and E) the deletion involved exon 1 only, differences in the restriction fragment
patterns generated by Southern blot analysis indicated that the deletions were distinct
and had different breakpoints. Our results indicate that Southern blot analysis (and
FISH when necessary) should be implemented in routine diagnostic screening protocols
for VHL gene mutations. The Eco RI / Ase I double-digestion hybridised with g7
cDNA and a control probe is becoming the method of choice in screening for large
deletions in the VHL gene.4 Southern blot analysis using Eco RI only is a less sensi-
tive method of detecting VHL gene deletions, as illustrated in family E and two cases
in the study by Stolle et al. 1998.4 Each of these cases had rearrangements detectable
by Eco RI / Ase I digestion that were not found after  Eco RI digestion. The Eco RI /
Ase I double-digestion has a high resolution because it isolates exactly the coding
region of the VHL gene. To further delineate the molecular nature of the deletion, the
enzymes Bam HI, Ksp 632I and Bgl II, which have restriction sites in exons 1, 2 and 3,
respectively, may be applied as well as hybridisation of Southern blot analysis with
probes for the individual exons of the VHL gene.
When Southern blot analysis of the VHL gene, using Eco RI alone or the Eco RI
/ Ase I double-digestion, demonstrates a diminished band intensity, FISH analysis
should confirm the deletion of one VHL allele. The presence of large deletions may
also be revealed in studies involving highly polymorphic short-tandem repeat (STR)-
markers. Deletions encompassing polymorphic marker loci will result in loss of spe-
cific alleles and reduced intensities for observed alleles.
Genotype-phenotype correlations
Phaeochromocytoma The five families were affected with various VHL-related tu-
mours, except for phaeochromocytoma. This relationship between genotype and the
VHL phenotype has been described in several studies.3,4,7,15,16 Families with a deletion
or a mutation that predicts a truncated VHL protein are predominantly associated with
a disease phenotype without phaeochromocytoma (VHL type I). Whereas, 69% of
families with phaeochromocytoma (VHL type II) is associated with specific missense
mutations.4 It is hypothesised that phaeochromocytoma may arise from a dominant-
negative effect of VHL proteins, based on the involvement of VHL in the multi-pro-
tein VCB (VHL-Elongin C-Elongin B) complex that may target proteins for degrada-
tion (via a process called ubiquitination).17 Structural analysis of this complex re-
vealed that VHL has two protein-binding sites. A mutant (type II) having a defect in
only one site may exert a dominant-negative effect by sequestering key components
of the ubiquitin pathway.17,18 However, the dominant negative model would implicate
that one ‘hit’ may be sufficient for the initiation of phaeochromocytoma tumourigenesis.
This hit will probably concern a specific missense mutation, that occurs either in the
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germline or as a somatic mutation. Since oncogenesis is a multi-step process, other
genes must also be involved in tumourigenesis, otherwise every carrier of such a mis-
sense mutation would develop phaeochromocytoma. In addition, one would expect
also very young patients with phaeochromocytoma.
In contrast, mutations found in families without phaeochromocytoma (type I)
are predicted to cause a complete unravelling of the VHL structure.17 This genotype-
phenotype correlation was confirmed in a comparison of phenotypes of our families
with those reported in the literature.15,16 with deletions and missense mutations associ-
ated with VHL types I and II (Fig. 5). The absence of phaeochromocytoma in our
families may be explained by the presence of deletions that are unlikely to result in
dominant-negative VHL proteins.
Fig. 5 The frequency of patients with four types of VHL tumours associated with their genotype.
This figure shows pooled data of genotypes and phenotypes in families from the present study, and
in families studied by Glavac et al. and Chen et al.15,16   Phaeo: phaeochromocytoma; RCC: renal cell
carcinoma; cHAB: central nervous system haemangioblastoma; rHAB: retinal haemangioblastoma.
The missense mutation T505C (Tyr98His) was the only missense mutation that we included in the
missense type IIa group. More missense type IIa mutations could still be hidden in the missense IIb
group. Data from the three studies were pooled, but we excluded those deletion patients from our
study since they differed significantly (p < 0.001) in their incidence of RCC compared to the two
other studies.
Renal cell carcinoma Our families showed a relatively low frequency of renal cell
carcinoma (9%), compared to other studies (41%).15,16 We therefore did not include
our deletion patients in Fig. 5. Renal cell carcinoma in VHL patients occur at a mean
age of 36 years,19 and the mean age, as well as the median age, of the VHL patients we
studied was 47 years. The mean age of the patients in the two comparison articles was
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not reported. It was hypothesised that renal lesions develop as a consequence of sev-
eral structural aberrations such as large deletions, nonsense, splice and frame shift
mutations, and insertions.16 So far, a low frequency of renal cell carcinoma has only
been reported in families (VHL type 2A) with specific missense mutations.20 (Fig. 5).
The above suggests that the relationship between germline mutation and renal
cell carcinoma in VHL appears to be rather complex. Apart from chance, the rela-
tively low frequencies of renal cell carcinoma reported in our clinically well-moni-
tored families could be due to other factors. Like retinal haemangioblastoma in VHL
patients, modifier genes.21 or external factors may contribute to a renal cell carcinoma
risk (e.g. smoking is associated with a higher risk).22-24
Haemangioblastoma So far, the risks of CNS haemangioblastoma in VHL disease
have not been correlated with allelic heterogeneity. Our deletion families exhibited a
phenotype with a preponderance of CNS haemangioblastoma (Table 1). This prompted
us to investigate whether phenotypes of families with VHL gene deletions differ from
families with other VHL gene germline mutations (Fig. 5). With respect to the inci-
dence of CNS haemangioblastoma, we noted that families with deletions did not sig-
nificantly differ from other types of VHL gene germline mutations; except for fami-
lies with missense mutations, who exhibited a low frequency of CNS haemangioblas-
toma. On a closer look, we identified that this relatively low frequency of CNS hae-
mangioblastoma in families with missense mutations was caused by a specific subset
of missense mutations, i.e. type IIa (Fig. 5). Thus, VHL deletion families show a
significantly (Chi-square 85, p < 1x10-10) higher incidence of CNS haemangioblas-
toma compared to type IIa missense mutations. Apparently, VHL IIa mutations are
not only associated with a low risk for renal cell carcinoma, but also for CNS haeman-
gioblastoma.
In contrast to CNS haemangioblastoma, the risk for retinal haemangioblastoma
is comparable for all kinds of VHL gene germline mutations. Since retinal and CNS
haemangioblastoma are histopathologically identical and both arise from stromal
cells.25,26 one would also expect a relatively low frequency of retinal haemangioblas-
toma in families with type IIa mutations. However, this was clearly not the case. These
two findings (the high frequency of CNS haemangioblastoma in VHL deletion fami-
lies compared to type IIa missense mutations, whereas the risk of retinal haemangiob-
lastoma is similar for both groups) tempted us to speculate upon possible explana-
tions.
Assuming that type IIa missense mutations result in a high frequency of
phaeochromocytoma, the same mutations seem to have the opposite effect on the
incidence of CNS haemangioblastoma. However, apart from considering the different
functional effects of VHL mutations, it is clear that other factors, including tissue-
specific differences may also play a role. For instance, stromal cells in the retina could
require a different level of functional VHL protein to maintain cellular homeostasis
than stromal cells in the CNS. Also, the multi-functional VHL protein may be impli-
cated in different cellular pathways in the retina and the CNS. Moreover, there is
evidence that modifier genes play a role in the aetiology of retinal haemangioblas-
toma.21 and this could be similar for other target tissues in VHL disease.
Five families with VHL germline deletions
Interestingly, in family C the deletion of the entire VHL gene is associated with
a phenotype with a preponderance of CNS haemangioblastoma. Given that deletions
of the entire VHL gene represent true null alleles, this family supports the manifesta-
tion of haemangioblastoma occurring when the VHL gene is in the hemizygous state.
Although complete VHL gene deletions occur in approximately 9% of VHL families.4
no clinical details have been published for complete gene deletion families. Addi-
tional studies embodying carefully executed clinical analysis of patients with entire
VHL gene deletions are required to test our hypothesis.
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Abstract
Objective In addition to families with Von Hippel-Lindau (VHL) disease, sporadic
patients with haemangioblastoma (HAB) in the central nervous system have also been
found to carry VHL germline mutations. Carriers of such a mutation and their rela-
tives have a risk of developing multiple tumours. We investigated the frequency of
VHL germline mutations in HAB-only patients.
Patients and methods 84 patients with a single HAB (23 Dutch, 61 UK) and four
with multiple HAB (two Dutch, two UK), with no clinical or radiological evidence of
VHL disease, were studied by direct sequencing of the coding region and quantitative
Southern blotting.
Results A VHL germline mutation was found in three of 84 (3.6%) single HAB pa-
tients. A germline VHL mutation was detected in a 44-year old woman with a solitary
cerebellar HAB, as well as in four clinically unaffected close relatives, and in two
single HAB cases presenting at ages 29 and 36 years. Germline VHL mutations were
detected in two of four cases with multiple HAB.
Conclusions VHL gene mutation analysis should be offered to all HAB patients
younger than 50 years. Further data is required to evaluate the detection rate in late-
onset cases. The low detection rate in patients with multiple HAB may indicate the
presence of somatic mosaicism or additional HAB susceptibility genes.
Patients with CNS haemangioblastoma-only
Introduction
Haemangioblastomas (HAB) are non-metastasising tumours of the central nervous
system and account for about 2% of all intracranial tumours.1 HAB arise preferen-
tially in the cerebellum (~ 75%), medulla and spinal cord (~ 25%).2 HAB in the cer-
ebrum are rare.3 HAB are regarded as benign on their histopathological characteris-
tics and do not normally invade the surrounding brain. However, complications may
arise due to the tendency of HAB to form expanding cysts, leading to elevated or even
life-threatening intracranial pressure.2 They are composed predominantly of vascular
and stromal cells.2,4 The frequent presence of haemorrhages and cysts means the tu-
mours vary in morphological appearance.2 Four types of HAB can be recognised
macroscopically: 5% are cysts, 60% predominantly cystic, 26% predominantly solid,
and 9% solid.5
The standard treatment is complete microsurgical removal,5-7 aided if necessary
by preoperative embolisation to reduce the tumour’s vascularity.8 Stereotactic radio-
surgery shrinks or stops the growth of small- or medium-sized HAB.7,9,10 Adjoining
cysts, however, do not respond to radiosurgery and require later and sometimes re-
peated evacuation.7
HAB may occur in sporadic form or as a manifestation of Von Hippel-Lindau
(VHL) disease.11 VHL disease is an autosomal dominant tumour syndrome with an
estimated birth incidence of approximately 1:36,000.12 The disease is characterised
by a predisposition to bilateral and multifocal tumours. The most common tumours in
VHL disease are HAB in the central nervous system and retina, clear cell carcinoma
in the kidney, phaeochromocytoma in the adrenal gland, endolymphatic sac tumours
in the inner ear, as well as cysts in the kidney, pancreas and epididymis. In the pres-
ence of a positive family history, a diagnosis of VHL disease can be made by the
identification of a single retinal or cerebellar HAB, renal cell carcinoma,
phaeochromocytoma, or multiple pancreatic cysts in an at-risk individual.13,14 In iso-
lated cases of VHL disease, two or more HABs, or a single HAB in association with a
visceral manifestation are required.14
The basis of familial inheritance of VHL disease is a germline mutation in the
VHL tumour suppressor gene, first identified in 1993 and located in chromosome
region 3p25.15 In both VHL disease and sporadic HAB, allelic losses and mutations of
the VHL tumour suppressor gene affecting stromal cells have been found, suggesting
that stromal cells represent the neoplastic component of a HAB.4,16 In addition, it was
demonstrated that vascular endothelial growth factor (VEGF) is upregulated in stro-
mal cells as a consequence of mutations in the VHL gene.17
VHL disease demonstrates variable expression, age-dependent penetrance, and
a low but consistent new mutation rate.12,18 The diagnosis of VHL disease should be
considered in all patients with a HAB, as early recognition of a predisposition to
develop further HAB and other tumours (e.g. renal cell carcinoma) may reduce mor-
bidity and mortality. The diagnosis of ‘new mutation’ VHL cases is frequently de-
layed because at least two typical manifestations are required, whereas molecular
genetic diagnosis of VHL disease offers the potential to detect subclinical cases of
VHL disease in sporadic patients with a single HAB. VHL disease demonstrates com-
plex genotype-phenotype correlations. Most VHL gene mutations predispose to HAB,
Genetic investigations 3.3
but specific missense mutations may cause high or low risks for renal cell carcinoma
or phaeochromocytoma.19-23 In addition, rare missense mutations may produce a
phaeochromocytoma-only phenotype.24-26 This suggests that specific VHL gene muta-
tions might cause a HAB-only phenotype.
To investigate the genetic epidemiology of HAB in the central nervous system,
we performed an international multicentre study of patients with single HAB and
multiple HAB without evidence of VHL disease (i.e. HAB-only). As the mean age of
VHL patients with HAB is significantly younger than that for sporadic cases, 29 vs 48
years27 (or 33.5 vs 43.6 years28), we directed our study towards younger patients with
single HAB as these present the most difficult diagnostic problems in clinical prac-
tice.
Patients and methods
Patients
We investigated two groups of patients with HAB-only in the central nervous system.
Group 1 consisted of 61 UK and 23 Dutch HAB patients with a single HAB. These
cases were ascertained with the help of neurosurgeons, neurologists, internists and
clinical geneticists. In addition to DNA analysis, all patients underwent clinical ex-
aminations for detection of VHL associated tumours (ophthalmological examination
and abdominal sonography or MRI) with negative findings. Group 2 consisted of four
patients with multiple HABs, but no other evidence of VHL disease (i.e. absence of
further VHL-related tumours) on clinical screening and radiological screening. All
patients had histopathologically confirmed HAB at operation.
Age at diagnosis
Between 1973 and 1996 a total of 182 HAB patients were reported to the National
Dutch Pathological Archive (Palga). Figure 1 shows the age at diagnosis of Palga
patients as well as studied patients. Details of age distribution of a previous popula-
tion based cohort of UK HAB patients have been reported previously.27
Fig. 1 Number of patients and age at
diagnosis for:
182 patients with haemangioblas-
toma (HAB) in central nervous sys-
tem (CNS) reported in the  National
Dutch Pathological Archive (Palga),
between 1973 and 1996.
23 Dutch patients in this study with
a single HAB, between 1996 and
1999.
The x-axis represents the age at di-
agnosis, the y-axis represents the
number of patients with haeman-
gioblastoma
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In 1996, guidelines were distributed via the Dutch newsletter for neurologists on
screening all patients with a HAB for a VHL germline mutation. The Dutch patients in
the present study were referred for DNA diagnosis from 1996 to 1999, and the mean
age at diagnosis was 37.5 years (range 14-71 years). Compared to unselected cases,
the age distribution in the UK as well as in the Dutch cases in this study was biased
towards an earlier age at onset.
DNA analysis
High molecular weight DNA of the probands was isolated from peripheral blood ac-
cording to established procedures. Exons 1, 2 and 3 of the VHL gene and their imme-
diately flanking sequences were amplified using the polymerase chain reaction.29 The
flanking sequences included 90 nucleotides upstream of the start codon (the first nu-
cleotide of the coding region is 214) and 45 nucleotides downstream of the stop codon.
The nucleotides are numbered according to Latif et al. (Genbank accession number
L15409).15 PCR products were purified and subjected to sequence analysis using ei-
ther an ABI automated sequencer or the dideoxy-chain termination reaction with a
pUC-sequencing kit (Boehringer Mannheim, Mannheim, Germany), using g-35S dATP
(600 Ci/mmol). The amplification primers were used as primers in the sequencing
reactions. In the UK cases, intragenic mutations were also sought by Single-strand
conformation polymorphism (SSCP).
Screening for genetic rearrangements and deletions was performed by Southern
blot analysis, or a novel PCR-based deletion assay (Dow et al. in preparation). In
Southern blot analysis DNA was digested with Eco RI alone or with Eco RI and Ase I
double digest. After gel electrophoresis and transfer to Hybond-N filters, the genomic
DNA was hybridised with the VHL g7-cDNA probe,15  according to the manufactur-
er’s instruction. Quantitative Southern blotting was performed by hybridising genomic
DNA with the VHL g7-cDNA probe and with a beta-globin probe, to detect deletions
encompassing the entire VHL gene.30
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Fig. 2 Distribution of single
HAB patients by age at
diagnosis.
dark  = UK
light = Dutch
The x-axis represents the age
at diagnosis, the y-axis repre-
sents the number of patients
with haemangioblastoma
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Results
Single HAB
84 patients with single HAB in the central nervous system (23 Dutch, 61 UK) were
investigated. The age distribution of the studied patients is shown in Figure 2. VHL
germline mutations were identified in three patients (see Table 1). The incidence of a
VHL germline mutation in single HAB patients younger than 30 years was 4.3% (1/
23), 30-39 years was 4.5% (1/22), 40-49 years was 4.2% (1/24) and age 50 years or
older was 0% (0/15).
Details of the three germline mutations identified were:
(a) a C to T transition at nucleotide 454 was detected in a 47-year old woman (D24)
with a single cerebellar HAB, diagnosed at an age of  44 years (Fig. 3). This missense
mutation leads to a change of Proline to Serine at codon 81 (P81S) in the VHL protein.
DNA analysis of other close relatives revealed that four clinically unaffected first and
second degree relatives (age 17-77 years) were also carriers of a P81S germline muta-
tion;
(b) a 7 basepair frameshift mutation (del 582 GACACAC) was detected in a 29-year
old patient (B1) with a single cerebellar HAB with no family history and no evidence
of VHL disease on clinical and radiological screening. However, she subsequently
developed pancreatic cysts at age 34 years;
(c) a large germline deletion was identified by Southern blot analysis in a 36-year old
woman (B2) with a single cerebellar HAB but no other features of VHL disease.
Two patients with a single HAB developed some additional features of VHL
disease during the study: one patient (B1) with a VHL gene mutation (del 582
GACACAC) developed pancreatic cysts (see above) and one patient (B3) developed
renal cell carcinoma aged 44 years following a cerebellar HAB at age 40 years, but no
VHL mutation was identified.
Table 1 Summary of results
Pat Age Clinical features Fam Hist Mutation Previously
HAB Other reported
D24 44 Solitary cerebellar - - P81S (21,30,31)
B1 29 Solitary cerebellar Subsequent - del 582 GACACAC No
pancreatic cysts
B2 36 Solitary cerebellar - - Deletion n/a
B5 40 Cerebellar & medullary - - Deletion n/a
B6 44 Multiple spinal - - Deletion n/a
Pat, patient’s unique identification number; Age, age at diagnosis, in years; HAB, type and origin of
haemangioblastoma; Clinical features, Other, further VHL associated manifestations after clinical
screening; Fam Hist, family history, further VHL associated manifestations in family members of
proband; Mutation, VHL germline mutation; Previously reported, whether the mutation has been
published (references); n/a, not applicable.
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Multiple HABs
Four patients with multiple HABs (two Dutch and two UK) and without additional
VHL-related tumours were analysed for VHL germline mutations. Deletions were
detected in two patients: (a) a male (B5) with one cerebellar and one medullary HAB
at age 40 years; and (b) a male (B6) with multiple spinal HABs at age 44 years.
Germline mutations were not identified in the two Dutch patients (D13 and D32) with
both cerebellar and spinal HABs (ages 44 and 66 years).
Discussion
We found that the overall risk for finding a VHL germline mutation in a population of
84 patients with a single HAB in the central nervous system and no further features of
VHL disease at the time of diagnosis was approximately 4%. In clinical studies of
sporadic patients with a HAB it was suggested that a substantial proportion of HAB
could be associated with VHL disease upon more detailed examination; i.e. 23% to
34.3% was found to be afflicted with VHL disease.6,28 Molecular genetic analysis of
the VHL gene indicated that sporadic patients with a HAB have a risk of a VHL gene
germline mutation of approximately 10%.32,33 The lower detection rate in our cases,
despite use of more sensitive methods of VHL gene analysis, is presumably related to
better clinical and radiological screening prior to entry into our study. The identifica-
tion of a VHL germline mutation has important implications for the risk of further
tumours and for the risk of VHL disease in relatives.
Statistical analysis of the age at onset of HAB in VHL disease and non-VHL
cases (based on clinical criteria) is consistent with a one- and two-hit tumourigenesis
model as predicted by the Knudson hypothesis.27 Mean age at diagnosis of cerebellar
HAB in VHL disease is younger than in sporadic cases (29 years versus 48 years,
respectively) so we anticipated a higher incidence of unsuspected VHL gene muta-
tions in early onset cases. Older patients with VHL gene mutations would be more
likely to manifest other evidence of VHL disease and so be excluded from our study.
Thus, although our results were broadly compatible with this hypothesis, the identifi-
cation of germline VHL gene mutations in two of a group of 46 patients aged 30-49
years with a single HAB and no clinical or radiological features of VHL disease sug-
gests that molecular genetic analysis should be employed in all single HAB patients
younger than 50 years. For older onset patients the frequency of germline mutations is
likely to be less and larger research-based studies are required to define the risks more
precisely.
A major strength of the present study was the use of recently developed tech-
niques to detect large germline deletions. Prior to the introduction of these techniques,
there was a VHL germline mutation detection rate (with Southern blotting and
sequencing of the coding region) of approximately 80% in known VHL families.22
However, methods to detect large deletions (e.g. quantitative Southern blotting) have
significantly increased the detection rate, reaching 100% in proven familial VHL dis-
ease.30 Therefore a conservative estimate of the mutation detection sensitivity of the
strategy used in this study would be in the order of 95%. Although other studies of
sporadic patients with a HAB have used less sensitive techniques,32-34 it is of interest
that Oberstrass et al. detected a germline mutation in 2 of 20 patients (aged 18 and 40
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years) with HAB of the central nervous system (although no data were available about
a possible family history of VHL disease).32 Decker et al.34 reported a 29-year-old
patient with recurrent spinal HAB, a negative family history of VHL disease and a de
novo frameshift VHL gene exon 2 mutation. However, this case differed from any of
those in our study because a renal mass and pancreatic and renal cysts were detected
on clinical screening. In a series of 18 sporadic patients with a HAB, Olschwang et
al.33 found a missense mutation in two patients (42 and 56 years of age) without clini-
cal investigations revealing any evidence of VHL disease. The latter case would only
have been detected by also screening single HAB patients aged over 50 years for a
VHL gene mutation.
Although specific missense VHL mutations may cause a phaeochromocytoma-
only phenotype,24-26 we did not find unequivocal evidence for VHL gene mutations
that would predispose to a HAB-only phenotype. However, the VHL germline muta-
tion (P81S) that was found in a 47-year old woman with a solitary HAB and in four
clinically unaffected family members was associated with an unusually low penetrance
within this family. To reduce the possibility of a genetic polymorphism, 50 non-VHL
patients were sequenced. Sequence analysis of exon 1 demonstrated that all persons
were homozygous for nucleotide 545C (data not shown). Phenotypic expression in
VHL disease is influenced by allelic heterogeneity, stochastic events and genetic modi-
fiers.35
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Fig 3.  Sequence analysis showing
the P81S mutation (left) and normal
sequence (right). Below, the pedi-
gree of patient D24, depicting four
clinically unaffected relatives with
the VHL germline mutation P81S
and their ages .
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The P81S mutation has been reported four times previously: 1) in an isolated
German patient with a full-blown VHL tumour spectrum (i.e. cerebellar and spinal
HAB, renal cell carcinoma, and renal, pancreatic and epididymal cysts); 2) in a 34-
year-old American patient with HAB-only; 3) in 35-year-old American patient with
retinal haemangioblastoma and islet cell tumour of the pancreas, the father is the only
other relative with a VHL-related tumour and had a phaeochromocytoma; 4) in an
isolated Japanese patient with multiple HABs and a renal cell carcinoma.21,30,31 These
findings suggest that P81S mutation carriers in the family are also at risk of renal cell
carcinoma. Moreover, only one of the P81S carriers had affected family members,
which may imply that this missense mutation has a low penetrance.
Interestingly, we did not find VHL germline mutations in two of the four pa-
tients with multiple HABs. As the presence of two or more retinal or cerebellar HAB
satisfies the strict diagnostic criteria for VHL disease,12,14 this was an unexpected find-
ing in the light of the high sensitivity of the mutation detection methods used, and
could perhaps indicate additional HAB susceptibility gene(s). Alternative explana-
tions would include a mutation in part of the VHL gene not analysed (e.g. regulatory
domain) or somatic mosaicism. In this context it is interesting, that the two multiple
HAB patients with germline mutations had the earliest age at onset and the patients
with later onset may be mosaic and so have a milder phenotype or represent pheno-
copies (independent mutation events giving rise to various HAB could also be ex-
pected by chance). Although mosaicism has so far been described in only two VHL
families,30 it is frequent, for example, in neurofibromatosis type 2.36
We have demonstrated that VHL gene mutation analysis facilitates the manage-
ment of sporadic patients with HAB and should be performed in patients younger
than 50 years with a single HAB even if there is no other clinical or radiological
evidence of VHL disease. Although the detection rate in older patients should be lower,
we suggest that such patients need to be studied on a research basis, using the latest
mutation detection strategies to define cost–benefit consequences for molecular ge-
netic analysis of this group of patients.
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Abstract
Objective Phaeochromocytoma may occur in sporadic forms or as a manifestation of
Von Hippel-Lindau (VHL) disease. Germline mutations in the VHL gene are detected
in virtually all well-defined families. In addition to VHL families, sporadic patients
with VHL-related tumours have been found to carry germline mutations in the VHL
gene. Because carriers of a VHL germline mutation and their relatives risk developing
multiple tumours, we investigated the frequency of VHL germline mutations in pa-
tients with phaeochromocytoma-only.
Patients and methods Between 1996 and 1999, 24 probands (14 with solitary tu-
mours, 7 with multiple, bilateral or recurrent tumours and 3 with familial phaeo-
chromocytoma) were investigated. Mutation screening of the VHL gene was performed
by direct sequencing of the coding region and quantitative Southern blot analysis.
Results VHL germline mutations were not found in any proband of the solitary
phaeochromocytoma group (mean age at diagnosis 49 years, range 17-70 years), nor
in any of the multiple phaeochromocytoma (mean age at diagnosis 37 years, range 19-
64 years) or familial phaeochromocytoma groups.
Conclusions VHL germline mutations were not found in 24 probands with
phaeochromocytoma, even when features suggesting a germline mutation (early on-
set, multiple, recurrent, bilateral or familial tumours) were present. However, the ab-
sence of VHL germline mutations in these phaeochromocytoma patients may indicate
the possible occurrence of somatic mosaicism or the presence of additional
phaeochromocytoma susceptibility genes. Since mutation analysis of the VHL gene
detects germline mutations in virtually all well-defined VHL families, we conclude
that annual clinical monitoring for further VHL-related tumours in patients with
phaeochromocytoma and without a VHL germline mutation should not be recom-
mended.
Patients with phaeochromocytoma-only
Introduction
Phaeochromocytoma are neuro-endocrine tumours arising from chromaffin cells in
the medulla of the adrenal gland. They may also occur in the ganglia of the autonomic
nervous system at extra-adrenal sites and in this case are called paraganglioma. Func-
tioning tumours usually secrete the catecholamines norepinephrine and epinephrine,
and may cause palpitations, chest discomfort, sweating attacks, hypertension or par-
oxysmal unstable blood pressure, and headache.
Diagnosis is based on biochemical tests and radiology. Laboratory tests may
include evaluation of catecholamines in serum as well as in urine.1,2 Measurement of
plasma normetanephrine and 24-hour urinary norepinephrine excretion are the most
sensitive tests.2 Radiology testing may include ultrasound (US), computed tomogra-
phy (CT), magnetic resonance imaging (MRI) and metaiodobenzylguanidine (MIBG)
scintigraphy. T2-weighted MRI demonstrates high signal intensity for phaeochromo-
cytoma in 95-100% of the cases.1,3 MIBG is sensitive for 75-95% of phaeochromo-
cytoma and is 100% specific, but may not depict very small lesions.1,3,4
Phaeochromocytoma may occur both in sporadic and in familial forms. Familial
manifestation of phaeochromocytoma may occur in hereditary neoplastic syndromes
including Von Hippel-Lindau (VHL) disease, multiple endocrine neoplasia type IIA
and IIB (MEN IIA and MEN IIB) and neurofibromatosis type I (NF-I). In 1993, a
study by Neumann showed, upon more detailed examination, that 19 of 82 patients
(23%) with phaeochromocytoma had either VHL disease (19%) or MEN II (4%).1
Pooled data from three more recent studies5-7 indicated that 13 of 133 patients with
phaeochromocytoma (10%) were familial cases. These cases could be associated with
either VHL disease (n=1), MEN IIA (n=1), MEN IIB (n=5), NF-I (n=3) or genuine
familial phaeochromocytoma (n=3).
VHL disease is an autosomal dominant tumour syndrome with an estimated birth
incidence of 1/36,000.8 The disease is characterised by a predisposition for bilateral
and multi-centric tumours. The most common tumours in VHL disease are haeman-
gioblastoma in the central nervous system and retina, clear cell carcinoma in the kid-
ney, and phaeochromocytoma in the adrenal gland. VHL patients are enrolled on an
annual screening programme to enable early detection (and treatment) of these tu-
mours. The basis of familial inheritance of VHL disease is a germline mutation in the
VHL tumour suppressor gene located in chromosome region 3p25-26.9
The mean age at diagnosis in VHL patients with phaeochromocytoma is ap-
proximately 28 years,1,10,11 with the youngest reported patient being five years old.11 In
VHL patients, phaeochromocytoma often remain quiescent or produce few symp-
toms, and biochemical tests may reveal normal results. 2 However, the behaviour of
phaeochromocytoma remains unpredictable: biologically inactive lesions may sud-
denly become dangerous, benign phaeochromocytoma may become malignant.12 About
5% of VHL patients die from phaeochromocytoma-induced endogenous catecholamine
intoxication, which has also caused fatal pregnancy outcome (for the mother and/or
the child).13-15
Adrenalectomy is the standard treatment for phaeochromocytoma. Satisfactory
results have been reported from laparoscopic removal of adrenal tumours,16-18 and
also in VHL patients.19 Since bilateral tumours develop in 47% of VHL patients with
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phaeochromocytoma, most patients become steroid-dependent upon bilateral adrena-
lectomy.20 Enucleation rather than adrenalectomy is therefore recommended by an
increasing number of surgeons.20,21 Adrenal-sparing surgery is safe, effective and can
preserve adrenal function in VHL patients.
Since the identification of the VHL gene in 1993, studies of the disease have
intensified and clinical studies have suggested that the number of phaeochromocytoma
patients associated with a hereditary neoplastic syndrome has diminished from 23%
in 1993 to 10% in 1998.1,5-7 We think that the putative pool of phaeochromocytoma
patients possibly affected by VHL disease has decreased as the number of VHL fami-
lies being identified has increased in the past few years. We therefore investigated the
prevalence of VHL germline mutations in 24 probands with phaeochromocytoma-
only, with the purpose of identifying new cases with VHL disease.
Patients and methods
Patients
Between 1996 and 1999, 24 patients with phaeochromocytoma-only were referred for
VHL mutation analysis by endocrinologists, internists and clinical geneticists. In ad-
dition to DNA analysis, all patients underwent clinical examination for detection of
VHL-associated tumours (opthalmological examination and abdominal sonography
or MRI). At the time of referral, clinical screening revealed no evidence that any of
the patients had VHL disease. Cases 22, 23 and 24 had other family members with
phaeochromocytoma but none of the probands’ family members exhibited other VHL-
related lesions. All patients had been operated for phaeochromocytoma, later con-
firmed histopathologically.
The Dutch Pathological Archive (Palga)
Between 1973 and 1996, a total of 395 phaeochromocytoma patients were reported in
the Dutch Pathological Archive (Fig. 1). The mean age at diagnosis of these patients
was 46 years. Figure 1 demonstrates that the patients studied (mean age at diagnosis
45 years, range 17-70 years) are a representative selection of phaeochromocytoma
patients by age at diagnosis.
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Fig. 1 Number of patients and age at
diagnosis for:
395 patients with phaeochromo-
cytoma reported in the National
Dutch Pathological Archive (Palga),
between 1973 and 1996.
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DNA analysis
High molecular weight DNA of the probands was isolated from peripheral blood ac-
cording to established procedures. Exons 1, 2 and 3 of the VHL gene and their imme-
diately flanking sequences were amplified using the polymerase chain reaction (PCR),
using oligonucleotides according to Gnarra et al.22 The flanking sequences included
90 nucleotides upstream of the start codon (the first nucleotide of the coding region is
214) and 45 nucleotides downstream of the stop codon. The nucleotides are numbered
according to Latif et al. (Genbank accession number L15409).9 PCR products were
purified and subjected to sequence analysis using an ABI 377 automated sequencer.
The amplification primers were used as primers in the sequencing reactions.
Screening for genetic rearrangements and deletions was performed by Southern
Blot analysis. DNA was digested with Eco RI alone or with Eco RI and Ase I double
digest. After gel electrophoresis and transfer to Hybond-N filters, the genomic DNA
was hybridised with the VHL g7-cDNA probe,9 (kindly provided by I. Kuzmin,
Frederick, MD, USA) according to the manufacturer’s instruction. Quantitative South-
ern blotting was performed by hybridising genomic DNA with the VHL g7-cDNA
probe and with a beta-globin probe (kindly provided by C. Stolle, Philadelphia, PA,
USA), to detect deletions encompassing the entire VHL gene.
Results and discussion
We found no VHL germline mutations in all the studied probands with phaeochromo-
cytoma-only (table 1). However, our study included at least eight cases that are asso-
ciated with a potentially higher risk for a hereditary tumour syndrome. These eight
cases were the three patients with bilateral phaeochromocytoma (age 24, 28, 30 years),
patient number 8 with a solitary tumour at an early age (17 years), patient number 21
with recurrent tumours at an early age (19 years), and three cases of familial phaeo-
chromocytoma.
VHL-associated phaeochromocytoma differ from sporadic phaeochromocytoma in
having multiple or bilateral tumours and an average manifestation two decades earlier
(27 years versus 46 years, respectively).1 Based on Knudson’s two-hit theory, patients
with a germline mutation in a tumour suppressor gene are predisposed to multi-cen-
tric tumours that are likely to manifest at a younger age than in sporadic patients
(since the first hit has already taken place).23 Therefore, familial phaeochromocytoma
and also childhood cases show a tendency to multi-centricity and recurrence of tu-
mours. Consequently, patients and at risk family members have to undergo life-long
surveillance. It is important to ascertain whether a patient has an associated hereditary
syndrome in order to monitor not only phaeochromocytoma, but also further lesions
associated with that disease.
Six other studies have also investigated the genetic epidemiology of (familial)
phaeochromocytoma (Table 2).24-29 21 VHL germline mutations but no RET gene mu-
tations were found in a total of 225 observations. However, we would like to comment
on two of the VHL gene mutations found in one study.27 First, the P25L mutation is
probably not a disease-causing mutation. So far, no VHL germline mutations have
been described in VHL families upstream of the start site located at codon 54.30,31
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Table 1 Age at diagnosis and type of phaeochromocytoma
Pat Unr Age Type RET
1 6 56 Solitary -
2 7 65 Solitary -
3 12 38 Solitary
4 35 42 Solitary -
5 42 43 Solitary -
6 48 70 Solitary
7 56 35 Solitary
8 66 17 Solitary
9 67 49 Solitary -
10 68 53 Solitary -
11 70 66 Solitary
12 73 62 Solitary
13 76 49 Solitary
14 79 43 Solitary
15 20 28 Bilateral -
16 43 24 Bilateral -
17 59 30 Bilateral -
18 60 42 Multiple
19 62 52 Multiple -
20 11 64 Recurrent
21 37 19 Recurrent -
22 9 64,?,? Familial, three brothers -
23 80 57,59 Familial, mother and daughter
24 31 23,32,44 Familial and bilateral, two brothers and uncle -
Pat, patient number; Unr, unique identification number; Age, age at diagnosis; RET, germline
muation in the RET proto-oncogene.
13 of 23 probands were screened for RET mutations and were all negative (-)
Mean age at diagnosis in solitary phaeochromocytoma is 49 years; in the bilateral, multiple and
recurrent group it is 37 years old.
Second, the R64P mutation, found in two related patients (uncle and nephew) should
be considered as one case of familial phaeochromocytoma. Consequently, the pres-
ence of three patients with a VHL germline mutation in 66 sporadic patients with
solitary phaeochromocytoma (i.e. 5%)27 is in better agreement with the other studies
(table 2).24,25,29 Joint data demonstrate that seven out of 17 cases with familial
phaeochromocytoma (41%) had a VHL germline mutation.26,28,29 In addition, case
records have been published of VHL germline (missense) mutations in familial
phaeochromocytoma.13,32 These cases suggested a distinct VHL phenotype, i.e. VHL
type IIC.
Patients with phaeochromocytoma-only
Table 2 Comparative studies analysing the genetic epidemiology of patients with
phaeochromocytoma-only.
Study Patients n VHL Mutation (age) RET
Bar sporadic 24 0 - 0
Brauch sporadic 62 2 (3%) codon167 (33), splice site codon 155 (63) 0
Giraud sporadic 11 0 - n.t.
v/d Harst sporadic 68 6 (9%) P25L (38)(a), L63P (26), R64P (24)(b), n.t.
G144Q (39), I147T (58)
Hes sporadic 14 0 - 0 (6/14 tested)
Bar bilateral 3 1 (33%) R161Q (13) 0
Giraud bilateral 5 4 (80%) Y98H, L129P, R167Q, V170G (m=17.5)(c) n.t.
Woodward bilateral 2 1 (50%) R167W (?) 0
Woodward multiple (d) 6 0 - 0
Hes multiple 7 0 - 0 (5/7 tested)
Crossey familial 3 2 (67%) V81L, R167Q 0
Giraud familial 6 2 (33%) P97L, R167Q n.t.
Woodward familial 8 3 (38%) S80G, R161Q, R167W 0
Hes familial 3 0 - 0 (2/3 tested)
Total 225 21 0
This table includes patients with phaeochromocytoma from our study and those reported in the
literature.24-29
Patients, type and (n)umber of patients studied; VHL, number of patients with a VHL germline
mutation; RET, RET proto-oncogene germline mutation (exons 10 and 11 tested and sometimes
also exons 13 and 16); n.t., not tested;
P25L(a), so far, no VHL germline mutations have been described in VHL families upstream of
codon 54; R64P(b), found in two related (uncle and nephew) patients;
(m=17.5)(c), mean age at diagnosis was 17.5 years; multiple phaeo(d) were all cases of multiple
extra-adrenal or adrenal phaeochromocytoma with a family history of neuro-ectodermal tumours.
Nearly all the mutations (20 out of 21) identified in phaeochromocytoma
patients from these six reports concerned missense mutations. A hot spot was
located at and around codon 167 of the VHL gene, confirming previously estab-
lished genotype-phenotype correlations in VHL disease.30,31 There is evidence that
the presence or absence of phaeochromocytoma is correlated with the type of VHL
germline mutations.30,31 It was suggested that especially specific missense mutations
would lead to phaeochromocytoma by a dominant negative effect of the mutated
VHL protein.33 However, besides this clear interfamilial difference, intrafamilial
differences have also been observed, suggesting that genetic or environmental
modifiers play a role in the manifestation of VHL disease.34
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The fact that we did not detect VHL mutations in our phaeochromocytoma pa-
tients was to be expected given the relatively low number investigated. VHL germline
mutations are detected in virtually all well-defined VHL families.31 A conservative
estimate of the mutation detection sensitivity of the strategy used in this study would
therefore be in the order of 95%. Moreover, since most VHL germline mutations in
phaeochromocytoma patients concern missense mutations, these are not likely to be
missed easily. This would suggest that as well as familial phaeochromocytoma asso-
ciated with VHL disease (approximately 41%), there is also room for familial cases
with a distinct genetic basis. From this point of view, our case 24 is of major interest,
since it shows multiple features (i.e. young age at diagnosis, bilateral and familial
tumours) that would indicate a germline mutation. This type of family would be an
appropriate candidate for a genome-wide screening to identify candidate genes asso-
ciated with the inheritance of phaeochromocytoma. Alternative explanations would
include a mutation in part of the VHL gene not analysed (e.g. regulatory domain) or
somatic mosaicism. Although mosaicism has so far been described in only two VHL
families.31
We have demonstrated that sporadic patients with solitary phaeochromocytoma
and even those exhibiting aspects normally regarded as caused by a hereditary muta-
tion (early onset, multiple, recurrent, bilateral or familial tumours) could not be asso-
ciated with VHL germline mutations. However, we still advise genetic screening for
VHL mutations in all cases with possibly hereditary features since the costs are rela-
tively low, the molecular genetic analysis of the VHL gene is readily feasible and the
vast majority of VHL mutations can be detected. Annual clinical screening for further
VHL-related tumours in patients with phaeochromocytoma-only and a negative test
for VHL germline mutations seems not recommended. Since each identified proband
may provide appropriate clinical management for possibly affected family members,
molecular testing is likely to be cost-effective.25,35 Moreover, the absence of germline
VHL gene mutations in cases showing strong hereditary features may indicate the
occurrence of somatic mosaicism for VHL mutations or, alternatively, suggest that
other phaeochromocytoma susceptibility loci exist.
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General discussion
Following the identification of the VHL tumour suppressor gene in 1993, studies on
VHL disease intensified. The studies outlined in this thesis have focused on the clini-
cal and genetic aspects of VHL families and of sporadic patients with VHL-related
tumours in the Netherlands. These studies are summarised and discussed in the light
of reports in the literature. Since one of the main objectives of this research is to
identify as many carriers of germline mutations in the VHL gene as possible, we also
discuss the efficiency of methods used in detecting patients. In addition, psychologi-
cal, social, political and ethical issues are addressed, as well as the financial and legal
repercussions for persons identified as being at risk for a hereditary cancer syndrome.
4.1 Summary of clinical aspects of VHL disease
In chapter 2 the management of two organs (kidneys and eyes) in VHL disease has
been considered in detail and the radiological monitoring in VHL patients for the
upper abdominal VHL-related organs is described. The clinical and radiological as-
pects of the remaining VHL-related organs are reviewed in chapter 1. The last section
deals with guidelines for the diagnosis and clinical monitoring of VHL patients in the
Netherlands.
Studies on the natural history of a complex disorder such as VHL disease de-
pend on clinical data gathered from long and intensive studies of VHL patients moni-
tored according to an uniform clinical surveillance protocol. In the Netherlands, the
relatively small numbers of such VHL patients has hampered these studies. It is im-
portant that, over the coming years, we continue collecting clinical data on as many
VHL patients as possible, in order build up a sufficiently large data collection to per-
mit valid conclusions on the complex manifestations and natural history of VHL dis-
ease within our own country. Given that VHL disease is a complex disorder, it can not
be assumed that the phenotypical expression will be identical in all countries. Differ-
ent environmental and genetic modifiers may play different roles in different coun-
tries. However, multi-centered European studies should be also initiated to increase
the number of VHL patients investigated. Moreover, it is important that the Dutch
studies are as complete as possible to permit valid comparisons with trans-European
studies and to provide an as comprehensive as possible identification of VHL fami-
lies. In this context, the natural history of retinal haemangioblastoma and renal cell
carcinoma in a limited series of Dutch VHL patients are reported in detail. In addition,
the management of CNS haemangioblastomas is considered as these present a press-
ing problem in clinical practice.
4.1.1 Ocular haemangioblastoma
In section 2.3, the results of long-term follow-up in Dutch patients (as long as 23 years
for some patients) are reported. Ophthalmological data are described with special
attention to the natural course of development of ocular haemangioblastoma. Five
stages of development of ocular haemangioblastoma are distinguished and illustrated
by fluorescein angiographic pictures. Although the limited number of VHL patients
available unfortunately hampers in depth studies on additional aspects of the natural
history - such as age of onset, the frequency of visual impairment, etc -, one of the
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main conclusions was that isolated occurrence of haemangioblastomas, particularly
when associated with young age, multicentricity or bilateralism, is a strong indication
for carrying out DNA diagnosis (see 4.2).
The mean age at diagnosis of tumours for VHL mutation carriers is lower than in
(sporadic) patients who do not carry a germline mutation (Table 1). Retinal haeman-
gioblastoma is the first tumour manifestation in many cases of VHL disease and this
may be the sole manifestation for some time. Solitary retinal haemangioblastoma can
also occur in the absence of VHL disease and has an estimated prevalence of 1:110,000
persons.1 This is in contrast to other typical VHL tumours that occur more commonly
as isolated forms than as part of VHL disease. Webster et al. provided two possible
explanations, with reference to Knudson’s hypothesis*, for the relatively low frequency
of solitary retinal haemangioblastoma. Firstly, the risk that an ocular cell is affected
with two independent somatic hits is likely to be lower than in other VHL associated
organs, because the number of susceptible cells in the eye is lower. Secondly, the
critical period for tumourigenesis may be limited to early retinal development and
growth, as in retinoblastoma, whereas it may be life-long in other organs (as illus-
trated by the old age of sporadic patients in which renal cell carcinoma occur, see
section 1.3.3). Since the frequency of solitary retinal haemangioblastoma is rarer than
VHL associated haemangioblastoma, we recommend performing VHL germline mu-
tations analysis in all sporadic patients.
Further, recommendations are provided in section 2.3 for the annual monitoring
and treatment of ocular lesions in VHL patients. We stress that only early detection
and treatment of peripheral retinal haemangioblastoma can be expected to decrease
the percentage of patients with impaired visual acuity. Ophthalmological monitoring
(and subsequent treatment) of patients and persons at risk should therefore start as
early as possible. Since the prevalence of retinal tumours does not increase in older
VHL patients,1,4 it should be questioned whether all carriers of a VHL germline muta-
tion should undergo similar ocular monitoring. Younger patients (e.g. younger than
30 years) may be monitored more frequently (e.g. twice a year), whereas older pa-
tients (e.g. older than 60 years) could be monitored every two years. In addition,
reduced probability of new haemangioblastoma formation in older gene-carriers may
also allow us to reassure haemangioblastoma-free VHL patients in the clinic.5
Tumour VHL Sporadic
Retinal haemangioblastoma1,5,6 24 years 31 years
CNS haemangioblastoma6-10 29-33 years 44-48 years
Renal cell carcinoma6,11-17 36 years 60-70 years
Phaeochromocytoma18-20 28 years 47 years
* In 1999, the two-hit model was demonstrated in ocular lesions of VHL patients with markers
flanking the VHL gene. Two research groups independently confirmed, by microdissection of ocu-
lar haemangioblastoma, that a somatic deletion of the VHL gene locus (the second hit) took place in
stromal cells.2,3 This demonstrated that stromal cells (as in CNS haemangioblastoma, see 1.3.2)
represent the true neoplastic component in these tumours.
Table 1 Age at diagnosis of
solitary VHL-related tumours
in sporadic patients and carri-
ers of a VHL germline muta-
tion.
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4.1.2 CNS haemangioblastoma
Despite the fact that many haemangioblastoma grow little or not at all for years, CNS
haemangioblastoma remain responsible for considerable morbidity and mortality in
VHL disease and many patients require emergency treatment, especially in cases of
delayed diagnosis.8 The standard treatment for symptomatic lesions is complete micro-
surgical removal. The treatment of asymptomatic cerebellar haemangioblastoma how-
ever, remains controversial. There are clinics in the Netherlands that do not perform
radiological monitoring of the CNS in VHL patients. In their opinion, radiological
monitoring using MRI is too expensive and has no consequences for treatment since
many neurosurgeons will not operate on asymptomatic lesions. Although proponents
of monitoring asymptomatic haemangioblastomas are most commonly aware that the
monitoring of CNS lesions has no therapeutical consequences, these clinicians feel
reassured when such potentially life-threatening tumours can be closely monitored.
A consensus for the monitoring interval of CNS lesions in VHL patients does
not exist in the literature. Some recommendations are: 1) every two years from the
age of 11 years and every three-five years after an age of 60 years (NIH);21 2) every
three years from mid-teens to an age of 50 years and there after every five years
(Cambridge);6 3) after the age of 20 years, at least once per decade.19 This illustrates
the variability in the choice in frequencies of monitoring for CNS related haeman-
gioblastoma. This difference in opinion is also present within the Dutch VHL working
group. At present, it is not possible to propose a single uniform standard for this com-
ponent of clinical monitoring in VHL disease.
The multidisciplinary team at the UMC Utrecht recently agreed that CNS imaging
could be combined with the monitoring of the upper abdominal organs. Since this
single procedure evaluates both the CNS and the upper abdominal components of
VHL disease, patients in our hospital are now given a double MRI appointment every
two years. In conjunction with ultrasound, this protocol monitors the kidneys, adrenal
glands, pancreas and liver of VHL patients alternately using ultrasound and MRI.
In my opinion, clinical research is, next to reassurance of the attending physi-
cian, a second argument to perform radiological monitoring of CNS lesions. Radio-
logical data can be studied to further evaluate the natural history of CNS haemangiob-
lastoma in VHL patients. These data could, for example, favour presymptomatic treat-
ment in some clinical situations. It is conceivable, that a neurosurgeon would operate
on an asymptomatic lesion when MRI indicates the presence of a developing hydro-
cephalus due to herniation of the cerebellar tonsils through the foramen magnum.
Moreover, the possibility of treating small solid lesions presymptomatically with ra-
diosurgery may justify radiological follow-up of cerebellar lesions in the near future.
Chang et al.22 are already treating asymptomatic haemangioblastomas in VHL pa-
tients with radiosurgery if the lesions are larger than 5 mm and when the tumours are
observed in a setting of other progressive symptomatic tumours, or if there is evi-
dence of progressing in serial imaging studies. It is evident that this aspect, above all
other facts of VHL monitoring, gives the largest problems to define an uniform na-
tional monitoring program. In the mean time, the proponents and opponents of CNS
monitoring in VHL disease have agreed to disagree and each centre will proceed ac-
cording to their own vision.
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4.1.3 Renal cell carcinoma
We give recommendations for the management of renal lesions in VHL patients in
section 2.2. If both kidneys are affected with multiple cysts and renal cell carcinomas,
a difficult decision has to be made between radical nephrectomy and nephron-sparing
surgery (Fig.1). This decision depends on risk factors (size, progression, capsule in-
volvement and whether the tumour is symptomatic) for metastatic spread. Manage-
ment of metastatic lesions is a difficult problem, since response to chemotherapy and
radiotherapy is poor.
Metastases in VHL patients with renal cell carcinoma have until recently been
associated with a seemingly critical tumour size of 7 cm.17 However, an arbitrary 3 cm
surgical threshold has been postulated by many authors. In 1999, the first report of a
prospective analysis on treatment of renal cell carcinoma in VHL patients appeared
and supported the 3 cm threshold.16 The presence of metastases was demonstrated in
eight of the 17 patients with tumours larger than 6 cm, in three of 27 VHL patients
with tumours of 3-6 cm, but in none of the 52 studied patients with tumours smaller
Fig. 1 Flow-chart for VHL patients with renal cell carcinoma larger than 3 cm. In the first part of this
scheme decisions for treatment are made by a multidisciplinary team consisting of an urologist (or
surgeon), a nephrologist, a radiologist, and an oncologist (or internist). Once the patient becomes
dependent on dialysis, we advise attending physicians to follow the flow chart.
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than 3 cm. However in our study, five out of 17 lesions had pseudocapsular invasion
(and four of these tumours were smaller than 3 cm). Breakthrough was observed in
three of the five tumours that measured 1.3, 2.6 and 5.5 cm respectively. It is impor-
tant to note that our observations of breakthrough were made on pathological speci-
mens following kidney removal and there is no guarantee that we could have made
these observations in vivo. In practice, there is a problem that the resolution of even
the most refined imaging techniques will probably not permit detection of breakthrough
in such small (e.g. 1.3 cm) renal lesions. We anticipate that pseudocapsular break-
through of renal cell carcinoma is associated with a higher risk for metastases. Our
results indicate that the 3 cm guideline should be validated in a larger set of inten-
sively studied patients. In addition, it should be studied whether a correlation exists
between a VHL germline mutation and (late or early) breakthrough. Meanwhile, from
a pragmatic point of view, we should like to advocate that attending medical special-
ists follow the surgical threshold of 3 cm in VHL patients.
Monitoring renal lesions
In the literature an annual CT scan is recommended to monitor renal lesions in VHL
patients.6,19,21 For reasons of possible increased radiation susceptibility - advanced
elsewhere in this chapter - the VHL working group subjectively prefers alternate moni-
toring of renal lesions using MRI and ultrasound. Although it should be stated that the
combination of these methods has not been demonstrated to be cost-effective. To re-
duce costs, abdominal surveillance might be performed using only ultrasound. How-
ever, the use of ultrasound alone, in the opinion of the VHL working group, would not
constitute an optimal monitoring procedure. Firstly, pseudocapsular breakthrough,
which is important to initiate surgical treatment of renal cell carcinoma, cannot be
detected by ultrasound. Secondly, MRI gives better insight into the exact location of a
renal lesion; this may lead to an early operation when growth of the tumour towards
blood vessels or renal pyelum is anticipated.
Renal cell carcinoma and fibrous pseudocapsule
We concluded that, in our patients, renal cell carcinomas grew slowly, were of low
grade, and had a dense fibrous pseudocapsule. They are thus good candidates for
nephron-sparing surgery. The fibrous pseudocapsule has been described as a typical
feature of renal cell carcinoma in VHL patients.17,23,24 The fibrous pseudocapsule may
be a critical differential feature between renal cell carcinomas arising via a VHL
germline mutation and those arising via other mutational mechanisms. Consequently,
less stringent surgical procedures, such as nephron-sparing surgery, may be generally
indicated in VHL patients.
We consider that at least two mechanisms are responsible for the fibrous capsule
formation. Firstly, fibrous tissue formation may be the result of an inflammatory reac-
tion caused by haemorrhage in the cysts. These haemorrhages in tumours and cysts
may well be caused by abundant and vulnerable neovascularisation. Secondly, an en-
larging renal cell carcinoma may lead to compression of renal stroma and disappear-
ance of normal parenchyme tissue. This leaves the resistant connective tissue skel-
eton, which normally supports the renal tubuli.
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Recently, further evidence was presented for the slow growth and relatively late
metastasis of VHL-induced renal cell carcinoma. The urokinase-type plasminogen
activator system mediates proteolysis of the extracellular matrix and is therefore im-
portant for tumour cell invasion, metastases and angiogenesis. In this system, plas-
minogen is converted by urokinase-type plasminogen activator into the proteolytic
enzyme plasmin. Los et al. demonstrated that the VHL gene plays a role in the regula-
tion of this system.25 They demonstrated that inactivation of the VHL gene results in a
decreased overall urokinase activity. As a result proteolysis of the extracellular matrix
is hampered. In the presence of wild-type VHL, urokinase is upregulated and plas-
minogen activator inhibitor-1 is downregulated. This might explain, to a certain ex-
tent, the clinical observations that: (1) in VHL patients with renal cell carcinoma,
metastases are rarer than in sporadic patients with renal cell carcinoma, and (2) at
initial diagnosis, renal cell carcinoma can be very large without evidence of metastases.
However, since the VHL gene is frequently involved both in renal cell carcinoma of
sporadic patients as well as VHL patients, it remains difficult to explain these differ-
ences in biological behaviour.
Multi-centric renal lesions
By extrapolation of tissue surrounding renal tumours, the number of microscopic le-
sions in an average VHL kidney was estimated at 1100 cysts and 600 clear cell neo-
plasms.26 Close microscopical examination of five kidneys in our study only revealed
incidental small lesions, mainly in the direct vicinity of the macroscopical visible
studies. We therefore referred to them as satellite lesions, indicating that the tissue
surrounding renal lesions is not representative for the entire kidney. A relatively low
number of renal lesions per kidney is also in agreement with other studies.13,19,27,28
Multi-centricity can either arise from independent somatic mutations or multi-
ple lesions can originate from a common initial tumour. Loss of heterozygosity (LOH)
of the VHL chromosome region has been demonstrated in both cystic lesions and
renal cell carcinoma by microdissecting material from individual lesions.29 This strongly
suggests that cysts and microcysts are precursors for renal cell carcinoma, but leaves
unanswered whether the somatic mutation has occurred independently at many sites
or singly followed by dispersal. A more detailed molecular analysis of either the pat-
tern of LOH or the somatic mutation would distinguish between the two possibilities.
We hypothesise that three phenomena may play a role in the origin of satellite
lesions in patients with renal cell carcinoma. Firstly, the paracrine effect of large and
enduring renal cell carcinoma produces factors such as vascular endothelial growth
factor (VEGF), which has been demonstrated to be the key tumour angiogenesis fac-
tor in VHL.30 Secondly, satellite lesions may be the consequence of metastasis in the
same kidney. Thirdly, tumour growth may lead to compression of the directly sur-
rounding renal tissue, followed by dilation of tubuli and may thereby promote the
formation of microcysts with proliferation of the lining cells. Therefore, satellite le-
sions are more likely to be found only in the close vicinity of expanding renal lesions.
An increased rate of cell division is associated with a higher rate of errors in DNA and
chromosome replication, leading to further mutations and the possibility of the renal
lesion acquiring a more malignant character.
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Interestingly, this same phenomena is also observed in retinal haemangioblas-
toma, where small secondary lesions appear near areas of detached or treated retina.4
The authors suggested that new retinal lesions are most likely to occur when retinal or
endothelial or vascular cells are mitotically active and susceptible to mutation, such
as in the developing retina or areas that turned ischaemic through detachment or abla-
tive treatment.
4.1.4 Clinical management of VHL patients: organisation and recommendations
One of the most important challenges in the management of VHL disease is to estab-
lish an intercentre co-operation between medical specialists who advise VHL patients
and their families. Some doctors tend to keep patients as a curiosity for themselves
since they exhibit ‘such an interesting syndrome’. However, not all clinicians may be
aware of the complex factors involved in the disease. Nowadays, some VHL patients
and families are still monitored and treated by individual doctors. This has resulted in
unnecessary morbidity and even mortality. Examination of our database showed that
predominantly patients that had not been regularly monitored died of VHL-related
tumours in the last four years. These involved four patients who died of complications
from renal cell carcinoma, and a patient who, although intensively monitored over the
past 25 years, died as a result of complications following a surgical procedure. It is
clear that well-organised, multidisciplinary teams following national and international
guidelines, with access to reliable databases for patient status, will guarantee the best
result in the management of patients and families with VHL disease.
Collaboration on a rare disease in a small country may avoid individual insti-
tutes following their own protocol for patient care. A central organisation, led by inde-
pendent representatives from various institutes, can define and secure a uniform clini-
cal management of VHL patients as well as lead to nationally structured research
projects.  We therefore initiated a national VHL working group in 1996. The six goals
of this working group are: (1) to draft guidelines for diagnosis of the disease, DNA
testing, and periodical clinical monitoring; (2) to provide attending physicians with
uniform information; (3) to provide co-ordination of multidisciplinary teams in re-
gional VHL centres; (4) to establish a central registration of clinical and genetic data;
(5) to stimulate research; and (6) to raise funds for periodical clinical monitoring. At
the moment we are in contact with some 80 doctors from eleven different medical
fields. A board will be selected (preferably with representation of all the medical spe-
cialists involved in VHL) with three representatives from each of the eight university
hospitals. A smaller board takes care of the day-to-day organisation.
However, we anticipate some problems in the continuity of clinical surveillance
of VHL patients. Firstly, the responsibility for guaranteeing the continuity in periodi-
cal clinical monitoring places a heavy burden on the attending physician.31 Secondly,
continuation of periodic monitoring cannot be guaranteed if the attending physician
departs, or if there is loss of funds or facilities, conclusion of short-term research
programmes, or if patients move house. Such factors disrupt the continuity of health
care, are disturbing to the families, and may lead to patients and families feeling frus-
trated or neglected. The working group therefore contacted the Netherlands Founda-
tion for the Detection of Hereditary Tumours (STOET - Stichting Opsporing Erfelijke
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Fig. 2 Clinical monitoring of
VHL patients, a cartoon adapted
from Dr. G. Oppocher of the
University of Padua, Italy (re-
produced with permission).
Internal Med. Radiology  Neurosurgery OphthalmologyNeurology 
A VHL patient enters the hospital.
He realises that he has to visit
various departments and doctors
with his disease ...
Internal Med.  RadiologyNeurosurgery Ophthalmology Neurology
He has to make separate 
appointments for every 
individual item of the VHL
screening protocol ....
VHL
Would it not be better if the departments 
were organised around the patient rather
than around the doctors ...?
VHL
Why not organise a VHL 
outpatient clinic?
In this way, the patient 
(and his family members) 
can do the VHL-tour in
just one day!
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Tumoren) which maintains a register of families with inherited tumours. This organi-
sation has the following objectives: (1) to improve the surveillance of family mem-
bers; (2) to guarantee the continuity of periodical clinical examination; (3) to serve
general practitioners and specialists by advising them about matters related to diagno-
sis, treatment, and monitoring procedures as well as referral of subjects to clinical
genetic centres for genetic counselling; and (4) to collect data as a basis for scientific
investigations.32 Another option is that members of the working group themselves
carry out the above mentioned tasks.
In the UMC Utrecht, the annual clinical monitoring for VHL patients and their
affected family members is organised in a production line fashion. In one day the
patients complete the entire ‘VHL tour’ along various medical specialists, radiologi-
cal monitoring, and blood and urine tests (Fig. 2). A central administrator books ap-
pointments approximately a year in advance. Within a month the families return for
the clinical test results. This multidisciplinary, centrally organised approach has now
been adopted by five of the eight Dutch university clinics.
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4.2 Molecular genetic analysis of VHL disease
Germline mutations of the VHL gene have been identified in families and patients
who meet the clinical diagnostic criteria as well as in sporadic patients with a solitary
VHL-related tumour. Since the costs of DNA analysis of the VHL gene are relatively
low, molecular genetic analysis of the VHL gene is readily feasible and the vast ma-
jority of VHL gene mutations can be and have been detected in the Netherlands. Every
patient suspected of having VHL disease should, in my opinion, be tested. In this
section the results of case findings using VHL germline analysis are compared to the
clinical diagnostic criteria and the eligibility of patients for DNA analysis. In addition,
genotype-phenotype correlations are discussed.
4.2.1 Diagnostic criteria for VHL disease and implications for case finding
Diagnosis of VHL disease follows two routes: the classic pedigree analysis method
and VHL gene mutation analysis. However, for pedigree analysis, family history data
may be incomplete and the results of clinical screening are age-dependent.6,27,33 Moreo-
ver, the value of the clinical data for pedigree analysis depends on family size and
penetrance of the disease, and the reliability and extent of clinical monitoring. There-
fore, the assessment of a VHL gene germline mutation must be considered as the gold
standard in carrier detection. Since DNA analysis detects mutations in virtually all
‘well defined’ VHL families,34 clinical diagnostic criteria are in themselves only sig-
nificant for classic VHL patients or families that decline DNA testing. In the few
remaining cases with patently obvious VHL disease where the germline mutation has
not been found and linkage studies are not informative, all family members at risk
have to be monitored annually.
In order to set diagnostic criteria for a complex disorder like VHL disease we
need to be aware of circular reasoning. Firstly, clinical diagnostic criteria are defined
and then, using these criteria, germline mutations are found with varying success rates
for different manifestations of VHL disease. Subsequently, these findings may be used
to adjust the clinical diagnostic criteria for VHL disease. In order to study this in the
Dutch VHL population, the probands referred for DNA analysis were divided into
groups based on existing clinical diagnostic criteria (see Table 2, Fig. 3). Since these
criteria were drawn up retrospectively, after identification of the VHL gene, they are
likely to have been influenced by case findings of VHL germline mutations. We dis-
cern six types of patient categories:
Familial cases
1. VHL germline mutations are consistently detected in 100% of families with
more than two affected family members, with multiple or single VHL-related tumours.
This finding agrees the clinical diagnostic criteria of Maher and Kaelin,35 who de-
scribed how VHL disease could be diagnosed in patients with a typical VHL-related
lesion in combination with a positive family history.
2. VHL germline mutations are NOT detected in ALL cases in which only two
first-degree relatives exhibit VHL-related tumours. This observation suggests that a
VHL family history requires sometimes more than two family members or alterna-
tively, a multiple VHL-related tumour spectrum in two close relatives. However, in
such clinical situations persons should always be tested for a VHL germline mutation.
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3. VHL germline mutations are found in varying success-percentages in families
with two or more first-degree relatives exhibiting a single type of VHL related tu-
mour. However, next to the type of tumour, factors such as age of onset, multi-centricity
and number of affected family members, are important indicators for the presence of
VHL germline mutations. It is generally accepted that VHL germline mutations are
found in up to 100% of families with haemangioblastomas, since these families meet
the VHL diagnostic criteria.35 Variable percentages are reported in familial renal cell
carcinoma (0-100%),17,36,37 and in phaeochromocytoma families (33-67%).38-40
Sporadic cases
4. In ALL sporadic patients exhibiting a clear multi-organ expression of VHL-
related tumours a VHL germline mutation is identified. This finding agrees with the
clinical diagnostic criteria for sporadic patients of Maher and Kaelin.35
5. In sporadic patients with a single type but multiple sites of VHL-related tu-
mours the success rate for identifying a VHL germline mutation depends partly on the
tumour type, but also on features such as: age at diagnosis, multi-centricity and
bilateralism. For example, in patients with multiple CNS haemangioblastoma how-
ever, who meet the clinical diagnostic criteria for isolated patients35, a VHL germline
mutation is NOT always identified. Examples of finding VHL germline mutations are
described in sections 3.3 and 3.4 for patients with multiple CNS haemangioblastoma
(50%) and multiple phaeochromocytoma (0-80%). Moreover, 10% of the patients
with bilateral renal cell carcinoma is a carrier of a VHL germline mutation.17
6. In sporadic patients with a single VHL-related tumour the success rate for
identifying a VHL germline mutation is generally low (i.e. <5%, see sections 3.3 and
3.4). However as described in section 4.1.1, retinal haemangioblastoma form an ex-
ception. Identification of a VHL germline mutation in sporadic patients with a single
VHL-related tumour depends not only on the tumour type, but also on the age at
diagnosis. We agree with the members of the Dutch VHL working group that the cut-
off point for ‘young age at diagnosis’ should be 50 years for CNS haemangioblastoma
and phaeochromocytoma. In contrast, renal cell carcinoma requires a much younger
age at diagnosis (<30 years), since this tumour is relatively common in the general
population at older age. These age differences are based on studies that reported the
age at diagnosis of VHL-related tumours both in sporadic patients without germline
mutations as well as in proven carriers of a VHL gene mutation (Table 2). In category
6 we would also like to include the sporadic patients with a single VHL-related tu-
mour and a less specific VHL-related tumour such as a renal cyst.
Although, this classification is an arbitrary way of categorising patients, it gen-
erally reflects the chance of finding a germline mutation for each type of patient.
Taking into account that VHL germline mutations have been identified in situations
varying from classic VHL families to sporadic patients with a history suggesting just
one or some features of VHL disease, clinical diagnostic criteria must be neither too
restrictive nor too open-ended. It therefore remains questionable whether unambigu-
ous clinical diagnostic criteria can be defined at all for this tumour syndrome. We
suggest treating each patient suspected of having VHL disease, according to the six
categories above, with an open mind and performing: (1) an extensive pedigree analy-
sis, (2) DNA analysis, and (3) clinical screening for further VHL-related tumours.
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Moreover, the discussion about establishing definite criteria for diagnosing VHL
disease has often been confused by the criteria for eligibility for VHL germline muta-
tion analysis. In my opinion, the question of ‘which persons should be tested for mu-
tation analysis of the VHL gene’, is far more important than somewhat arcane discus-
sions on what constitutes the perfect combination of clinical criteria for a VHL diag-
nosis. We consider all the conditions listed in table 3, and defined by our six criteria
eligible, for DNA analysis.
Clinical situations leading to suspicion of VHL disease
Family history of VHL disease Bilateral and multi-centric renal cysts
Retinal haemangioblastoma Phaeochromocytoma (paraganglioma)
CNS haemangioblastoma - familial
- familial - bilateral
- multi-centric - diagnosis at age 50 years or younger
- diagnosis at age 50 years or younger Bilateral ELSTs
Renal cell carcinoma (type clear cell or non-papillary) Multiple pancreatic cysts
- younger than 30 years Multiple pancreatic islet cell tumours
- bilateral or multi-centric Bilateral or multi-centric epididymal cystadenomas
- familial Bilateral or multi-centric APMO
Table 3 Clinical situations leading to suspicion of VHL disease
CNS, central nervous system; ELST, endo-lymphatic sac tumour; APMO, adnexal papillary cystad-
enoma of probable mesonephric origin.This table is based on recommendations from Glenn et al.41
Finally, we discuss the numbers of tested patients with and without a VHL
germline mutation in table 2. When we pool sporadic and familial VHL patients and
their first and second degree relatives from the Utrecht data (categories 1, 2 and 4), 48
of the 111 persons tested have a VHL germline mutation (43%), which is in a reason-
able concordance with an autosomal dominant inheritance. The remaining clinical
situations (categories 3, 5 and 6) lead to five identified VHL germline mutation carri-
ers in 67 persons (8%). These figures indicate that procedures for VHL germline analysis
in VHL disease are effective in detecting carriers of a VHL germline mutation. In
section 4.2.5 VHL disease is compared in this respect to other hereditary cancers and
in section 4.3.5 cost-effectiveness of screening for VHL germline mutations are dis-
cussed.
An estimate of the prevalence of VHL disease in the Netherlands
By 1999, 34 probands with a germline mutation in the VHL gene had been reported
after a joint effort by the two VHL DNA diagnostic centres in Utrecht and Rotterdam
(section 3.1). Exclusion of seven Belgian and Turkish families leaves 27 ‘Dutch fami-
lies’. At the moment, at least 15 known VHL families have not yet been subjected to
DNA analysis and six families are in progress. This indicates that the provisional
number of detected VHL families in the Netherlands is approximately 48.
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However, a more difficult problem is how to extrapolate the number of families
to an estimated number of VHL germline mutation carriers. An indication that the
number of mutation carriers detected is proportional to the amount of time invested in
investigating each family is indicated by the four families referred at the start of this
study in 1996 (Fig. 3). These four extensively monitored families comprised 35 pa-
tients, including persons ‘said to be affected’, giving a mean number of nine patients
per family. However, these families probably represent a selection bias. During the
last four years we have detected 15 new families with a mean number of almost four
patients per family (range 1-12). This is almost certainly a more realistic determina-
tion of the average number of carriers in each per family. If we extrapolate the average
of four to the total of 48 known families we come to a total of approximately 200
patients.
It is reasonable to assume that the chance of clinically diagnosing a family is
directly related to the number of affected patients present in the family. As a result we
are very unlikely to detect entirely new families with a large number of patients (i.e.
larger than four), but may detect many more families with just one or two patients.
However, it is difficult, perhaps impossible, to define what number of new families
still need to be detected. An interesting aspect is that all seven families with just one
single affected person (defined at the moment of diagnosis) were associated with de
novo mutations, either on the basis of DNA diagnosis or family history (see section
3.1). These observations suggest a relatively high mutation frequency, which will re-
quire further future investigations.
However, the estimate of 200 Dutch persons carrying a VHL germline mutation
is probably too low. Firstly, there will still be unidentified VHL families, despite the
fact that health care is well organised in the Netherlands and well-defined large fami-
lies are not likely to be missed. Secondly, the mean number of four patients per family
is most likely an underestimate. Thorough genealogical research in families of identi-
fied VHL carriers should result in a higher number of mutation carriers detected per
family. These considerations lead us to give a conservative estimate of a total number
of VHL germline mutation carriers in the Netherlands at 250. With a population of 16
million people this would give a prevalence of 1:64,000; which is lower than esti-
mates made in areas in Germany and England that vary between 1:31,000 and
1:53,000.42-44. This aspect requires also further investigations.
4.2.2 Molecular genetic implications of sporadic patients with VHL-related tu-
mours
We describe several clinical situations that exhibit features suggesting a germline
mutation, such as multi-centric, bilateral, or familial tumours, but that are not associ-
ated with a VHL germline mutation. These situations may provide evidence for addi-
tional VHL-related-tumour-susceptibility genes, or alternatively, mutations in parts
of the VHL gene not investigated (e.g. promoter area).
The absence of VHL germline mutations in all phaeochromocytoma patients,
particularly in those diagnosed at a young age, or with multiple/bilateral tumours,
suggest the presence of additional phaeochromocytoma susceptibility genes. Moreo-
ver, four families with phaeochromocytoma, including one family displaying bilateral
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tumours that also manifest at a young age, open the possibility of investigating whether
indeed other (familial) phaeochromocytoma susceptibility loci are involved. Another,
but less likely explanation is, that these patients are somatic mosaics for VHL muta-
tions. Either of these two explanations would also account for the absence of a germline
mutation in the VHL gene in patients with multiple CNS haemangioblastoma, or those
who were diagnosed at a young age.
Candidates genes may be found by studying genes that are involved in the bio-
chemical pathway of the VHL protein. So far, only the role of the putative tumour
suppressor gene Cullin2 (Cul2) has been investigated in the pathogenesis of
phaeochromocytoma.45 Elongin C, Elongin B, Rbx1, etc. have not been studied yet.
Cul2 is part of the VCB complex (described in the introduction) that plays a role in the
ubiquitination of proteins. Only one of 26 studied tumours showed a hemizygous
deletion of the Cul2 gene, and it was suggested that this gene does not play a major
role in the tumourigenesis of phaeochromocytoma. In addition, candidate genes may
be found using the same method as for the VHL gene. The group that linked the VHL
gene to chromosome region 3p25-26 was inspired by Zbar et al., who found loss of
alleles of loci on 3p in renal cell carcinoma, a common manifestation of VHL dis-
ease.46 Other candidate loci (in the 3p14.2 and 3p21.2-p21.3 regions) for tumour sup-
pressor genes involved in renal cell carcinoma were also identified on the short arm of
chromosome 3.47 However, none of these genes have been cloned yet and hence they
provide no useful information for the attending physician of such a patient.
De novo VHL germline mutations
In section 3.1 we identified four de novo VHL germline mutations (12%). Although,
not all parents could be tested, the lack of clinical expression of the parents and other
close relatives led us to conclude that the occurrence of de novo mutations in the VHL
gene in the Netherlands could be as high as 21%. However, as advanced in the previ-
ous section, sporadic patients are likely to be an under-diagnosed group of VHL pa-
tients and this is one of the many unknown factors preventing conversion of the number
of de novo mutations in our sample group into a VHL mutation frequency for the
Netherlands.
Diagnosis of VHL disease may be hampered in sporadic patients by lack of
additional symptoms of VHL-related tumours. It is conceivable that a relatively low
number (n =25) of de novo mutations has been reported in the literature so far,48-50
since most sporadic patients with VHL-related tumours remain unrecognised. How-
ever, seven of nine of our sporadic patients with a VHL mutation met the clinical
diagnostic criteria for VHL disease, and four of these patients exhibited a clear multi-
organ expression of VHL disease. Alternatively, sporadic patients with VHL-related
tumours may be mosaic, although mosaicism has so far been described in only two
instances.34. Another possibility is that these patients represent phenocopies. How-
ever, we think that it is very unlikely that independent somatic mutation events giving
rise to multiple VHL-related tumours in one patient could be expected to occur by
chance (see 4.2.5). On the assumption that, averaged over time, de novo mutations
replace the disease genes lost through natural selection, there is a simple relationship
between the rate at which natural selection is removing disadvantageous genes, the
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rate at which de novo mutations creates them, and their frequency in the population.51
We think this model has three implications: VHL patients are reproductively less effi-
cient because of: (1) early death in some instances, prior to completion of families; (2)
diminished male or female fertility, because of epididymal lesions or adnexal papil-
lary tumours of probable mesonephric origin (APMO); and (3) an unwillingness to
pass the disease on to the next generation. This last consideration is likely to be that
with the highest impact. In any case our observation of a high de novo mutation fre-
quency is compatible with these arguments.
4.2.3 Clinical implications of DNA analysis
Section 4.2.1. clearly illustrates that VHL germline mutations are identified in all
classic VHL families as well as in classic sporadic VHL patients. Consequently, is not
necessary to test  patients with patently obvious VHL disease, except for possible
probands. DNA analysis can therefore be restricted to relatives with less distinctive
expression of VHL disease (e.g. a solitary renal cell carcinoma) and/or to young rela-
tives at risk for the disease, in order to establish presymptomatic (or prenatal) diagno-
sis and prevent unnecessary monitoring.
In clinically less well-defined situations of patients with VHL-related tumours, DNA
analysis plays an important role to confirm (or to reject) the diagnosis of VHL dis-
ease. The studies described in sections 3.3 and 3.4 indicate that a relatively small
number of VHL germline mutations may be found in the population of sporadic pa-
tients with an apparently solitary VHL-related tumour. For example, before the iden-
tification of the VHL gene it was suggested that a substantial proportion of sporadic
patients with CNS haemangioblastoma could be associated with VHL disease. Upon
more detailed examination 23% to 34.3% was found to be afflicted with VHL dis-
ease.10,52 Our findings, based on DNA diagnosis of 4% indicate that, the clinical crite-
ria used at that time by Neumann and Richard were not as critically defined as the
current situation is. However, periodic clinical monitoring is warranted for the small
group of patients without a VHL germline mutation, but with features suggesting the
presence of a germline mutation (e.g. one type of multiple VHL-related tumours). In
families with only one type of hereditary VHL-related lesions and without a VHL
germline mutation, periodic monitoring should at least be focussed on the tumour
concerned. In all other patients with apparently solitary VHL-related tumours and
without a VHL germline mutation, outgrowth of the tumour needs to be regularly
controlled. In these latter cases once-only clinical screening combined with molecular
genetic analysis of the VHL gene is probably sufficient to rule out VHL disease.
Detection of the family-specific VHL germline mutation can identify persons at
risk for the disease. This is illustrated well by the following case from section 3.2. In
a large classic VHL family, a 55 year old female was originally considered to be a
VHL patient when diagnosed with a renal cell carcinoma. Since this tumour predomi-
nantly occurs in the seventh and eighth decade of life,53 a person with a renal cell
carcinoma in a VHL family and diagnosed at a relatively young age would certainly
be suspected of having VHL disease. However, Southern blot analysis demonstrated
that this patient did not carry the deletion associated with VHL in her family. Conse-
quently, she could be released from the annual clinical monitoring protocol. One should
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keep in mind that renal cell carcinoma is a relatively common malignancy. Kidney
cancer accounts for 3% of adult malignancies, and the world incidence is increasing at
an annual rate of 2%.54 We feel this case history establishes that VHL diagnosis should
be confirmed, wherever possible, by molecular genetic analysis and particularly in
situations where the patient concerned exhibits only a limited spectrum of VHL fea-
tures.
4.2.4 Genotype-phenotype correlations in VHL disease: do they exist?
Our studies support the well-established observation in the literature that there is a
relationship between the presence of a VHL germline mutation and the occurrence of
one or more VHL-related tumours. In chapter 3 (sections 3.1 and 3.2) however, we
provided evidence for reduced or even non-penetrance of some VHL germline muta-
tions. Two missense mutations (P81S and R64P), that were not associated with a ge-
netic polymorphism by screening 50 non-VHL patients, suggested non-penetrance in
some older carriers of the VHL germline mutation concerned. In four earlier reported
cases of the P81S mutation a higher penetrance is described,34,55,56 and may indicate
the presence of modifying genes that influence the expression of VHL disease. In my
opinion however, these observations of reduced or even non-penetrance of VHL
germline mutations have no substantial implications for the clinical practice; carriers
of such a mutation can not be relieved from clinical surveillance of VHL-related tu-
mours. At most, the frequency of monitoring can be lowered at an older age.
Earlier observations suggested that almost all families with phaeochromocytoma
were associated with missense mutations. We confirmed the recent observation that
missense mutations were found in 30% of the VHL type I (without phaeo-
chromocytoma) families and in 71% of the VHL type II (with phaeochromocytoma)
families, which is significantly higher than the proportion of missense mutations (~40%)
in all VHL germline mutations. Apparently, germline VHL mutations that are associ-
ated with a loss of function, such as partial deletions or micro deletions, also predis-
pose carriers of such a mutation to the occurrence of phaeochromocytoma. We hy-
pothesise that, with respect to the dominant negative model - proposed for the asso-
ciation between specific missense mutations and the occurrence of phaeochromocytoma
- one ‘hit’ may be sufficient for the initiation of phaeochromocytoma tumourigenesis.
This hit will probably concern a specific missense mutation, which occurs either in
the germline or as a somatic mutation. Since oncogenesis is a multi-step process,
other genes must also be involved in tumourigenesis, otherwise every carrier of such
a missense mutation would develop phaeochromocytoma. In addition, one would ex-
pect also very young patients with phaeochromocytoma. The involvement of other
genes is also supported by: (1) the absence of VHL germline mutations in some pa-
tients with multiple, bilateral or familial phaeochromocytoma, and (2) the low fre-
quency of somatic VHL mutations in sporadic patients with solitary
phaeochromocytoma, in contrast to renal cell carcinoma and CNS haemangioblas-
toma (Fig. 4).
We conclude that there is no apparent simple relationship between a germline
mutation in the VHL gene and the manifestation (age of onset and type) of VHL-
related tumours. Since the germline mutation in the VHL gene is most commonly
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defined as the genotype, we would question whether it is appropriate to speak of
genotype-phenotype correlations, especially since it is now appreciated that many
genetic events and environmental factors are involved in the mechanism of oncogen-
esis. Moreover, these observations do not enable the conversion of the risk for spe-
cific VHL-related tumours - associated with a particular VHL germline mutation - to
individualised monitoring of VHL disease.
Fig. 4 Somatic mutations in solitary VHL-related tumours from sporadic (non-VHL) patients. Left-
hand bars represent the frequency of somatic mutations in the VHL gene, bars on the right represent
the frequency of loss of the wild-type allele (i.e. loss of heterozygosity). The frequencies in bold
represent the (minimal) percentages in which both VHL alleles are inactivated. RCC, renal cell
carcinoma;57 HAB, CNS haemangioblastoma;58-60 Phaeo, phaeochromocytoma.61,62 In sporadic RCC
and HAB, hypermethylation (*) plays a role in 19-33% of the tumours.62,63
RCC HAB Phaeo
*
57% 98% 10-50% 50% 8% 56%
*
75% 50%? 8%?
External risk factors for the development of VHL-related tumours
VHL patients display both inter- as well as intrafamilial differences in manifestations
of renal tumours. This variation may be caused by differences in the timing of origin,
and nature of the somatic mutation. In turn, these somatic mutations may be induced
by environmental factors, e.g. smoking. A current opinion is that smoking (particu-
larly in males), obesity, hypertension and certain professions are correlated with the
development of renal cell carcinoma (see 1.5.6). In this respect, it may be coincidence
that in a family living near a nuclear power station, we observed early (<30 years) and
aggressive (metastases) renal cell carcinoma in seven members of a VHL family with
twelve patients. However, no further data are available, either in our study or the
literature, to substantiate the effects of smoking and/or nuclear radiation on the induc-
tion of tumours in patients with VHL disease. We recommend collecting more data on
past smoking habits as well as the working and living conditions of VHL patients, in
order to investigate putative variances in multi-centricity, aggressiveness, and age of
onset of renal cell carcinoma. These data should be compared to the manifestations of
renal cell carcinoma in VHL patients who do not smoke and who have different work-
ing and living conditions. In retrospect, it is a pity that we did not make use of the
opportunity to question our patients in a consisting fashion as to their smoking habits
and other environmental influences.
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Radiation risk
We advocate annual monitoring of VHL lesions with MRI and ultrasound rather than
CT (section 2.1). Ionising X-rays emitted by CT may mutate the DNA of the second
(non-mutated) VHL allele. However, there are no data available showing that exposed
carriers of a germline mutation in the VHL gene develop tumours earlier than non-
exposed patients. So far, there are only limited data available on tumourigenic radio-
sensitivity in cancer-prone genetic conditions. A review of epidemiological, clinical
and experimental data suggested a ten times greater-than-normal risk after radiation
in heterozygous patients with breast cancer.64 It is prudent, in my opinion, to regard
VHL as a disease where carriers of a VHL germline mutation have an increased risk
for tumours, since tumourigenesis may be initiated with only one somatic hit. How-
ever, in view of the multi-step mechanism in tumourigenesis, it is still an open ques-
tion whether there is a linear dose-effect relationship between radiation and tumouri-
genesis via induced mutations.65
4.2.5 Comparison of VHL disease with other hereditary cancers
At first glance, VHL disease represents an extraordinary form of hereditary cancer.
Since VHL disease is classically defined as a composite of different tumours in differ-
ent locations, by definition, a sporadic VHL patient can only arise from an inherited
mutation. We think that screening procedures for germline mutations in VHL disease
are going to have a relatively larger effect in reducing morbidity and early mortality
than for other forms of hereditary cancer, in particular hereditary breast cancer (HBC)
and hereditary colorectal cancer, including hereditary non-polyposis colorectal can-
cer (HNPCC). In the latter conditions, the chances of detecting a germline mutation in
the respective disease gene(s) is generally much smaller than in a sporadic VHL pa-
tient. Although, in absolute quantities the morbidity and lethality prevented by DNA
diagnosis for HBC and HNPCC is larger than for VHL disease. The DNA diagnostic
load is several orders of magnitudes higher and the identified number of germline
mutations relative to all patients investigated much lower. In addition, there are sev-
eral other factors that should be taken into account when comparing VHL disease to
other hereditary cancer susceptibilities.
Firstly, VHL disease is a disorder characterised by tumours in many different
organs. In contrast, in hereditary breast cancer and hereditary colorectal cancer, tu-
mours mostly occur in a single, major target organ. The sporadic or non-inherited
counterparts of these tumours occur at a relatively high frequency in the general popu-
lation. Consequently, there are many families in which a high incidence of breast or
colorectal cancer is, in fact, due to chance clustering of sporadic tumours. In many
cases it is difficult, if not impossible, to distinguish such families from families with a
hereditary predisposition. Because the individual VHL-related tumours are far less
common, sporadic patients with a solitary VHL-related tumour are more easily distin-
guished from patients with VHL disease who either display multiple tumours in vari-
ous organs or have a positive family history for VHL-related tumours. Moreover,
sporadic cases of classic VHL disease arising from somatic mutations of both VHL
alleles in multiple target organs are extremely unlikely to occur.
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Secondly, VHL disease is a genetically homogeneous disorder with respect to
well-defined VHL patients, whereas it is well known that HBC and HNPCC display
genetic heterogeneity. No matter how strictly one defines the eligibility criteria for
molecular genetic analysis of HBC and HNPCC families, or how extensively muta-
tion analysis is carried out, BRCA1/BRCA2 and MLH1/MSH2 germline mutations
will probably never be detected in 100% of the affected families.
Thirdly, a major difference between mutation studies of the VHL gene and of
those for HBC and HNPCC is that VHL analysis is facilitated by the small size of the
gene, allowing direct sequencing to detect alterations. Moreover, large deletions (which
represent a major proportion of the mutations) can be efficiently identified. In con-
trast, BRCA1, BRCA2, as well as the genes responsible for HNPCC, are large, com-
plex genes, which preclude comprehensive mutation analysis by sequencing in a rou-
tine diagnostic setting, at least for the time being. Usually, less sensitive, pre-screen-
ing methods are used for the analysis of these genes, resulting in a lower detection
rate.
In short, DNA diagnostic procedures are much more likely to make significant
inroads into combating VHL disease in it’s entirety within the Dutch population than
is the case for many other inherited tumours.
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4.3 Detecting persons at risk for VHL disease
In the Netherlands there has been an estimated 30-fold increase in cancer-related ge-
netic counselling over the last eleven years.66 The rising number of cancer genetics
referrals could be due to an increasing awareness of doctors and patients. On the other
hand, in some hospitals and areas in the Netherlands hereditary cancer may have been
under-recognised in the past and suggests that information on hereditary cancer has
not been adequately provided or ‘consumed’.66
In order to detect new families and patients possibly affected with VHL disease,
we took several initiatives (see 1.1.1). The five lines resulted in an increase in the
number of probands with VHL disease as well as sporadic patients with VHL-related
tumours referred to the Department of Medical Genetics in Utrecht (Fig. 3). The re-
quest to the Departments of Ophthalmology resulted in the referral of one VHL fam-
ily. The appeal in the journal of the Dutch Association for Neurology resulted in the
referral of 14 probands with haemangioblastoma in the central nervous system, of
whom two had multiple tumours. The 80 medical specialists and the eight genetic
centres resulted in the referral of 12 VHL families, seven sporadic patients with VHL
disease, 17 patients with haemangioblastoma in the central nervous system (of whom
two had multiple tumours), 24 patients with phaeochromocytoma, one with renal cell
carcinoma, and one with retinal haemangioblastoma. Moreover, the genetic centres
are in contact with at least another 15 VHL families that have not undergone DNA
analysis so far. Via information on the Internet, three VHL families contacted the
Dutch VHL support group and asked for DNA analysis.
A drawback in the detection of new VHL patients was the varied co-operation of
their doctors. We encountered difficulties in reaching patients through their attending
physicians or clinical geneticists. Much time and effort was invested in convincing
some doctors of the purpose of this study. A few were opposed to approaching pa-
tients, others to the methods used for collecting or storing the clinical and genetic
data. We also experienced difficulties in collecting clinical data on VHL patients. For
example, some institutes were not willing to hand over data upon the patients’ indi-
vidual informed consent or they charged for sending copies of the patients’ clinical
notes. In contrast, the patients themselves were favourably disposed to the research
project. People at risk for the disease came forward, on their own initiative, at meet-
ings of the VHL support group or via the information found on the Internet. Most
(97%) of the patients we approached to sign the informed consent form kindly co-
operated and gave us permission to retrieve their clinical data. In the last phase of the
study, the collecting and storing of data was speeded up with the help of two genetic
assistants.
4.3.1 Evaluation of methods of detecting persons at risk for VHL disease
Individuals with a predisposition for an inherited tumour syndrome such as VHL dis-
ease are most likely to benefit from early identification of the disease followed by
periodic clinical monitoring. Potentially life-threatening tumours can be removed at
an early stage and may improve both prognosis and life expectancy. These advantages
of early identification are the ones most commonly mentioned, but these should be
weighed against the negative consequences of approaching patients. An active ap-
General discussion
proach in detecting persons at risk for VHL disease raises the problem of intruding
into their privacy and provoking feelings of threat. However, there is the problem of
the responsibility and liability of doctors performing insufficient or incomplete inves-
tigations, and/or treatment of identified VHL patients and persons at risk for the dis-
ease.
Active versus passive methods for patient detection
An active approach towards discovering new patients in a population is likely to re-
sult in a higher number of detected patients than a passive approach. But an active or
even aggressive approach could result in emotional problems for persons at risk for
the disease (see 4.3.2). Patients and relatives are confronted with the disease in all its
aspects. For example, they are faced with the death of their parents and close relatives,
the fear of losing other relatives and especially their children, or developing life-threat-
ening tumours themselves.66 This burden is well expressed by the Dutch saying: “one
suffers most from the suffering one fears” (men lijdt het meest, van het lijden dat men
vreest).
A passive approach is likely to result in more undiagnosed patients and in a
higher rate of morbidity and mortality among VHL patients. One advantage is, how-
ever, that persons at risk for the disease are not offended or threatened by doctors and
researchers convincing them to undergo clinical and genetic tests. This non-directive
approach leaves persons at risk for VHL free to make their own choice, if and when
they are prepared to consult their doctor.
The starting point in solving this dilemma is, in my opinion, that the motivation
and initiative for both DNA analysis and clinical monitoring should come from the
person at risk. Therefore VHL families and persons at risk for the disease should be
provided with clear oral and written information about the clinical symptoms and
signs, complications, treatment, prognosis and inheritance of the disease in order to
prevent both patient and doctor delaying a request for diagnosis or treatment.67 Per-
sons should be reached by non-threatening media such as information booklets handed
over by family members, general practitioners or medical specialists, and via the Internet
(www.vhl.org). In addition, doctors should be provided with information on the dis-
ease and on hereditary forms of cancer in general. This approach of spreading infor-
mation as much as possible will certainly take more time, but it is likely to be more
effective in the end, and it also keeps a balance between the over-active approach to
persons at risk and the doctors’ responsibility to guarantee health care.
Family support groups
The Dutch VHL support group provides patients and their relatives with information
from experts in the field, emotional support (companionship in distress), and organ-
ises discussions of common interests (about ethical, legal and social aspects, such as
employment and insurance) guided by a psychologist. The Dutch support group was
founded in 1996, following the American VHL Family Alliance that was the first to be
initiated in 1993. The VHL Family Alliance provides information for families and
physicians about this disorder and local self-help support groups for families affected
with VHL. Volunteers, mostly families living with VHL, health professionals, and
interested friends, run the Alliance.
Chapter 4
Most of the information on VHL disease is now published and edited by various
family support groups. Local family support chapters exist in many states in the USA,
and more are being formed. Local chapter meetings are scheduled periodically in
several states. International VHL Support Organisations have been established in
Australia, New Zealand, Britain, Canada, Denmark, Germany, France, Italy, Belgium
and the Netherlands. The American VHL Family Alliance is in touch with nearly
6,000 affected people in 27 countries, the latest additions being from Brazil and Ne-
pal.
4.3.2 Detection of VHL patients and presymptomatic persons; psychological dis-
tress
Hereditary diseases in general and hereditary forms of cancer in particular, harbour
more far-reaching consequences than other ‘apparently ordinary’ diseases. Genetic
testing not only provides information of carriership to the person tested, but also af-
fects family members that may or may not want to receive this information. So far, no
studies have been undertaken to investigate the psychological consequences of gene
testing in VHL disease. However, in many respects multiple endocrine neoplasia type
2A (MEN 2A) is comparable to VHL disease and it may be reasonable to assume that
many of the patients responses described for MEN 2A will also be applicable to VHL
disease.68,69  In addition, data are available from studies on other hereditary forms of
cancer such as breast and ovarian cancer, and familial polyposis.70-74
Data from MEN 2A studies suggest that some VHL patients undergoing
presymptomatic DNA testing will experience increased levels of psychological dis-
tress (F. Grosfeld, personal communication). In particular, elevated pre-test anxiety,
poor socio-economical background, lack of information, young age, individual ten-
dency towards anxiety and depression, and a defensive style of coping, are risk fac-
tors for psychological complaints. Caution is therefore warranted towards a directive
approach in offering DNA tests, since this is also likely to reach persons that are more
vulnerable to psychological distress.
In MEN 2 patients an unfavourable test outcome resulted in anxiety and depres-
sion but also relief.68 Anxiety and depression may come from concern about how the
test outcome may affect the future of the carrier or their family.71,75 The feeling of
relief derives from the benefits of this outcome.70,71,73 The options of close clinical
monitoring and preventive treatment help to reassure carriers that they had made the
right decision.
A favourable test leads, in most applicants and partners, to relief, especially
because of the health benefits for their offspring.68 On the other hand, a favourable test
may also lead to worry, some non-carriers may feel guilty (‘survivors’ guilt) and iso-
lated from their families.76 In addition, some applicants may have planned their lives
accordingly, acting as if they in fact have the disease (e.g. with low expectations for a
career). A favourable test outcome can be difficult for them to accept. Suddenly, the
applicant has to reject his or her old philosophy of life (living in fear of the disease)
and has to build up a new concept of life, without the threat of the disease.77 In addi-
tion, they face the same responsibilities as any other healthy member of society. This
may cause depression or even suicidal behaviour.
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4.3.3 Prenatal and infantile DNA analysis
Since curative treatment is impossible in VHL, arising tumours should be treated
electively but preventive (bilateral) removal of organs such as kidney, adrenal glands
or eyes, is not a desirable option in VHL patients. Therefore, the detection of VHL
carriership brings a life-long and close monitoring for multiple and recurrent tumours.
Understandably most parents wish to have an unaffected child.
At present, there are technical possibilities for prenatal diagnosis, i.e. chorion
biopsy, amniocentesis or pre-implantation genetic diagnosis (PGD) following in vitro
fertilisation (IVF).78 When future parents decide to perform chorion biopsy or amnio-
centesis and the result indicates VHL carriership of the foetus, they can choose to
terminate the pregnancy. When parents decide to have PGD performed, the embryos
can be checked for carriership before implantation. Recently, the Dutch National Health
Council has decided that inclusion criteria for PGD are, in principle, similar to ac-
cepted medical indications for prenatal diagnostics (with the exception of tests based
on maternal age).79 Since VHL is a Mendelian inherited disease this opens the door
towards PGD. So far, one patient has requested PGD in the Netherlands (and one in
Belgium).
After the Sixth International Workshop on multiple endocrine neoplasia (MEN)
and VHL in 1997, in Noordwijkerhout, the Netherlands, an opinion poll was held
about PGD among 76 medical professionals (Table 4).80 The results showed that both
prenatal and presymptomatic diagnosis remain controversial or may suggest that the
participants are unaware of the pros and cons of PGD. In my opinion, this issue has to
be solved in individual encounters between parents, clinical geneticists and attending
physicians.
In VHL patients, tumours, especially retinal haemangioblastoma, may occur at an
early age. Symptomatic lesions, even leading to unilateral or bilateral blindness have
been reported before the age of five years old. (Third International VHL symposium,
Paris, France, personal communication).6,81 Early detected haemangioblastoma in the
eye are an outstanding example of how presymptomatic and preventive treatment of
VHL disease should work. Because of the chance of early disease symptoms mani-
festing in the eye, genetic testing of young people with a high risk of VHL disease
must be carried out as early as possible, in order to be fully prepared to treat the
disease if it occurs. Unfortunately, this position is not supported by every clinical
genetic centre in this country. One can not refrain from observing that this is a posi-
tion which would not be supported in the US, where the chance of legal action against
medical practice failing to carry a timely DNA diagnosis is much higher than in the
Netherlands.
4.3.4 Financial and legal consequences
Unfortunately, some VHL patients have difficulty in obtaining insurance, applying
for a job, or getting a mortgage. Legal and financial issues involved in cancer genetics
differ between countries. The Dutch situation described here is adapted, with permis-
sion, from Dr. R.H. Sijmons.66 DNA testing for hereditary disorders is restricted by
national law to the non-commercial clinical genetics centres. The health insurance
companies cover the costs of clinical genetic services, as well as periodic monitoring
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Table 4 An opinion poll* on pre-implantation genetic diagnosis (PGD) and in vitro
fertilisation (IVF).
and prophylactic surgery in individuals with a high genetic cancer risk. Because of a
self-imposed restriction, these companies do not ask for disclosure of the DNA test
results when selling life insurance or disability insurance, unless the amounts to be
covered by a policy are higher than average (respectively, Euro 150.000 and Euro
30.000). Employers are prohibited by law from asking their new employees for infor-
mation on genetic diseases.
As the knowledge about the genetic basis of disorders grows, so does the poten-
tial for discrimination in health insurance coverage. Insurance companies with ge-
netic information could convert current risks for certain customers into demands for
higher contributions from persons with a predisposition to a hereditary disease. In
addition, they could also deny health insurance to such persons and thereby limit their
own risk. The fear of discrimination has other undesirable effects. People may be
unwilling to participate in family investigations, including DNA diagnosis, and to
share information about their genetic status with their attending doctors or family
members because of concerns about misuse of this information.
Genetic information has already been used in discrimination. In the early seven-
ties, some insurance companies denied coverage and charged higher rates to African
Americans carrying the gene for sickle cell anaemia.82 This has also been reported in
American patients with Huntington’s disease.83 In a study from Georgetown Univer-
sity 22% of the people with a known genetic condition in the family indicated that
they had been refused health insurance coverage because of their genetic status, whether
they were affected or not.82
‘Would you advise IVF and PGD?’
42% ‘never’
32% ‘yes, for MEN 1, and MEN 2, as well as VHL
13% ‘yes, only for MEN 1 and VHL (because MEN 2 may be cured)’
13% ‘yes, only for VHL
‘If a specific mutation in the VHL gene is present in an affected family member,
at what age would you advise having DNA analysis performed in his/her offspring?’
5% prenatally
15% at birth
36% between 1 and 5 years
15% between 5 and 10 years
8% at the start of the periodic clinical examination
18% at an age that the children can make their own choice (puberty)
3% if symptoms are present
*This opinion poll was held among 76 medical professionals after the Sixth International Workshop
on Multiple Endocrine Neoplasia (MEN) and VHL in 1997, in Noordwijkerhout, the Netherlands.
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We consider using genetic information, to exclude persons from insurance cov-
erage, represents genetic discrimination. In 1995, the National Action Plan on Breast
Cancer and the working group on Ethical, Legal, and Social Implications of the Hu-
mane Genome Project drew up recommendations to protect people against genetic
discrimination. Insurance providers should be prohibited from: (1) using genetic in-
formation to deny or limit any coverage; (2) establishing differential rates or premium
payments based on genetic information; (3) requesting or requiring collection or dis-
closure of genetic information; (4) releasing genetic information without prior written
authorisation of the individual.82 VHL disease should be considered, along with many
other inherited disorders, in preventing genetic discrimination and protecting the in-
terests of these patients concerning insurance and work (see also 4.2.4).
4.3.5 Cost-effectiveness of early detection
Genetic screening of individuals presenting with clinical features suggesting VHL
disease facilitates confirmation of the diagnosis, accurate genetic counselling and clini-
cal monitoring of at risk family members. The necessity for costly and time-consum-
ing monitoring programs can be reduced and surveillance directed at those carrying
the mutation.84 Assuming that the aim of a screening test is to detect a genetic disease
and allow therapeutic intervention that reduces morbidity and mortality, the real ‘cost’
of the test represents the total cost of treating the disease and ultimately saving a life
(i.e. the ‘cost-benefit’ of the test).85 ‘Cost-benefit’ is a term derived from the financial
sector. In a medical context the term ‘cost-effectiveness’ is preferred, because the
outcomes are seen not only from a financial point of view, but also from looking at the
consequences that accumulate for an individual and society.86,87
Beforehand, we would like to state that it is exceedingly difficult to calculate
costs and effectiveness of early detection and we emphasise that further investiga-
tions are required. In order to calculate the cost-effectiveness of detecting patients
with VHL disease by DNA analysis, we start from the 100 VHL patients that have
been identified so far (section 3.1). Although we report a disease prevalence in the
Netherlands of ~ 1:64,000, in this model we assume that a prevalence of 1:40,000.
The hypothetical Dutch VHL population would therefore comprise 400 patients. We
estimate that the remaining 300 patients are identified in 200 first- and 800 second-
degree family members who are at 50% and 25% risk for the disease, respectively.
This results in an estimated population of 1100 patients (100 + 200 + 800) to be
monitored for VHL disease each year, while only 400 persons would, in fact, have
VHL disease. The cost of annual VHL monitoring is estimated at Euro 525 per patient
and DNA analysis could consequently save Euro 367,500 each year (Table 5).
At the moment, the actual costs are likely to be much higher, because sympto-
matic patients needing expensive and extensive treatment are still being diagnosed at
an advanced stage of the disease. Moreover, it seems likely that identification of VHL
carriership by DNA analysis (cost of test is Euro 600) is not only cost-effective but
may also save lives. We recommend that clinical criteria for DNA analysis, as defined
in section 4.2.1, should therefore include both patients meeting the VHL diagnostic
criteria as well as sporadic patients with solitary VHL-related tumours, in order to
identify as many VHL mutation carriers as possible.
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Table 5 Technical assessment of clinical monitoring of persons at risk for VHL
‘Test’ Costs ‘Test’ Costs
 in Euro in Euro
Consultations Radiological monitoring**
Ophthalmologist 35 MRI CNS and abdomen 390
Neurologist 80 Ultrasound abdomen 70
Internist 80
195 230
Biochemical urine tests 75 Blood tests** 25
ureum blood count
creatinin creatinin
VMA ureum
norepinephrine Na, K, Cl, P
metanephrine
adrenaline
noradrenaline
Total costs of annual clinical monitoring 525
Costs of monitoring 1100 persons 577,500/year
Costs of monitoring 400 persons 210,000/year
Savings 367,500/year
This table contains figures from the UMC Utrecht and may not be representative for other Dutch
hospitals.
* The cost for a biochemical test is calculated in points representing approx. Euro 0.8
(Euro 1 ~ NLG 2.20).
** An MRI of the CNS (including spine) is made every two years, and also depicts the upper ab-
dominal organs. Therefore, ultrasound and MRI are used alternately each year in monitoring VHL
patients.
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4.4 Future perspectives
From the VHL families identified, we need to collect detailed clinical data of long and
extensively monitored patients with complete DNA analyses. With these clinical data
we could investigate:
- the natural history of VHL disease,
- new entities (VHL-related tumours) within VHL disease,
- genotype-phenotype correlations,
- cost-effectiveness rates of early detection and periodic clinical monitoring.
The identified VHL families should be investigated using pedigree analysis to
detect further carriers of germline mutations in the VHL gene. Importantly, this would
allow us to make a more reliable estimate of the prevalence of VHL disease in the
Netherlands.
VHL disease seems to be a genetically homogeneous disorder from the perspec-
tive of large and well-defined families, but this leaves unanswered which molecular
genetic mechanism accounts for the patients and families having some VHL charac-
teristics but who do not carry a germline mutation in the VHL gene. Therefore, data
on families that are affected by one of the tumours from the VHL spectrum, and in
particular those suggesting a germline mutation (with multi-centric, bilateral, familial
tumours, or a young age at diagnosis), should be collected. These families should be
investigated by linkage studies in order to identify other candidate genes that are in-
volved in the tumourigenesis of VHL-related lesions.
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Chapter 1, objectives and general introduction
Chapter 1 is the introduction to this thesis and describes the main objectives and
methods. It provides an overview of the history of VHL disease, as well as the clinical
and molecular genetic aspects of the disease. In addition, the VHL protein and its
possible functions are reviewed.
Clinical picture
Von Hippel-Lindau (VHL) disease is an autosomal, dominant inherited tumour syn-
drome. A germline mutation in the VHL gene predisposes carriers to tumours in mul-
tiple organs. These tumours may include haemangioblastoma in the retina and central
nervous system (CNS), renal cell carcinoma, phaeochromocytoma, islet cell tumours
of the pancreas, and endolymphatic sac tumours (ELST), as well as cysts and cystad-
enoma in the kidney, pancreas, epididymis and broad ligament. The estimated preva-
lence of the disease varies between 1:31,000 and 1:53,000 persons. The disease is
named after the German ophthalmologist Eugen von Hippel, who described retinal
haemangioblastoma in 1904, and the Swedish pathologist Arvid Lindau who associ-
ated retinal and CNS haemangioblastoma with cysts of the kidneys, pancreas and
epididymis in 1926. Most tumours in VHL patients are multicentric or bilateral, and
manifest at a younger age than in patients without a VHL germline mutation. The
mutation spectrum is heterogeneous, with mutations scattered throughout most of the
VHL gene. Although some recurrent mutations have been reported, most families
have their own unique germline mutation.
Penetrance of VHL disease is high, most carriers of a VHL germline mutation
develop one or more tumours by the age of 60 years. The most common symptoms
include: loss of vision, raised intracranial pressure, neurological deficits, paroxysmal
raised blood pressure and local pain. The median expected survival, based on life
table analysis, has been estimated at 49 years. At present, metastases from renal cell
carcinoma and neurological complications from cerebellar haemangioblastoma are
the most common causes of death in VHL disease. However, it is anticipated that
intensive radiological and clinical monitoring, and advanced operation techniques will
reduce both morbidity and mortality.
Objectives of this thesis
The main objective of this thesis is to identify patients and families with VHL
disease by molecular genetic analysis. New families with VHL disease can be found
by screening patients with VHL-like tumours (with a positive or a negative family
history) for germline mutations. Identification of a VHL germline mutation confirms
the clinical diagnosis. Presymptomatic DNA analysis and identification of carriers of
VHL germline mutations in families then permits tumour development to be followed
from a relative early age, and optimises the time at which treatment is carried out.
Since clinical surveillance can be specifically directed towards carriers of a VHL
germline mutation, the cost-effectiveness of annual monitoring is expected to im-
prove. Moreover, tested individuals are no longer uncertain regarding their risk for
developing the disease and family members who are non-carriers are relieved of the
burden of repeated clinical monitoring.
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Patients and methods
In order to detect new VHL families and patients, we took several initiatives to
increase the number of persons possibly affected with VHL disease being referred for
DNA diagnosis. Firstly, we asked the Departments of Ophthalmology in the univer-
sity hospitals for patients with retinal haemangioblastoma. Secondly, we put an ap-
peal in the journal of the Dutch Association for Neurology asking for patients with
haemangioblastoma in the central nervous system. Thirdly, we approached approxi-
mately 80 medical specialist (including clinical geneticists, internists, endocrinologists,
urologists, surgeons, neurosurgeons and paediatricians) with a known interest in he-
reditary tumour syndromes. Fourthly, we contacted the eight genetic centres in the
Netherlands and fifthly, we distributed patient information via the Dutch VHL sup-
port group and the Internet.
DNA analysis for VHL in the Netherlands is performed at the Department of
Medical Genetics, UMC Utrecht and in the Department of Clinical Genetics, Rotter-
dam University Hospital. DNA analysis included sequencing of the coding region and
quantitative Southern blot analysis, complemented by Fluorescence in situ hybridisa-
tion (FISH) analysis when necessary. Clinical data were collected after patients had
signed an informed consent form.
Summary of objectives
1. To detect VHL families and determine the family-specific germline mutation.
2. To identify presymptomatic relatives who carry a VHL germline mutation.
3. To screen for VHL germline mutations in patients with a single VHL-related
tumour and without a distinct family history.
4. To improve DNA analysis techniques in identifying germline mutations in fami-
lies where no mutation could be detected.
5. To collect clinical and genetic data to identify possible genotype-phenotype cor-
relations.
6. To formulate national guidelines for diagnosis and periodic monitoring of VHL
patients.
Chapter 2, clinical investigations
This chapter focuses on clinical aspects of VHL disease and describes radiological
techniques (2.1) and guidelines for diagnosis and monitoring of the disease (2.4). Two
organs that are involved in VHL disease are discussed in more detail, the kidney (2.2)
and the eye (2.3).
Imaging of renal-, adrenal- and pancreatic masses
Section 2.1 reviews developments in the imaging of renal, adrenal and pancreatic
masses in VHL disease. The imaging of other organs involved in VHL disease is
described in chapter 1. Radiological imaging may favour early detection and monitor-
ing of VHL-related lesions and is likely to lead to a reduction of morbidity and early
mortality. Ongoing follow-up by careful radiological monitoring with ultrasound and
especially MRI (magnetic resonance imaging) plays a central role in managing the
disease.
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We advocate annual monitoring of VHL lesions with MRI and ultrasound rather
than CT (Computed Tomography). Ionising X-rays emitted by CT may mutate the
DNA of the second (non-mutated) VHL allele. It is prudent to regard VHL as a disease
where carriers of a VHL germline mutation have an increased risk for tumours, since
tumourigenesis may be initiated with only one somatic hit.
Management of renal cell carcinoma
Since renal cell carcinoma occur often multiply and bilateral in carriers of a
VHL germline mutation, a choice has to be made between careful radiological moni-
toring, nephron-sparing surgery and nephrectomy. This decision depends on size,
growth and biological behaviour of renal tumours.
Renal cell carcinoma in our patients showed a slow growth rate (on average 0.3
cm/year) and asymptomatic patients presented with tumours of low-grade malignancy.
In all patients, a fibrous pseudocapsule surrounded tumours. In five of 17 tumours,
pseudocapsular invasion was observed and three of the five tumours had broken through
the pseudocapsule. These patients did not show a less favourable outcome than those
without pseudocapsular involvement by tumour growth. Multicentricity of renal cell
carcinoma was relatively low (4.6 lesions per kidney). In two of the three patients that
underwent a nephrectomy, only a single satellite lesion, in the direct vicinity of a renal
cell carcinoma, was found in one kidney. Six tumours (1.8-5.5 cm) were enucleated
by nephron-sparing surgery. During a mean follow-up of 30 months, renal function in
these patients was well preserved. We concluded that, in our patients, renal cell carci-
noma grew slowly, were of low grade, had a dense fibrous pseudocapsule and were
hence good candidates for nephron-sparing surgery.
Ocular haemangioblastoma
Haemangioblastoma are the most common and early occurring tumours in VHL dis-
ease. In the eye the typical lesion is the peripheral retinal haemangioblastoma. Most
ocular haemangioblastoma occur peripherally and 8% occur on the optical disc.
We describe long-term follow-up, ophthalmological data from 20 patients from
six families, with special attention to the natural course of ocular haemangioblastoma.
Five stages of the natural course of development of ocular haemangioblastoma are
discerned and illustrated by fluorescein angiographic pictures. The patient from fam-
ily C is an example of the ability of DNA analysis to find cases of VHL disease with a
negative family history. After five years of extensive clinical monitoring, retinal hae-
mangioblastoma are still the only manifestations of VHL disease. We advocate that
only early detection and treatment of peripheral retinal haemangioblastoma can be
expected to decrease the percentage of patients with impaired visual acuity. Since
ocular haemangioblastoma are early tumours in carriers of a VHL germline mutation,
ophthalmological monitoring (and subsequent treatment) of VHL patients and per-
sons at risk should start as early as possible.
Guidelines for diagnosis and monitoring
The Dutch VHL Working group presents guidelines to enhance the early detection
and treatment of VHL patients in the Netherlands.
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For diagnosing VHL disease in a patient, both clinical manifestations and family
history are important. Typical tumours that are associated with VHL disease are: reti-
nal and CNS haemangioblastoma, phaeochromocytoma, renal cell carcinoma, ELST
and multiple pancreatic cysts. Multiple pancreatic cysts are specific for VHL disease
because they are rare in the normal population. In contrast, renal or epididymal cysts
occur more often in the normal population. In the presence of a positive family his-
tory, VHL disease can be diagnosed in a patient with a typical VHL tumour. In the
absence of a VHL family history, two or more haemangioblastoma, or a haemangiob-
lastoma combined with a further typical VHL tumour are required.
Clinical diagnosis of VHL disease can be confirmed by molecular analysis of
the VHL gene and is informative in virtually all classic VHL families (families with
multiple tumours) and classic sporadic VHL-patients (individuals with multiple VHL-
related tumours).
Guidelines for clinical monitoring of VHL patients are presented. This monitor-
ing protocol is recommended for carriers of a VHL germline mutation; members of
VHL families with an unknown familial mutation; members of VHL families who
decline testing for the familial mutation; and patients suspected of having VHL dis-
ease but without a VHL germline mutation.
Chapter 3, genetic investigations
Chapter 3 focuses on the clinical genetic and molecular genetic aspects of VHL dis-
ease. Section 3.1 describes VHL germline mutations and section 3.2 focuses on five
families with a germline deletion of the VHL gene.  Sections 3.3 and 3.4 report on
case findings of VHL germline mutations in sporadic patients with a single type of
VHL-related tumours.
VHL-germline mutations in the Netherlands
In the DNA laboratories of Utrecht and Rotterdam, VHL germline mutations were
detected in 25 familial and seven sporadic VHL patients. We also identified VHL-
germline mutations in two sporadic patients with VHL-related tumours who did not
fulfil the current diagnostic criteria for VHL disease. Analyses of genotype-pheno-
type correlations were consistent with previous reports. Our study shows that de novo
mutations represent at least 12% - and potentially 21% - of the germline mutations
detected in the VHL gene in the present series, and provides evidence for non-penetrance
and reduced penetrance of VHL germline mutations.
Five families with VHL germline deletions
We describe four families with partial deletions removing one or more exons of the
VHL gene and one family with a deletion of the entire VHL gene. The deletions were
detected by Southern blot analysis. In the fifth family, FISH analysis confirmed the
deletion of the entire VHL gene. Our results showed that (quantitative) Southern blot
analysis is a sensitive method for detecting germline deletions of the VHL gene and
should be implemented in routine DNA diagnostics for VHL disease. Germline dele-
tions in the studied patients were associated with a low risk for phaeochromocytoma
and a preponderance of CNS haemangioblastoma.
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Patients with CNS haemangioblastoma-only
We report on the frequency of VHL germline mutations in 88 patients from the United
Kingdom (n=63) and the Netherlands (n=25), with only CNS haemangioblastoma. A
VHL germline mutation was found in three (3.6%) of 84 sporadic patients with a
single haemangioblastoma and in two (50%) of the four sporadic patients with multi-
ple haemangioblastoma. We concluded that VHL gene mutation analysis should be
offered to all haemangioblastoma patients younger than 50 years. Further data are
required to evaluate the detection rate in late-onset cases. The fact that we did not find
a VHL gene germline mutation in two of the four patients with multiple haemangiob-
lastoma may indicate, next to coincidence, the presence of additional haemangioblas-
toma susceptibility genes or alternatively, somatic mosaicism.
Patients and families with phaeochromocytoma-only
We investigated the frequency of VHL germline mutations in Dutch patients with a
phaeochromocytoma-only phenotype. A total of 24 probands (14 with solitary, seven
with multiple, bilateral or recurrent, and three with familial phaeochromocytoma),
were tested by molecular genetic analysis of the VHL gene. VHL germline mutations
were not found in any of these probands with phaeochromocytoma, even when fea-
tures suggesting a germline mutation - such as early onset, multiple, recurrent, bilat-
eral or familial tumours - were present. However, the absence of VHL germline muta-
tions in the phaeochromocytoma families may indicate the presence of additional
phaeochromocytoma susceptibility genes. Since mutation analysis of the VHL gene
detects germline mutations in virtually all well-defined VHL families, we conclude
that annual clinical monitoring for further VHL-related tumours in patients with
phaeochromocytoma and without a VHL germline mutation should not be recom-
mended.
Chapter 4, discussion
In this chapter the principal findings of this research are discussed. This chapter fo-
cuses on the implications of the study and also provides conclusions and recommen-
dations on some clinical and genetic aspects of VHL disease.
Carriers of a VHL germline mutation are predisposed for developing multiple
tumours that often manifest at a relatively early age. In order to prevent both patient
and doctor delay in the diagnosis of VHL disease, persons at risk for the disease as
well as doctors should be provided with clear oral and written information about the
clinical and genetic aspects of the disease. In addition, an intercentre co-operation
should be established between the medical specialists involved to prevent unneces-
sary morbidity and mortality in patients with VHL disease. Multidisciplinary teams
following national and international guidelines should guarantee the best results in
the management of patients with VHL disease. A national VHL working group, led by
a multidisciplinary board representing various institutes, has been established in the
Netherlands to ensure uniform clinical management of VHL patients and families, as
well as to carry out structural research projects. Clinical monitoring should be prima-
rily organised around those VHL patients who have tested positive for a VHL germline
mutation. To diminish the burden of frequent clinical surveillance, monitoring should
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be organised in a production line fashion so that all the necessary tests can be carried
out during one hospital visit.
Although VHL germline mutations are identified in 100% of the classic families
and patients with VHL disease, we report here on patients and families who exhibit
some VHL characteristics but who do not carry a germline mutation in the VHL gene.
Patients with multicentric, bilateral or familial VHL-related tumours and without a
VHL germline mutation could play a role in identifying genes that are involved in
their specific tumourigenesis. We demonstrate genotype-phenotype correlations for
some tumours in VHL disease, but there appears to be no simple relationship between
a germline mutation in the VHL gene and the manifestation of VHL-related tumours.
For example, there is intrafamilial variability in the age of onset and the manifestation
of different types of VHL-related tumours. There is evidence that genetic factors (so
called modifier genes) and environmental influences play an additional role in the
clinical expression of VHL germline mutations. Furthermore, we provide evidence of
reduced penetrance and non-penetrance of certain VHL germline mutations.
It is not possible to accurately define the prevalence of VHL disease in the Neth-
erlands from this study because of particular selection biases and incompleteness of
information. However, our rough estimate of 1:64,000 will almost certainly prove to
be higher and, interestingly, de novo mutations occur in a considerable proportion of
all the families we studied. We present reasons why this group of patients is under-
represented in our series and we demonstrate that de novo mutations represent at least
12% - and potentially 21% - of the VHL germline mutations detected in the Nether-
lands. In addition, we illustrated that VHL germline mutations can be identified in
sporadic patients with VHL-related tumours who do not meet the current diagnostic
criteria. These findings emphasise the importance of screening sporadic patients with
one or more typical VHL-related tumours for germline mutations in the VHL gene.
We suggest treating each patient suspected of having VHL disease, according to six
categories we define here, with an open mind and performing: (1) an extensive pedi-
gree analysis, (2) clinical screening for further VHL-related tumours, and (3) DNA
analysis. Moreover, clinical situations leading to a suspicion of VHL disease should
be eligible for DNA analysis in order to confirm, or exclude, the diagnosis of the
disease since: (1) carriers of a VHL germline mutation and their relatives have a risk
of developing multiple tumours; (2) molecular genetic analysis is readily feasible and
identifies virtually all the classic VHL families and patients.
A principal finding of this study is that the early detection of VHL families and pa-
tients using molecular genetic analysis is effective, assuming that annual monitoring
and timely treatment leads to a better prognosis for VHL patients. However, regarding
the early detection of VHL patients, we observe that: (1) there is insufficient evidence
of an improved quality of life or a longer life span; (2) there is no reliable analysis of
the cost-effectiveness; and (3) the psychological consequences have not been studied
sufficiently. These three observations should provide a basis for further clinical inves-
tigations. More extensive genetic research is indicated for clinical situations suggest-
ing the presence of VHL disease, but without a VHL germline mutation.
Samenvatting
Samenvatting
Samenvatting
Hoofdstuk 1, doelstellingen en algemene inleiding
Dit hoofdstuk bevat de inleiding van dit proefschrift en beschrijft de doelstelling en
methoden van het onderzoek. Tevens komen hierin de geschiedenis en klinische en
genetische aspecten van het ziektebeeld aan de orde.
Ziektebeeld
De ziekte van Von Hippel-Lindau (VHL) is een erfelijke vorm van kanker waarbij
verschillende organen kunnen zijn aangedaan. De ziekte is vernoemd naar de Duitse
oogarts Eugen von Hippel die in 1904 vaatrijke afwijkingen van het netvlies beschreef
en naar de Zweedse patholoog Arvid Lindau die deze oogtumoren in 1926 associeerde
met tumoren in de kleine hersenen en de buik. Schattingen van de prevalentie van de
ziekte lopen uiteen tussen 1:31.000 en 1:53.000. Bij mensen met een erfelijke aanleg
voor deze ziekte kunnen hemangioblastomen (vaatrijke tumoren) ontstaan in het cere-
bellum (kleine hersenen), myelum (ruggenmerg) en retina (netvlies). Daarnaast worden
ook de volgende gezwellen tot de typische VHL-tumoren gerekend: niercelcarcinomen
(tumoren in de nier), feochromocytomen (tumoren in de bijnier), tumoren in het
binnenoor en cysten in nieren, pancreas (alvleesklier), lever, en geslachtsorganen.
De meest voorkomende complicaties worden veroorzaakt door: hemangio-
blastomen van het netvlies (netvliesloslating, verminderd gezichtsvermogen of
blindheid), hemangioblastomen van de kleine hersenen en/of ruggenmerg (gevoels-
en/of krachtsverlies en/of pijn door verdrukking van kleine hersenen of zenuwen),
tumoren in het binnenoor (oorsuizen en doofheid), niercelcarcinomen (lokale pijn),
feochromocytomen (aanvalsgewijs verhoogde bloeddruk, met complicaties voor hart,
nieren en hersenen) en pancreastumoren (onder andere: galwegobstructie, ontsteking
van de pancreas en spijsverteringsproblemen). De meeste VHL-patiënten overlijden
aan de gevolgen van niercelcarcinomen of van hemangioblastomen in het cerebellum.
Door een ruimte-innemend gezwel in de kleine hersenen kan een gedeelte van het
cerebellum inklemmen in het grote achterhoofdsgat en stijgt de hersendruk. De
(levens)bedreigende gevolgen van niercelcarcinomen bestaan uit uitzaaiingen en
infiltratie in het omliggende weefsel. Het niercelcarcinoom is, vanwege de zojuist
genoemde eigenschappen, de enige kwaadaardige tumor die bij VHL-patiënten
voorkomt. De overige VHL-tumoren worden als goedaardig bestempeld, maar kunnen
desalniettemin (levens)bedreigend zijn.
De gemiddelde leeftijd waarop de ziekte zich manifesteert is voor retinale
hemangioblastomen 25 jaar, feochromocytomen 28 jaar, cerebellaire hemangio-
blastomen 30 jaar en voor niercelcarcinomen 36 jaar. De gemiddelde levensverwachting
van een onbehandelde VHL-patiënt wordt geschat op 49 jaar. Op 60-jarige leeftijd
ontwikkelt bijna iedereen met een erfelijke aanleg voor de ziekte wel één of meer
typische VHL-tumoren. De verwachting is dat vroegtijdige opsporing, periodiek
klinisch onderzoek en behandeling van VHL-tumoren, vooral van hemangioblastomen
en niercelcarcinomen, zowel ziekteverschijnselen als sterfte van VHL-patiënten zullen
doen afnemen. Voor de operatieve behandeling van de meeste VHL-tumoren zijn nog
geen definitieve richtlijnen opgesteld. Momenteel wordt in Boston (USA) onderzoek
verricht naar medicijnen die de groei van tumoren bij VHL-patiënten kunnen afremmen
of mogelijk zelfs kunnen verhinderen.
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Erfelijkheid
Het menselijk lichaam is opgebouwd uit levende eenheden die we cellen noemen.
Elke cel heeft een kern waarin zich 23 paren chromosomen bevinden. Eén chromosoom
van zo’n paar is afkomstig van de vader en één van de moeder. De chromosomen
bevatten de informatie voor alle erfelijke eigenschappen. Elk afzonderlijk chromosoom
van een paar bevat informatie over dezelfde eigenschappen. De aanleg voor elke
eigenschap is dus dubbel aanwezig.
Op de chromosomen liggen genen die, ieder voor zich, de informatie bevatten
voor één erfelijke eigenschap. De genetische informatie is opgeslagen in DNA-
moleculen. Het DNA van een bepaald gen codeert voor een eiwit, dat een specifieke
functie in de cel vervult. Genen kunnen beschadigd raken. Men noemt dit een mutatie.
Een gemuteerd gen werkt niet goed meer. Dit betekent dat eiwitten niet of slechts
gedeeltelijk, hun specifieke taak in een cel kunnen verrichten.
Bij de gezonde mens zorgen de twee kopieën van het VHL-gen ervoor dat een
cel zich niet ongeremd kan vermenigvuldigen. Men noemt het VHL-gen daarom een
tumorsuppressorgen. Een kind dat een gemuteerd VHL-gen erft van een ouder zal dit
gemuteerde gen in alle cellen hebben. We noemen dit een kiembaanmutatie. Het feit
dat iemand drager is van een kiembaanmutatie wil niet zeggen dat alle cellen zich
ongeremd zullen gaan delen. Omdat genen in paren voorkomen, is er ook nog een
gezond gen aanwezig dat wel normaal functioneert. Dit gen is geërfd van de niet
aangedane ouder. Iemand met een geërfd, gemuteerd VHL-gen loopt echter de kans
dat toevallig ook het andere gezonde gen wordt beschadigd. Het gevolg is dat de rem
op celdeling, in bijvoorbeeld een niercel, wegvalt. Uit deze niercel kan vervolgens
een niercelcarcinoom ontstaan. Het is bij deze ziekte overigens nog niet duidelijk
waarom sommige organen juist wel en andere niet aangedaan zijn.
Kinderen van een VHL-patiënt, zowel jongens als meisjes, hebben 50% kans
om het gemuteerde gen te erven. De aangedane ouder heeft immers ook nog een niet-
gemuteerd exemplaar van het VHL-gen. Hierdoor hebben kinderen ook 50% kans dat
zij de aanleg voor de ziekte niet krijgen. Een VHL-patiënt is dus een persoon met een
erfelijke aanleg voor de ziekte, omdat hij of zij in alle lichaamscellen een
kiembaanmutatie in het VHL-gen draagt. Omdat binnen één VHL-familie vrijwel iedere
drager van een VHL-kiembaanmutatie één of meer tumoren krijgt, spreekt men van
een ziekte met een dominant overervingspatroon.
Doelstelling van dit onderzoek
Het belangrijkste doel van het in dit proefschrift beschreven onderzoek is het
identificeren van VHL-patiënten en families door middel van DNA-onderzoek.
Vervolgens zijn ‘voorspellend’ genetisch onderzoek en erfelijkheidsadvisering
mogelijk. Aanvragers van een DNA-test kunnen worden verlost van de onzekerheid
omtrent hun risico voor het krijgen van deze ziekte. Familieleden die géén drager zijn,
kunnen uit levenslange controle worden ontslagen. Dragers van een VHL-
kiembaanmutatie kunnen, reeds vanaf jonge leeftijd, regelmatig gecontroleerd worden
op uitingen van de ziekte. De verwachting is dat hierdoor tijdig operatief kan worden
ingegrepen en dat zowel de levensverwachting als de kwaliteit van leven verbeteren.
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Omdat het periodiek klinisch onderzoek (kostbaar en tijdrovend) tot alleen die personen
die drager zijn van een VHL-kiembaanmutatie beperkt kan worden, is de verwachting
dat de kosten-effectiviteitsratio van onderzoek naar VHL-tumoren verbetert.
Patiënten en methoden
Nieuwe families met een erfelijke aanleg voor deze ziekte kunnen worden gevonden
door patiënten met typische VHL-tumoren met een belaste familiegeschiedenis, te
onderzoeken op mutaties in het VHL-gen. VHL-kiembaanmutaties kunnen ook
voorkomen bij sporadische patiënten met één of meer typische VHL-tumoren. Omdat
een kiembaanmutatie in alle lichaamscellen aanwezig is, wordt DNA gebruikt dat
geïsoleerd is uit bloedmonsters. DNA-onderzoek voor VHL wordt verricht bij de Divisie
Medische Genetica van het Universitair Medisch Centrum Utrecht en het Klinisch
Genetisch Centrum van het Academisch Ziekenhuis Rotterdam. Klinische gegevens
van geteste personen en hun familieleden werden verzameld nadat men een
toestemmingsformulier hiervoor had ondertekend.
Om te bereiken dat zoveel mogelijk potentiële VHL-patiënten voor DNA-
onderzoek werden aangemeld, werden de volgende stappen ondernomen:
1) het aanschrijven van de universiteitsklinieken voor Oogheelkunde (patiënten met
retinale hemangioblastomen);
2) het plaatsen van een oproep in het tijdschrift van de Nederlandse vereniging
voor Neurologie (patiënten met hemangioblastomen in het centraal zenuwstelsel);
3) het oprichten van een Landelijke VHL-werkgroep bestaande uit ongeveer 80
medisch specialisten met belangstelling voor erfelijke tumoren (klinisch genetici,
internisten, oogartsen, neurologen, neurochirurgen, chirurgen, urologen, en
kinderartsen);
4) het benaderen van de acht Klinisch Genetisch Centra (bekende VHL-families,
maar nog niet aangemeld voor DNA-onderzoek);
5) het verspreiden van informatie-materiaal binnen de Belangenvereniging VHL
en op het Internet (zodat familieleden ook zelf initiatief konden nemen voor
DNA-onderzoek).
Samenvatting van de doelstellingen
1) Het opsporen van VHL-families en het identificeren van de kiembaanmutatie;
2) Het diagnosticeren van presymptomatische (voordat er klachten optreden)
familieleden met een VHL-kiembaanmutatie;
3) Het identificeren van VHL-kiembaanmutaties bij sporadische patiënten met een
typische VHL-tumor, maar zonder een VHL-familiegeschiedenis;
4) Het verbeteren van DNA-analysetechnieken om genetische afwijkingen aan te
tonen in families waarin tot nog toe géén VHL-kiembaanmutaies zijn gevonden;
5) Het verzamelen van genetische en klinische gegevens om mogelijke relaties aan
te tonen tussen specifieke VHL-kiembaanmutaties en de expressie van het
ziektebeeld (genotype-fenotype correlaties);
6) Het opstellen van landelijke richtlijnen voor diagnostiek en periodiek klinisch
onderzoek.
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Hoofdstuk 2, klinisch onderzoek
In dit hoofdstuk komen voornamelijk klinische aspecten van de ziekte aan de orde.
Het hoofdstuk beschrijft radiologische technieken voor het in beeld brengen van
organen in de bovenbuik (2.1) en richtlijnen voor diagnostiek en periodiek klinisch
onderzoek (2.4). Twee organen worden in het bijzonder besproken, de nieren (2.2) en
de ogen (2.3).
Radiologische afbeelding van nieren, bijnieren en alvleesklier
Diverse beeldvormende technieken, zoals MRI (Magnetic Resonance Imaging of
magnetische kernspinresonantie), CT (Computer Tomografie-scan) en echografie,
spelen een belangrijke rol in het periodiek onderzoek van VHL-patiënten. Met deze
technieken kunnen VHL-tumoren vroegtijdig opgespoord worden en nauwlettend in
de gaten worden gehouden. Vanwege mogelijk stralingsgevaar verdienen MRI en echo
de voorkeur boven CT bij het radiologisch onderzoek van organen van VHL-patiënten.
Niercelcarcinomen bij VHL-patiënten
Bij VHL-patiënten komen vaak multipele tumoren in beide nieren voor. Er moet dan
een afweging gemaakt worden tussen een afwachtend beleid met periodieke controles,
niersparende chirurgie of verwijdering van één of beide nieren. Deze beslissing hangt
af van de grootte, de groei en het gedrag van de tumor. Indien het technisch mogelijk
is, wordt niersparende chirurgie verricht. Niersparende chirurgie heeft als belangrijk
voordeel dat de nierfunctie meestal behouden kan blijven. Bij VHL-patiënten met een
sterk progressief ziektebeeld rest soms geen andere oplossing dan de verwijdering
van beide nieren. Deze patiënten worden dialyse afhankelijk en/of komen in aanmerking
voor niertransplantatie.
Wij toonden aan dat niercelcarcinomen relatief langzaam groeien (0,3 cm per
jaar) en omgeven worden door een bindweefselachtig pseudokapsel. In vijf van 17
bestudeerde tumoren werd ingroei van de tumor in het kapsel gezien en bij drie van
deze vijf tumoren werd een doorbraak van de tumor door het pseudokapsel heen
waargenomen. Het aantal tumoren (4,6 per nier) was relatief laag. Bij drie patiënten
werden één of beide nieren verwijderd en microscopisch bestudeerd. Bij twee van de
drie patiënten werd in één nier, in de directe omgeving van het niercelcarcinoom,
slechts één enkel satelliet tumortje waargenomen. Bij vijf patiënten werden zes
niercelcarcinomen (met een grootte van 1,8 tot 5,5 cm) met niersparende chirurgie
verwijderd. Regelmatige controle van deze patiënten na de operatie, met een gemiddelde
controle-duur van 30 maanden, toonde aan dat hun nierfunctie goed behouden bleef.
Patiënten met kapsel in- of doorgroei vertoonden geen ongunstiger verloop van de
ziekte. Wij concludeerden dat, in de onderzochte VHL-patiënten, niercelcarcinomen
langzaam groeien, relatief goedaardig zijn en een stevig kapsel bezitten. Hierdoor zijn
VHL-patiënten met niercelcarcinomen goede kandidaten voor niersparende chirurgie.
Hemangioblastomen in de ogen
Wij beschrijven het natuurlijk beloop van oogheelkundige afwijkingen bij 20 patiënten
uit zes VHL-families. Er worden vijf stadia in de ontwikkeling van een hemangio-
blastoom onderscheiden en geïllustreerd door foto’s (fluoresceïne angiografie). Retinale
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hemangioblastomen worden in het algemeen behandeld met laserbestraling, of
cryo(vries)therapie. Tevens wordt er een casus (familie C) beschreven die de waarde
van DNA-onderzoek illustreert voor het opsporen van VHL-patiënten met een negatieve
familiegeschiedenis. Bij een jonge patiënt die alleen haemangioblastomen in de ogen
had, werd een VHL-kiembaanmutatie gevonden. Omdat VHL zich niet zelden voor
het eerst in de ogen manifesteert, bevelen wij aan om periodiek oogheelkundig
onderzoek van personen met een hoog risico voor VHL zo jong mogelijk te laten
beginnen. De verwachting is dat door vroege opsporing (indien nodig gevolgd door
behandeling) het aantal VHL-patiënten met verminderd gezichtsvermogen beperkt
kan worden.
Richtlijnen voor diagnostiek en periodiek klinisch onderzoek
De Landelijke VHL werkgroep geeft richtlijnen om het beleid van vroege opsporing
en behandeling van VHL-patiënten in Nederland te ondersteunen.
Voor het stellen van de diagnose VHL bij een patiënt zijn zowel klinische
verschijnselen als familiegeschiedenis belangrijk. Typische met VHL geassocieerde
tumoren zijn hemangioblastomen, feochromocytomen, niercelcarcinomen, binnenoor-
tumoren en multipele pancreascysten. Multipele pancreascysten zijn VHL-specifiek
omdat zij zeldzaam zijn in de normale populatie. Cysten in nieren of geslachtsorganen
daarentegen, komen relatief vaak voor in de populatie en zijn minder specifiek voor
VHL. De klinische diagnose VHL wordt gesteld bij een patiënt met een typische VHL-
tumor in combinatie met een positieve familie-anamnese. Bij een patiënt met een
negatieve familie-anamnese zijn twee of meer hemangioblastomen, of een
hemangioblastoom in combinatie met een andere typische VHL-tumor vereist voor
het stellen van de diagnose VHL.
De klinische diagnose kan worden bevestigd door het identificeren van een VHL-
kiembaanmutatie. DNA-onderzoek van het VHL-gen toont een kiembaanmutatie aan
bij vrijwel alle klassieke VHL-families (grote families met verschillende tumoren) en
klassieke VHL-patiënten (individuen met verschillende tumoren). Voor DNA-
onderzoek komen zowel patiënten met een VHL-tumor en een positieve
familiegeschiedenis als patiënten met een typische VHL-tumor en een negatieve
familiegeschiedenis in aanmerking. Tevens is (verdenking op) VHL een indicatie voor
erfelijkheidsadvisering.
De werkgroep heeft een protocol voor periodiek klinisch onderzoek opgesteld.
Hiervoor komen de volgende personen in aanmerking: dragers van een VHL-
kiembaanmutatie; familieleden uit VHL-families waarin geen kiembaanmutatie werd
gevonden; familieleden uit VHL-families waarin de kiembaanmutatie bekend is, die
geen DNA-diagnostiek wensen; patiënten bij wie de diagnose VHL wordt overwogen
maar geen mutatie werd gevonden.
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Hoofstuk 3, genetisch onderzoek
In dit hoofstuk worden de genetische aspecten van VHL belicht. Klassieke VHL-
patiënten en families met VHL-kiembaanmutaties worden beschreven (3.1 en 3.2) en
tevens komen sporadische patiënten met een typische VHL-tumor aan de orde (3.3 en
3.4). VHL-kiembaanmutaties worden namelijk ook gevonden bij een patiënt met één
of meer typische VHL-tumoren zonder een belaste familiegeschiedenis. Dit kan
optreden wanneer: 1) de familiegeschiedenis niet voldoende is (of kan worden)
uitgevraagd; 2) één van de ouders drager is van een VHL-kiembaanmutatie maar geen
uiting heeft van de ziekte (non-penetrantie); 3) een mutatie in het VHL-gen is
opgetreden in de zaadcel of eicel van respectievelijk de vader of moeder (de novo
mutatie). Deze personen worden aangeduid als (schijnbaar) sporadische VHL-patiënten.
VHL-kiembaanmutaties in Nederland
Tot nu toe werden 32 kiembaanmutaties in het VHL-gen aangetoond: 25 in VHL-
families en zeven in sporadische VHL-patiënten. Bovendien vonden wij VHL-
kiembaanmutaties in twee sporadische patiënten die niet aan de huidige VHL-criteria
voldeden. Acht van de 34 gevonden mutaties werden volgens de literatuur nog niet
eerder aangetoond bij VHL-patiënten. Een analyse van correlaties tussen de diverse
genotypes (kiembaanmutaties) en het fenotype (uiting van de ziekte) bevestigde de
bevindingen uit de literatuur. Zo hebben families met feochromocytomen vaak een
bepaald type missense mutatie (waarbij slechts één aminozuur is veranderd in het
VHL-eiwit) terwijl families met andere soorten kiembaanmutaties in het algemeen
juist geen feochromocytomen hebben.
Bij de negen sporadische patiënten met één of meer typische VHL-tumoren kon
in vier gevallen worden bevestigd dat een de novo mutatie betrof, doordat de mutatie
niet bij één van beide ouders aanwezig was. Bij één patiënt werd de kiembaanmutatie
juist wel bij één van beide ouders gevonden. Bij de vier overige patiënten kon geen
bewijs voor een de novo mutatie geleverd worden omdat de ouders niet beschikbaar
waren voor DNA-onderzoek. Bij drie van deze vier patiënten bleef echter de familie-
geschiedenis, mede door het ontbreken van VHL-gerelateerde tumoren ook bij naaste
familieleden op oudere leeftijd, suggestief voor een de novo mutatie. Deze resultaten
doen vermoeden dat de novo mutaties tussen de 12% (4/34) en 21% (7/34) van het
totale aantal gevonden VHL-kiembaanmutaties in Nederland vormen. Dit onderzoek
beschrijft tevens vier families met VHL-kiembaanmutaties en een verlaagde of zelfs
geheel afwezige expressie van het ziektebeeld. Deze twee bevindingen onderstrepen
het belang om ook bij schijnbaar sporadisch patiënten met één of meer typische VHL-
tumoren een DNA-test te verrichten.
Vijf families met een deletie van het VHL-gen
Een specifiek type mutatie is een gedeeltelijke of volledige afwezigheid van het VHL-
gen. Dit type mutatie noemt men een deletie. Bij vier families was er sprake van een
gedeeltelijke deletie van het VHL-gen en bij één familie was het gehele VHL-gen
afwezig in de kiembaan. Deze deleties werden aangetoond met behulp van de zogeheten
‘kwantitatieve Southern blot’ techniek. De deletie van het gehele VHL-gen werd
bevestigd met een andere techniek: ‘Fluorescence in situ hybridisation’, kortweg FISH
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genoemd. Met dit onderzoek toonden wij aan dat kwantitatieve Southern blot analyse
een betrouwbare methode is om deleties in het VHL-gen op te sporen. Deze techniek
moet daarom geïmplementeerd worden in de reguliere DNA-diagnostiek bij VHL.
In dit onderzoek probeerden wij ook correlaties tussen genotype en fenotype aan
te tonen. We bevestigden de bevinding dat patiënten met een geërfde deletie in het
VHL-gen in het algemeen een laag risico op het ontwikkelen van feochromocytomen
hebben. Daarnaast viel het ons op dat bij deze vijf families en vooral bij de familie
met een deletie van het gehele VHL-gen, relatief veel hemangioblastomen in het
centraal zenuwstelsel voorkomen.
Sporadische patiënten met hemangioblastomen in het centraal zenuwstelsel
Wij onderzochten hoeveel sporadische patiënten met louter hemangioblastomen in
het centraal zenuwstelsel drager van een VHL-kiembaanmutatie zijn. De onderzochte
populatie bestond uit 25 Nederlandse en 63 Engelse patiënten. Bij drie (3,6%) van de
84 patiënten met een solitair hemangioblastoom werd een kiembaanmutatie in het
VHL-gen aangetroffen. Aangezien alle mutaties werden aangetroffen bij patiënten
jonger dan 50 jaar concludeerden wij dat vooral in deze leeftijdscategorie DNA-
onderzoek voor een mutatie in het VHL-gen verricht moet worden.
Vier patiënten hadden veelvoudige hemangioblastomen en hierbij werd bij twee
patiënten (50%) een VHL-kiembaanmutatie aangetroffen. Het feit dat we geen VHL-
kiembaanmutatie vonden bij de twee patiënten met multipele hemangioblastomen kan
een aanwijzing zijn voor: 1) de aanwezigheid van nog-niet-ontdekte genen die van
invloed zijn op de ontwikkeling van hemangioblastomen; 2) het feit dat deze patiënten
niet in alle lichaamscellen een VHL-mutatie dragen (een ‘mozaïek’ patroon); 3) de
toevallige aanwezigheid van verschillende hemangioblastomen bij één patiënt.
Patiënten en families met feochromocytomen
Wij onderzochten 24 patiënten met louter feochromocytomen op een VHL-
kiembaanmutatie. Bij 14 patiënten was er sprake van een solitaire tumor, zeven
patiënten hadden veelvoudige tumoren en bij drie patiënten betrof het een familiaire
vorm van feochromocytomen. Bij geen van deze 24 patiënten werd een
kiembaanmutatie in het VHL-gen aangetroffen. Zelfs bij de patiënten met een sterke
verdenking op de aanwezigheid van een geërfde mutatie (zoals een jonge leeftijd,
veelvoudige tumoren of familiaire feochromocytomen) kon geen VHL-kiembaan-
mutatie worden aangetoond. Aangezien DNA-onderzoek van het VHL-gen in bijna
alle VHL-families een kiembaanmutatie aantoont, sluit de afwezigheid van een mutatie
de aanwezigheid van het ziektebeeld praktisch uit. Daarom lijkt het niet aanbevelens-
waardig om patiënten mét feochromocytomen maar zonder VHL-kiembaanmutatie te
onderzoeken op het eventuele voorkomen van andere typische VHL-tumoren.
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Hoofdstuk 4, dicussie
Dit hoofdstuk beschrijft de voornaamste bevindingen en de belangrijkste implicaties
en conclusies van het onderzoek.
Ethische, psychische en maatschappelijke aspecten
Wanneer de diagnose VHL gesteld is (of overwogen wordt), is verwijzing naar een
klinisch genetisch centrum van belang voor bespreking van de erfelijke aspecten. Het
stellen van de diagnose VHL heeft namelijk niet alleen gevolgen voor de patiënt maar
ook voor zijn of haar familieleden. Bij het overwegen van erfelijkheidsonderzoek kan
echter bij arts en patiënt een conflict van belangen ontstaan tussen enerzijds het
respecteren van de privacy van de familieleden en anderzijds de verantwoordelijkheid
voor de gezondheid van de familieleden. Met een voorlichtingsbrochure (verspreid
via de patiënt en/of geïnformeerde familieleden) kunnen familieleden van informatie
over VHL worden voorzien en gewezen worden op de mogelijkheid zelf erfelijkheids-
advisering te vragen. Op deze manier kunnen zij zelf kiezen of zij (of hun nageslacht)
voor onderzoek in aanmerking willen komen.
Presymptomatisch DNA-onderzoek vormt een aanzienlijke psychische belasting.
De psychische last, ontstaan uit de angst om ziek te zullen worden en de onzekerheid
over dragerschap van de erfelijke aanleg, kan groter zijn dan de belasting voortvloeiend
uit de wetenschap dat er een grote kans bestaat op het ontwikkelen van de ziekte.
Derhalve is deskundige begeleiding van de patiënt, volgens de daarvoor door de klinisch
genetische centra landelijk gehanteerde richtlijnen, tijdens de procedure van
erfelijkheidsonderzoek gewenst.
Een erfelijke ziekte kan van invloed zijn indien men een nieuwe verzekering wil
afsluiten of van verzekering wil veranderen. Kennis omtrent de aanleg voor een erfelijke
ziekte stelt (ziektekosten)verzekeraars in staat om deze personen een verhoogde premie
te berekenen of zelfs een verzekering te weigeren. In deze situatie zou men kunnen
spreken van genetische discriminatie. Gelukkig bestaat er tussen overheid en
verzekeraars sinds 1990 een afspraak die betrekking heeft op het afsluiten van
verzekeringen in relatie tot erfelijkheidsonderzoek. Deze afspraak beschermt de patiënt
tegen misbruik van informatie betreffende de aanleg voor een erfelijke ziekte door
verzekeraars. Voorts is in 1997 de Wet op Medische keuringen aanvaard: werkgevers
mogen geen erfelijkheidsonderzoeken laten verrichten of gegevens daarover opvragen.
VHL-patiënten kunnen zich voor voorlichting en advies over de hierboven
genoemde aspecten wenden tot de Belangenvereniging Von Hippel-Lindau. De
Belangenvereniging kan tevens een rol spelen om een vertraging in de diagnosticering
van VHL te voorkomen. Door middel van brochures, een VHL-krant en een website
op het Internet worden personen met een verhoogd risico op deze ziekte alsmede
artsen, voorzien van informatie over de klinische en genetische aspecten van deze
ziekte. Het blijkt dat niet alle artsen die VHL-patiënten of patiënten met typische
VHL-tumoren behandelen, op de hoogte zijn van de klinische en genetische aspecten
van deze complexe ziekte. Een samenwerking van zowel artsen die VHL-patiënten
periodiek onderzoeken en/of behandelen als klinieken, is daarom van groot belang.
De Landelijke VHL werkgroep heeft een protocol opgesteld voor periodiek klinisch
onderzoek dat nu in veel ziekenhuizen in Nederland op één dag wordt uitgevoerd.
Samenvatting
Conclusies
Door middel van DNA-diagnostiek en een inventarisatie van VHL-families die nog
niet voor DNA-onderzoek zijn aangemeld, zijn er momenteel bijna 50 VHL-families
in Nederland bekend. Wij constateerden dat de novo mutaties  tussen de 12% en 21%
van het totaal aantal VHL-kiembaanmutaties vertegenwoordigen. Wij vonden ook
VHL-kiembaanmutaties bij patiënten die niet aan de huidige diagnostische VHL-cri-
teria voldoen. Deze bevindingen onderstrepen het belang om bij sporadische patiënten
met één (of meer) typische VHL-tumoren een DNA-test te verrichten om de diagnose
VHL aan te tonen of uit te sluiten, omdat: 1) dragers van een VHL-kiembaanmutatie
en hun familieleden een verhoogd risico hebben op het ontwikkelen van tumoren; 2)
DNA-analyse van het VHL-gen relatief eenvoudig uitvoerbaar is en in bijna alle
klassieke VHL-families en patiënten een kiembaanmutatie aantoont.
Op dit moment is het niet mogelijk om een betrouwbare schatting te maken van
de prevalentie van VHL in Nederland. Wij komen in dit proefschrift tot een voorlopige
schatting dat de ziekte bij één op de 64.000 mensen vóórkomt. De werkelijke prevalentie
zal waarschijnlijk hoger zijn omdat er nog steeds nieuwe VHL-families geïdentificeerd
worden en nog niet alle familieleden van bekende dragers van een VHL-kiembaan-
mutatie onderzocht zijn.
Het is moeilijk gebleken om strikte (klinisch diagnostische) criteria voor VHL
op te stellen. Ondanks het feit dat bij alle klassieke VHL-patiënten en families een
kiembaanmutatie wordt gevonden, blijkt anderzijds geen simpele relatie te zijn tussen
een kiembaanmutatie in het VHL-gen en de uiting van tumoren (genotype/fenotype-
correlatie). Bij niet-verwante dragers van een identieke kiembaanmutatie kunnen VHL-
tumoren zich verschillend manifesteren. Maar ook binnen één familie ontstaan tumoren
op verschillende leeftijden en ontwikkelen familieleden verschillende soorten tumoren.
De expressie van het ziektebeeld kan afhankelijk zijn van omgevingsfactoren (leefstijl,
roken en voeding) en van andere genen dan het VHL-gen. Bij sommige kiembaan-
mutaties komt het ziektebeeld verminderd of zelfs geheel niet tot expressie.
Bij sporadische patiënten met één type VHL-tumor wordt in een laag percentage
(0-5%) een VHL-kiembaanmutatie gevonden. Dit succes-percentage neemt toe wanneer
de tumor op jonge leeftijd voorkomt of dat één type VHL-tumor multipel, dubbelzijdig
of familiair voorkomt. Indien er bij laatstgenoemde patiënten en families geen VHL-
kiembaanmutatie wordt geïdentificeerd, is het van belang om te onderzoeken of andere
genen een rol spelen in de ontwikkeling van de betreffende VHL-gerelateerde tumor.
Een belangrijke conclusie van het onderzoek is dat, uitgaande van een verbeterde
prognose door periodiek onderzoek en behandeling, het opsporen van VHL-patiënten
door middel van DNA-diagnostiek zinvol is. Bij het nut van vroege opsporing van
VHL-patiënten dienen echter een paar kanttekeningen geplaatst te worden:
1) er is nog onvoldoende bewijs voor een verbeterde kwaliteit van leven en een langere
levensduur; 2) een betrouwbare kosten-effectiviteits-analyse ontbreekt;
3) de psychologische gevolgen zijn nog onvoldoende bestudeerd.
Deze drie punten kunnen een basis vormen voor nader klinisch onderzoek. Uitgebreider
genetisch onderzoek blijft aangewezen voor families en patiënten met typische VHL-
tumoren maar bij wie geen VHL-kiembaanmutatie is aangetoond.
Samenvatting
Woorden van dank
Vijf jaar geleden maakte ik, als dienstplichtig arts met veel vrije tijd, via de neurologen
Hanlo en Krouwer en de internist Lips voor het eerst kennis met het onderwerp van dit
proefschrift. Op dat moment wist ik niet zo heel veel meer over deze zeldzame erfelijke
vorm van kanker te vertellen dan dat het op de laatste bladzijde van het leerboek
neurologie beschreven stond. Tijdens mijn dienstplicht werd er subsidie voor een
onderzoeksproject aangevraagd en kon ik mij storten op een geheel te herziene versie
van de patiënten-informatiefolder. Nooit had ik kunnen bevroeden dat ik door deze
relatief zeldzame aandoening met zovele klinische en genetische collegae zou gaan
samenwerken. Dit maakt het onmogelijk om iedereen te noemen, laat staan persoonlijk
te bedanken.
Prof. Pearson, dear Peter, since you always have to do your best to speak Dutch,
I feel that I should now make an effort to address you in English. When I first met you,
the former Department of Human Genetics fitted easily into a small coffee corner in
Stratenum. Since 1995, your department has expanded to such an extent that it would
now be simply impossible to drink coffee with all our colleagues in the one room, let
alone do any work. I consider it my privilege to be the first post-graduate to be awarded
a Ph.D. during your second career as a professor in the Netherlands. I am very grateful
for all the times that you were prepared to discuss my research with me, and that you
were prepared to bat for me when it really mattered.
Prof. Lips, beste Kees, nu dit proefschrift tot een goed einde is gekomen, trek ik
eindelijk de stoute schoenen aan om u, de VHL-goeroe, bij de voornaam te noemen. U
bent de initiator van het onderzoeksproject en het is voor mij bijzonder leerzaam
geweest om van u de veelzijdige klinische aspecten van het ziektebeeld te leren kennen.
U weet als geen ander een multidisciplinair samenwerkingsverband te creëren waarin
klinische problemen door bijdragen uit verschillende invalshoeken opgelost kunnen
worden. Goede herinneringen bewaar ik aan het congres dat wij bezocht en in Hono-
lulu. Alhier had ik het voorrecht om, reeds vroeg in het onderzoek, met u de andere
VHL-grootheden van de wereld te ontmoeten. Reikhalzend kijk ik uit naar de volgende
gelegenheid waarop wij met een bloemenkrans een Luau mogen bijwonen.
Dr. van der Luijt, beste Rob, met al jouw enthousiasme heb je me gelukkig meer
dan alleen de moleculaire genetica bijgebracht. Bertje Vis (“dan weet je het echt niet
meer”), Formule-1 competitie, kamer 3.117 en vele andere hilarische dialogen (of
liever gezegd monologen) blijven dierbare herinneringen. Toch ben ik je de meeste
dank verschuldigd voor de vele uren waarin je deze onwetende arts diverse ingewik-
kelde aspecten van jouw vak uitlegde alsof hij zes jaar oud was. Hopelijk volgen er
nog vele promovendi na mij en bedenk: het belangrijkste bij het promoveren is …...
de helm.
De leden van de beoordelingscommissie (Prof. Staal, Prof. Buijs, Prof. Niermeijer,
Prof. Tulleken en Prof. Voest) ben ik zeer erkentelijk voor het zorgvuldig bestuderen
van het manuscript. Graag wil ik een tweetal persoonlijk bedanken. Ten eerste, de
voorzitter van deze commissie, Prof. Gerard Staal voor zijn onvolprezen inspanningen
voor de Divisie Medische Genetica en omdat ik bij hem altijd een gewillig oor vond
om mijn vragen omtrent het promoveren zelf voor te leggen. Ten tweede ben ik veel
dank verschuldigd aan Prof. Niermeijer voor zijn waardevolle suggesties bij het
schrijven van dit proefschrift.
Richard Zewald, zonder jouw inspanningen was dit proefschrift misschien wel
nooit van de grond gekomen. Niet alleen door jouw strakke resultaten, maar vooral
ook door jouw inspanningen om mij in het lab wegwijs te maken, ligt er nu een heus
VHL-proefschrift. Je weet trouwens niet hoe vaak ik mezelf heb moeten afvragen hoe
toch al die complexe zaken Zewaldiaans te verwoorden. Ik weet het, …... het is een
gave.
Jackie, het aantal uren dat jij in dit proefschrift hebt gestoken, overstijgt misschien
wel het aantal bladzijden van dit proefschrift. Ik ben je zeer dankbaar voor alle correcties
van steenkolen Engels naar Oxford consised texts. Mochten er nog fouten in dit proef-
schrift staan, dan is dat mijn schuld.
Marijke, veel dank voor al je ondersteuning bij het promoveren en het solliciteren.
Over drie jaar hoop ik de draad van de dinsdagochtend-koffie  weer met je op te
pakken.
Het bestuur van de Landelijke VHL werkgroep ben ik zeer veel dank verschuldigd
voor de ondersteuning van het onderzoek dat tot dit proefschrift heeft geleid. Nu onze
doelstellingen op schrift staan en onze adviezen voor diagnostiek en periodiek
onderzoek aanstonds gepubliceerd worden, kan ik alleen nog maar de wens uitspreken
dat de werkgroep een goede toekomst tegemoet kan zien. Beste Daniëlle, Gré, Jacques,
Rob, Rolf en Thera: hartelijk dank.
Hans-Kristian, Cisca en Richard, jullie ben ik zeer erkentelijk voor de keren dat
ik bij jullie terecht kon voor adviezen en kritisch commentaar. Mag ik jullie in de
toekomst ook gewoon lastig blijven vallen?
Jo, Dennis en Janine, hartelijk dank voor alle dinsdagochtenden dat jullie
meedachten over de moleculair genetische kant van dit onderzoek. Met veel plezier
denk ik terug aan de momenten dat jullie weer andere invalshoeken bedachten om de
zaken aan te pakken.
Joke en de VHL belangenvereniging wil ik graag danken voor de vruchtbare en
inspirerende samenwerking. Zonder directe belanghebbenden blijft onderzoek toch
iets abstracts. Ik heb veel van jullie geleerd en ik hoop dat jullie ook iets wijzer zijn
geworden van dit proefschrift.
Agnes en Inge, hartelijk bedankt voor al jullie inspanningen om alle klinische
gegevens te verzamelen en te beheren. Onze samenwerking is mij zeer goed bevallen
en ik hoop dat dit een aanzet moge zijn voor meer onderzoek dat ondersteund wordt
door genetisch assistenten.
Alle medewerkers van de DNA-diagnostiek wil ik hartelijk danken voor de
gastvrijheid in hun lab. Van blunder-cake tot publicatie-taart, het was een mooie tijd.
Een speciaal woord van dank richt ik aan Rumó. Je bent onmisbaar voor het goed
laten draaien van een lab, zowel op sociale als het vak-technische vlak. Chapeau en
....… een prettig weekend.
Wie had ooit kunnen vermoeden dat we het met alle researchers zo naar ons zin
zouden hebben in de AIO-kamer? Zeven (Alfons, Bart, Erik, Harm, Judith, Jonathan
en Martine) van negen (+ Olga en Vincent) waren hier toch maar al te vaak te vinden.
Van oud-Brabants klokwerpen en uitspraak-van de-week-bord, tot koffiegeleuter en
borrelpraat; ik zal alles erg gaan missen. Charlotte, Ruben en Steven, sterkte met dit
al. Michel, dank voor het waarnemen van de honneurs in het lab. Het jongste hoofd-
ICT van het UMC (en misschien wel ver daarbuiten) dank ik hartelijk voor al zijn
expertise en ondersteuning bij het vervaardigen van dit proefschrift.
Alle medewerkers van de audiovisuele dienst, Ingrid en Lilian in het bijzonder,
veel dank voor jullie illustraties die het ziektebeeld verhelderend in beeld brachten.
Zeer gewaardeerde collegae Los, Voest, Tulleken, van Vroonhoven, Slootweg,
Feldberg, Wittebol-Post, Hanlo, Hené, Beutler, Taphoorn, Elderson, Hiemstra en van
Moorselaar: dank voor de samenwerking en moge het multidisciplinair VHL-team
van het UMC Utrecht een voorbeeld zijn voor vele andere ziekenhuizen.
A special word of thank I would like to direct towards my foreign colleagues
Maher, Neumann, Cybulski, Opocher, Richard and Zbar. Thanks for the co-operation
and inspiration for research on VHL disease. Dear Joyce, good luck with continuing
your impressive organisation. I hope that the VHL Family Alliance will comfort and
support many more people who are involved in VHL disease.
Waarde paranimphen, dank voor alle bijstand. Feyo, gaan we ook eten iedere
keer als jij promoveert? Mario, ik kijk uit naar de dag dat onze rollen omgedraaid
zullen zijn. Toppen we vanavond nog even af bij meneer Cats?
Lieve Kathalijne, wederom bewees jij je talenten als illustratrice. Helaas schrijf
ik waarschijnlijk maar één keer in mijn leven een proefschrift, maar ik hoop dat op
nog vele andere boeken een echte Hes de omslag mag sieren.
Lieve Dies en Gies, er is weer een mijlpaal bereikt, maar zoals jullie als geen
ander weten; uitgestudeerd ben je nooit. Ik verheug mij erop dat jullie mij nog lang
zullen blijven steunen en stimuleren.
Lieve mammie en pappie, vanuit een genetisch oogpunt hebben jullie ieder de
helft van dit proefschrift geschreven. Hartelijk dank voor alles wat ik van jullie
meegekregen heb.
Lieve Nath, dank voor je liefdevolle zorg en aandacht bij het schrijven van dit
proefschrift. Het was een groot plezier en een voorrecht om deze klus met jou te
mogen klaren. Op deze alinea na, is geen woord, punt of komma aan jouw kritische
ontsnapt. Ik vinde je liev,.
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behaalde in 1995. Tijdens zijn studie werkte hij in vaatfunctie-laboratorium van het
Universitair Medisch Centrum Utrecht en voor het farmaceutisch bedrijf Eli Lilly.
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